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Abstract 
INVESTIGATION OF GENETICS AND GENOMICS IN ASTHMA 
Aristea Dimitriou Binia 
Molecular Genetics Group, NHLI, Imperial College London 
Thesis submitted for the degree of Doctor of Philosophy, 2010 
Asthma is the most common disease of childhood in the westernised world, affecting 
one child in seven in the United Kingdom alone. It is a complex disease involving both 
genetic and environmental factors. The financial burden for sufferers approximates £1 
billion per annum in the UK and 80% of the sum is attributable to the patients with the 
severe, “difficult/therapy-resistant” form of the disease. Previously, a Genome Wide 
Association Study (GWAS) for childhood asthma identified a number of loci 
significantly associated to the disease.  The top ten SNP hits with the highest association 
(0.0001>P>0.00001) were chosen for an investigation of their importance in cases of 
severe asthma, both childhood and adult. The 10 SNPs were genotyped in 397 adults 
and 94 children using TaqMan
®
 SNP Genotyping Assays.  Genotyping data was 
analysed for genetic associations to the severe asthma phenotype using chi-squared 
tests.  Control data was obtained from data generated in the original GWAS for the 
British controls.  SNP rs6585018 located in the PDCD4 gene predicted promoter was 
found to be significantly associated to childhood asthma (P=3.4x10
-7
). Additional 
markers on the PDCD4 gene area were chosen to be typed in 116 severe asthmatic 
children and 145 healthy children from the UK. SNPs rs6585018 (P=0.005), rs1322997 
(P=0.005) in the predicted promoter area and rs34104444 (P=0.01) in exon 5 were 
associated to severe asthma. The three SNPs were also correlated with PDCD4 
transcript levels. PDCD4 genomic area was analysed in silico and ElectroMobility Shift 
Assay (EMSA) experiments were designed for the rs6548018 alleles to examine how 
they alter transcription factor binding sites. SNP rs6585018 was found to alter the 
binding site of the Myb transcription factor possibly altering the expression of PDCD4 
gene. This study has provided insights into the genetic factors that are involved in 
disease aetiology of severe asthma. 
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Chapter I: General Introduction 
1.1 Asthma, a multi-factorial disease 
 
 
1.1.1 Definition of asthma  
Asthma is a chronic inflammatory disease of the lungs involving many different cells 
and physiological mechanisms. The inflammation of the small airways of the lung is the 
central characteristic of the disease causing an associated increase in bronchial hyper-
responsiveness, intermittent airway obstruction. In combination with mucus hyper-
secretion and smooth muscle hypertrophy this results in recurrent episodes of wheeze, 
breathlessness, chest tightness and cough, symptoms that are not necessarily present in 
all patients or to the same degree. Most patients are atopic, a state referring to the 
presence of immunoglobulin E (IgE) mediated skin-test responses to common allergens. 
A smaller percentage of the patients are non-atopic, and these individuals 
characteristically exhibit a late-onset form of asthma 
1
. Lung eosinophilia, mast cell 
degranulation and IgE release are common pathological events although due to the 
recognised subphenotypes of the condition (Section 1.1.5) it has been proposed that 
asthma could be regarded as a syndrome involving different mechanisms and causes
2
.  
 
1.1.2 Asthma prevalence 
 
Asthma is becoming an epidemic health problem particularly in the Western world with 
concomitant social and economic impact to both the patients and their families 
3
. 
According to the World Health Organisation (WHO; Geneva, Switzerland) the disease 
affects approximately 300 million people in the world and in 2005 the morbidity rate 
was 255,000 individuals (WHO, 2006). Although the prevalence of asthma is greatest in 
developed countries, reports suggest that it is also increasing in developing countries 
due to their adoption of a more westernised lifestyle
2
.  
Asthma is one of the most prevalent conditions in the developed world with a rate of 
15.1% in the United Kingdom. It has been identified as the most common chronic 
disease in childhood with 1.1 million children among 5.2 million people in the UK 
receiving treatment (Asthma UK, 2005/2006 report, 
www.asthma.org.uk/how_we_help/publishing_reports/index.html) (Figures 1.1-1.2) 
2
. 
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Worldwide asthma prevalence increases by an estimated 50% every decade with a 
striking rise in children in English-speaking countries and in the general populations of 
Southern African and Eastern European countries
2,3
. In Western Europe for example, 
the prevalence of the disease has doubled in the last decade with approximately 30 
million people exhibiting asthma symptoms
4
. In USA and Canada, almost 35.5 million 
people have asthma which relates to a prevalence of approximately 1 person in 10, with 
ethnic groups such as the Latinos or African Americans exhibiting higher rates
3
. In 
Japan, the number of asthmatics receiving medical treatment has increased from 3 cases 
30 years ago to 100 cases in a population of 100,000 individuals
3
. 
Urbanisation has been recognised to be an important factor underlying the increase in 
disease incidence in developing countries. More than 40 million people in South 
America are asthmatics with the highest prevalence in Peru (13%), Costa Rica (11.9%) 
and Brazil (11.4%)
2
. In Africa, more than 50 million people have the disease with South 
Africa having the highest prevalence of 8.1%
2
. In East Asia, 44 million people are 
asthmatics whereas in high-populated countries such as China or India an increase in 
prevalence could result in a significant number of sufferers. 
There is evidence showing that sex-specific, age-specific and race-specific differences 
exist in the prevalence of asthma. The majority of studies have found that during 
childhood asthma prevalence is double in boys compared to girls
5-7
.  This sex difference 
reverses after puberty
8
, although the sex ratio in asthmatic cases appeared to narrow in 
the last decades
9
 . The reverse post puberty in asthma sex-related ratio has been seen in 
a wide set of population groups from various developed countries with subjects from 
birth to 44 years being studied 
10
. A possible explanation for the disparity could be the 
hormonal differences between male and females
11
 or the gender differences in the rate 
of lung and airway growth
12
.  
Although as yet not entirely understood, the cause of the increasing asthma prevalence 
could be a combination of changes in allergen exposure, hygiene and lifestyle changes 
during the past decades
13
. Interestingly in parallel to the increase of asthma prevalence, 
an obesity epidemic has also been reported and this simultaneous rise may not be 
coincidental
14
. A reduction in physical activity, major changes in diet, such as elevated 
salt intake or vitamin D deficiency in pregnant women and their offspring
15-17
 and 
decreasing of the time spent outdoors have contributed to the increase of obesity. These  
14 
 
 
Figure 1.1. Current prevalence of childhood current asthma symptoms ranked by 
country. (Written Questionnaire: Self-reported wheezing in the previous 12 month 
period, in 13- to14-year-old children). Taken from Masoli et al. Allergy 2004: 59:  469-
478. 
15 
 
 
Figure 1.2. Current prevalence of adulthood current asthma symptoms ranked by 
country. (Written Questionnaire: Self-reported wheezing in the previous 12 month 
period, in 20- to 44-year-old adults). Taken from Masoli et al. Allergy 2004: 59:  469-
478. 
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factors have also been proposed to contribute to asthma and/or asthma-related 
phenotypes
18
.An association between asthma and obesity has already been investigated 
(the overweight hypothesis)
16,19
. There have been a number of studies demonstrating 
association between asthma and obesity
20,21
 as well as  others that have either shown an 
independent increase in the prevalence in the two conditions caused by lifestyle 
changes
22
 or alternatively suggesting a reverse association with asthma causing 
obesity
19
.  Further investigation is therefore needed to elucidate the cause and effect in 
the overweight hypothesis by prospective study design and by taking into consideration 
obesity subphenotypes such as BMI in asthma genetic studies. 
Another well-studied hypothesis linking increased rates of asthma to lifestyle changes 
and  westernisation is the so called “hygiene hypothesis”23,24. Originally proposed by 
David Strachan
23
 the hygiene hypothesis states that the recent increase in the prevalence 
of the disease in westernised societies is due to the lack of infectious burdens in early 
life, implying that the so called microbial effect might be protective against disease 
manifestation. These microbial substances contribute to the maturation of the immune 
responses during early childhood resulting in an immunity tolerance to environmental 
triggers such as pollen, house dust mites and animal danders
25,26
. When endotoxin levels 
in dust samples from mattresses of schoolchildren were measured they were found to be 
inversely associated with hay fever and atopic asthma
27
. The hygiene hypothesis cannot 
however explain the correlation of asthma and industrialisation, the increase of the 
incidence among poor urban areas in the USA and the simultaneous rise of the 
autoimmune T cell helper (Th1) diseases since a relationship between the decrease of all 
infectious and the rise of T cell helper (Th2) diseases has been well-established
28-30
.  
 
1.1.3 The socioeconomic burden of asthma  
A considerable rate of asthma morbidity and mortality is reported among sufferers
4
. As 
a result of the increase in asthma prevalence there has been a noticeable increase in 
hospital admissions.  Admissions are of the most severe type particularly in areas where 
disease management is inadequate due to poor life conditions or lack of information. In 
the UK, asthma is the most common cause of hospital admission in children
4
 and over 
the past year  27% of the population group required acute admission to the care unit or 
the emergency department due to an asthma attack. Despite the improvements in 
17 
 
mortality rates since the 1980s due to regular use of inhaled corticosteroids and asthma 
management
2
, the World Health Organisation (WHO; Geneva, Switzerland) estimates, 
asthma attacks result in approximately 180,000 deaths per year 
(www.who.int/mediacentre/factsheets/fs206/en). Ineffective use of inhaled 
corticosteroids and noncompliance of patients are the most common causes of asthma 
deaths reported for patients aged≥45 years (Global Initiative for Asthma, 
http://www.ginasthma.com). 
 The impact of asthma on the economy is two fold.  There is a direct effect due to the 
medical costs of hospital admissions and the cost of drugs and an indirect effect 
resulting from the loss of productivity relating to work or school absence and premature 
death. 
31,
 
4
 (WHO, 2006) (http://www.asthma.org.uk/). 
Interestingly, 80% of the entire expense is ascribed to the 20% of the patients with the 
severe form of the disease due to the frequent hospital admissions and the regular use of 
antiasthma treatment
31
. The overall cost of the disease, both direct and indirect was 
correlated to asthma severity when a broad range of asthmatics (intermittent, mild 
persistent, moderate persistent, severe persistent) were followed for 1 year and received 
the assigned treatment
32
. 
The high mortality rates and the substantial cost due to hospitalisation associated with 
the severe asthmatics group emphasize the importance of identifying the causes of the 
disease. 
 
1.1.4 The immunological mechanisms underlying asthma 
It is hypothesised that the development of asthma commences early in life, when an 
infant‟s immune system has contact with  environmental allergenic antigens33. Exposure 
to the antigens leads to formation of a Th1 or Th2-cell immunological memory.  
When non-atopic individuals are exposed to allergens, they produce allergen-specific 
IgG1 and IgG4 antibodies 
34
. T-cells respond to the allergen with a moderate degree of 
proliferation and production of the characteristic Th1 cells cytokines interferon-gamma 
(IF-γ) and tumour growth factor-β (TGF-β) 35. In contrast, in individuals with atopic 
diseases there is an exaggerated response upon contact with allergens and 
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overproduction of allergen-specific IgE antibodies. These patients exhibit elevated 
serum concentrations of IgE antibodies and a positive skin prick test
35
. 
Upon first exposure to the inhaled allergen, atopic individuals produce allergen specific 
IgE as the allergens are engulfed by the antigen- presenting cells (APC), dendritic cells, 
and processed to be presented to CD4+ T cells by the major histocompatibility complex 
(MHC) class II molecules and T cell receptors. CD4+ T cells mature into Th2 cells 
releasing a number of  potent inflammatory cytokines including interleukin IL-4, IL-5, 
IL-6, IL-9 and IL-13
36
. IL-4 and IL-13 activate B cells to produce allergen specific IgE 
by binding on specific receptors on B cells. The specific IgE molecule binds to the high-
affinity receptor (FcεRI) found on mast cells and basophils (Figure 1.3).  
 
 
Figure 1.3. Inflammatory events in asthma (Holgate S.T., Polosa R. , Nature Reviews 
Immunology 8, 218-230 (March 2008)). 
19 
 
When the allergen interacts with IgE bound on the surface of mast cells or basophils 
through the alpha chain of the FcRI, granule-associate mediators, membrane-derived 
lipids, cytokines, and chemokines are released resulting in acute allergic reactions 
which begins within minutes of the exposure to the antibody
37
.  
The complex of allergen, IgE and FcRI triggers a non-cytoxic, energy-dependent 
release of granule-associated histamine and tryptase in addition to the membrane-
derived lipid mediator leukotrienes, prostaglandins and platelet-activating factor (Figure 
1.3).  Mast cells produce the 3 cysteinyl leukotrienes C4, D4 and E4, causing the 
contraction of smooth muscles, increased vascular permeability and hypersecretion of 
mucus in the airways
38
. Mast cells contain tryptase, a protease that activates the 
protease-activated receptor on endothelial and epithelial cells. The activation of these 
receptors results in further promotion of the inflammatory events in the lungs by 
activating airway epithelial cells to release cytokines, such as IL-6 and IL-8
39
.  
Cytokines released by mast cells and activated Th2 cells contribute to the recruitment of 
inflammatory cells taking part in the late allergic response such as eosinophils
40
. IL-5 
produced predominantly by Th2 cells, but also mast cells and eosinophils, acts on the 
IL-5R receptor expressed on eosinophils to promote their terminal differentiation and 
release from the bone marrow and also promotes eosinophil survival in the tissues
41,42
. 
IL-4 produced by Th2 cells promotes the infiltration of eosinophils by maintaining the 
autocrine development of Th2 lymphocytes
43
, whereas both IL-4 and IL-13 have been 
shown to directly activate the epithelium and the eotaxin (such as eotaxin-1
44
) 
production in mouse models of asthma
45
. Eosinophils expressing the CCR3 eotaxin 
receptors are recruited to the lung via the vascular endothelium cell surface molecules 
(e.g. selectins, integrins) interactions
46,47
.  In the late-phase reaction, the eosinophils and 
neutrophils accumulate in the airways and then mature CD4+ T cells and basophils 
infiltrate the site 
48-50
.Eosinophils, macrophages and monocytes also produce 
leukotrienes, basic proteins (cationic proteins, eosinophils peroxidise and major basic 
protein). Th1 and recently identified Th17 lymphocytes associated with neutrophilic 
inflammation
51,52
 also contribute to the inflammatory events in asthma
53,54
. 
It has been proposed that microbial exposure during early life promotes the 
development of a Th1-cell response, suggesting a protective role of microbes and 
providing a possible explanation of the “hygiene hypothesis” (Section 1.1.2). With the 
20 
 
increasing standards of hygiene and the lack of any microbial exposure, Th2-cell 
responses become predominant contributing to the asthma atopic phenotype
33
(Figure 
1.4). 
 
 
 
 
 
 
 
 
Figure 1.4. The Th1/Th2 response hypothesis for allergic diseases. 
 
The promotion of Th2 responses in favour of Th1 in atopic disease is determined by 
other factors such as, in utero development of the immune system, amount of allergen, 
duration of exposure to the allergen and avidity of interactions between T cells and 
antigen presenting cells
55
. There is also strong evidence that peripheral T-cell responses 
play a crucial role in the control of T-cell responses. These peripheral T-cells, referred 
to as T-regulatory (T-reg) cells, act to suppress specific allergen-stimulated lymphocyte 
proliferation and Th1, Th2-cell cytokine production 
56
. Many types of T-regulatory cell 
have been identified which produce IL-10 and Tumour Growth Factor-β (TGF-β) 
(Figures, 1.3 and 1.5). It has been proposed that an immune suppression of the T-
regulatory cells may contribute to a Th2-skewed immune response among atopic 
individuals
35,57
. The relationship of environmental exposures to T-regulatory cell 
function in immune-system ontogeny in early life remains to be elucidated. 
Influence of in utero and postnatal events can have a substantial effect in the postnatal 
function of the lungs and can determine the development of atopy and asthma
58
. Major 
determinants of the in utero environment effect are maternal smoking, fetal nutrition 
Th cells 
balance 
Microbial exposures during early life 
Microbial infections 
Rural environment 
Having one or more older siblings 
Th1 phenotype: IFN-γ, TNF-β 
 
Westernised lifestyle 
Urbanisation 
Diet 
Use of antibiotics  
Th2 phenotype: IL-4, IL-5, IL-6, 
IL-13 
 
Protective 
immunity 
Allergic diseases 
(asthma) 
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and the maternal diet
59
. Childhood is the second critical period that has been shown to 
be influential in determining disease. Critical risk factors in the period include parental 
history of asthma
60
, sex and the presence of other atopic conditions such as, allergic 
rhinitis, atopic dermatitis, urticaria or other types of allergy. Adolescence is an age 
group in which active and passive smoking has been identified as a important predictor 
of asthma associated with a high likelihood of new asthma onset
61
. Asthma 
development in adults can be categorised as late-onset asthma and occupational asthma 
which refers to the type of the disease occurring as a consequence of exposure to 
causative substances in the workplace. Therefore factors associated with asthma onset in 
adults  include indoor and outdoor air pollution, occupational exposures, as well as 
active and passive smoking
62-64,65
. Dampness and mould have been shown to be 
sufficient to create the poor indoor air quality conditions attributing in asthma
66
 during 
all age groups.  
 
Figure 1.5. Immune and inflammatory mechanisms in which Treg participate (Broide et 
al. Journal of Allergy and Clinical Immunology, 12 (560–572), 2008)67. 
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1.1.5 Asthma phenotypes 
Different asthma phenotypes have been identified based solely on the clinical or 
physiological criteria such as frequency and level of severity of symptoms, treatment-
resistance, age of onset, chronic restriction and exacerbations. Asthma has also been 
classified depending on the age, gender, type of inflammation, severity of the disease, 
atopic status and type of triggers
68,
 
69
. Based on these observations asthma can be 
classified into three types: mild, moderate and severe.  
 In addition, National and International guidelines have been proposed for the 
classification of the disease according to the severity following a number of 
fundamental criteria
70,71
 including lung function, type of medication and different 
biomarkers. Possible informative biomarkers could be transforming growth factor β 
(TGF-β)68, interleukin 11 (IL-11)72, tumour necrosis factor α (TNF- α)66,73, and 
interleukin 8 (IL-8)
74
. 
An exception to the above classification is the so called trigger-defined asthma.  This 
type of asthma relates to triggers such as, aspirin, environmental and occupational 
irritants, exercise and menses. Alternatively, the asthmatic phenotype could be 
classified according to the type of inflammation generated such as the eosinophilic, the 
neutrophilic and the pauci-granulocytic types of asthma. 
A considerable overlap is evident among the different disease categories. The 
identification of these patterns and their characteristics is critical as it will aid in the 
identification of improved biomarkers for each phenotype and in the development of 
more appropriate, effective and safer therapies for treatment of each phenotype.  
What is evident is that multiple mechanisms and pathways lead to the various clinical 
manifestations of the disease and some of these mechanisms are common in all types of 
asthma whereas others are likely to be specific to different phenotypes
75
. . 
 
1.1.6 Factors contributing to asthma 
Asthma is a complex disease that is influenced by both genetic and environmental 
factors. Complex or so called multi-factorial diseases show familial aggregation that 
does not follow simple Mendelian patterns of inheritance but instead the diseases are 
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determined by an unknown number of multiple genes, environmental factors and the 
interactions between them
76
. Examples of complex diseases include diabetes, obesity, 
coronary heart disease, hypertension, Parkinson‟s and Alzheimer‟s disease and various 
cancers. The genetic loci contributing to complex diseases could have small effects on 
the disease risk and their magnitude is possibly modulated by other genes or genomic 
interactions. 
First evidence that there is a genetic component for asthma came from observations of 
clustering of the disease between first degree relatives of affected individuals and then 
from twin studies. Twin studies for asthma have shown a greater concordance amongst 
monozygotic twins compared to dizygotic twins, with an estimated heritability ranging 
from 37% to nearly 80% 
77-80
. Monozygotic twins share the same genetic material 
whereas dizygotic twins share half their genes on average.  The higher concordance 
seen in asthmatic monozygotic twins therefore suggests that genetic factors contribute 
to the disease. Shared genetic factors have been found to explain better the familial 
aggregation of asthma than shared environmental factors
81
.  
Segregation analyses for asthma also provide support for the involvement of genetic 
factors 
82,83
. It is also more likely that these genes are inherited co-dominantly and that 
there is no major locus involved in asthma susceptibility. In some cases, a 
polygenic/multifactorial or an oligogenic mode of inheritance was detected for asthma 
depending on how the residual family effects were applied to the model
84
. In addition, 
when segregation analysis was applied for important quantitative traits of the disease, 
such as airway hyper-responsiveness, elevated serum IgE levels and elevated blood 
eosinophil counts, it was shown that different genetic loci are important in determining 
the effects on these traits
85
.   
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1.2 Mapping and identifying genes conferring susceptibility to asthma 
Historically, there have been two predominant approaches used to investigate the 
molecular genetics of asthma, the candidate gene-association study and the whole-
genome screen followed by positional cloning. The main advantage of association 
studies is that genes with modest effects can be detected whilst retaining adequate 
statistical power. Although linkage studies can reveal novel genes and/or pathways and 
genes with substantial effects, a larger number of subjects have to be studied in order to 
ensure there is sufficient statistical power to detect true positives. These two approaches 
should be however considered as complementary methods as it will be explained later. 
 
1.2.1 Linkage analysis studies 
Linkage studies involve the investigation of families and the transmission of alleles or 
chromosomal fragments from one generation to the next based on genetic linkage, 
which shows the tendency phenotypic traits and marker alleles, to co-segregate in a 
pedigree because their determinants lie in close proximity on a chromosome. Two loci 
are considered linked if the probability of separating during meiosis is less than 50%
86
.  
The measure of linkage is expressed with the logarithm of the ratio of the likelihood that 
the loci are linked to the likelihood the loci are not linked and it is called the LOD 
(logarithm of odds) score
87
. Linkage extends in wide genomic areas and it is usually the 
first step in genetic mapping strategies since it can identify novel genes present in a 
specific region
88
.  
Markers such as the microsatellites which were initially used in genetic studies are 
evenly spaced in the whole genome, they are genotyped and their segregation through 
the pedigree is investigated. Markers that lie close to a disease locus in the genome 
(“linked” to the disease locus) will show a strong correlation with the transmission of 
the disease. As mentioned already, linkage analysis identifies broad regions extending 
to several centiMorgans (cM) that contain the disease locus of interest. Consequently 
even if the density of the markers genotyped is increased, the region can potentially 
contain hundreds of genes, meaning that disease gene identification is not trivial.  
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The usual next step after having detected genetic linkage and narrowing down the 
region by saturation genotyping is positional cloning. Prior to completion of sequencing 
of the human genome this involved a number of techniques both in silico and in vitro to 
define the genes present in the area 
89, 90
. In our days, however all the genes in the 
human genome have been mapped and they are available in public databases, 
facilitating this step of analysis
91
. 
Linkage disequilibrium, the statistical association between two or more alleles at 
separate but linked loci, can also be used to refine the area since it extends in shorter 
regions in the genome
92
. Allelic frequencies of single markers can be compared between 
cases of disease and controls to localise the disease locus. 
Over the last decade, several microsatellite genome screens for complex disease gene 
mapping have been conducted including a number for asthma in a variety of ethnic 
groups including, Australians, African Americans, Hispanics, British, Japanese, French, 
Finnish Chinese, Dutch, Danish and Icelandic 
93,94
. These screens have resulted in ten 
regions of linkage that have replicated in at least one independent sample. So far, 
following on from the screens, positional cloning has resulted in seven genes being 
identified under the linkage peaks, ADAM33 (A disintegrin and metalloproteinase 
33;20p)
95
, PHF11 (Plant homeodomain finger protein 11; 13p12)
96
, DPP10 (Di-
peptidyl peptidase 10; 2q14)
97
, GPRA (G-protein-coupled receptor for asthma 
susceptibility; 7p14)
98
, HLA-G (Human Leukocyte Antigen G; 6p21) class Ib
99
, CYFIP2 
(Cytoplasmic FMR1 interacting protein 2; 5q33)
100
 and IRAKM  (IL-1 receptor-
associated kinase-M;12q13-24)
101
. 
ADAM33 was the first susceptibility gene identified by a linkage study followed by 
positional cloning
95
. The study involved 460 Caucasian affected sib-pair families from 
the UK and the USA and resulted in two signals on chromosome 20p13 being 
associated to bronchial-hyperresponsiveness and asthma. Positional cloning and fine 
mapping methods identified ADAM33 as the candidate gene in the region. The gene is 
expressed in airway smooth muscle and fibroblasts suggesting a role in the remodelling 
process, a main characteristic in the asthmatic lung. The association of the gene to 
asthma has been replicated in a number of studies with populations of different ethnic 
origin
102-106
. Other studies, however, were unable to detect any association between 
asthma and ADAM33
107-111
. Functional studies initially associated ADAM33 to impaired 
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early-life lung function, airflow limitation and bronchial hyperresponsiveness 
112-114
. 
ADAM-33-null animal models showed that ADAM33 is not an essential gene for allergic 
asthma development
115
. 
Another asthma associated gene that is expressed in the airway epithelium and was 
identified by positional cloning is DPP10
97
. Data from linkage studies for asthma and 
asthma-related phenotypes and from mouse genome screens reported a linkage signal in 
the 2q14-2q23 chromosomal region. Association studies and sequencing of the area 
identified the DPP10 gene, encoding for a protein that cleaves terminal dipeptides from 
cytokines and chemokines. Case-control association studies replicated the result in 
different populations
106,116
. A recent study showed that DPP10 is expressed and 
regulated in bronchial epithelium of the airways in naive and asthmatic rat lungs
117
. 
Chromosome 13q14 was initially identified as a locus linked with total serum IgE and 
atopy
118
. SNP fine mapping of the region showed that PHF11 was the locus associated 
to IgE levels
96
. The PHF11 variants were shown to be associated with severe asthma in 
the same study. The gene encoded for a nuclear PHD-domain finger protein possibly 
implicated in transcription regulation through PHD interaction with tri-methylated 
lysine residue 4 on histone 3, a mark of trascriptionally active genes
119
. Polymorphisms 
on PHF11 are in high LD with polymorphisms on a gene next to PHF11, SET domain 
bifurcated 2 gene (SETDB2) which encodes for a histone 3 methyltransferase
120-122
. The 
adjacent positions of these two genes suggest that they could be co-regulated and/or co-
expressed
96
. Both genes are expressed in T and B cells and they could be involved in the 
transcriptional regulation of genes playing a role in inflammatory events in asthma
96
. 
The specific role of these two genes and their relevance to asthma development awaits 
further investigation. 
A G protein-coupled receptor, GPRA was a susceptibility asthma gene identified, 
located in chromosome 7p
98
. The protein shows distinct distribution of protein isoforms 
between bronchial biopsies of asthmatic and healthy subjects and GPRA haplotypes 
were associated with high serum IgE and asthma in three cohorts from Finland and 
Canada. The same study showed that a mouse ortholog of the protein was up-regulated 
in a model of ovalbumin-induced inflammation, proving functional support for GPRA‟s 
involvement in the pathogenesis of asthma. Subsequent to the initial study identifying 
GPRA as an important genetic factor for asthma, polymorphisms and haplotypes of 
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GPRA gene have been shown to be significantly associated with asthma in European 
children
123
, German children
124
 and Italian families
125
. The B isoform of the protein was 
highly expressed in epithelium and smooth muscle in asthma implying a role in the 
airway smooth muscle contractility
98
. 
HLA-G, a gene contributing to immuno-suppression and fetal tolerance in the maternal-
fetal barrier was identified as an asthma susceptibility gene in a genome-wide linkage 
screen of 129 white families
99. A polymorphism in the 3‟ UTR region of the gene was 
significantly associated with asthma and it was located in a region that appears to be a 
sequence recognised and targeted by a micro-RNA so can possibly alter expression of 
the protein 
126
. Allelic-specific interactions to maternal affection status were also 
evident in the same study. 
Mutation screening and linkage studies including 155 families with asthmatics showed 
linkage of 6 polymorphisms of the gene CYFIP2 on chromosome 5q33, to asthma 
development
100
. An association of CYFIP2 variations to childhood asthma was 
subsequently reported
127
. The protein presented differential expression in a haplotype-
specific manner in human lymphocytes. CYFIP2 was identified as a p53 target possibly 
implicated in caspase activation and cellular apoptosis
128
. 
By linkage and linkage disequilibrium studies, the gene IRAKM, an IL-1 receptor-
associated kinase, was found to be associated with early-onset persistent asthma in 
Italian and Sardinian families
101
. The gene encodes for a regulator of the Toll-like 
receptor/IL-1R and the NF-kappa B pathways. Sequencing analysis in asthmatic 
patients identified inactivating mutations in the gene and immuno-histochemistry in 
lung biopsies showed that the protein is highly expressed in epithelial cells, suggesting a 
role of IRAKM in the innate immune system and chromic airway inflammation events 
interplay. No replication has been reported  for the association of IRAK-M with 
asthma
129
, nevertheless the functional role of the protein makes it an interesting asthma 
candidate gene and the findings remain to be further investigated. 
Linkage analysis and positional cloning has resulted in the identification of both novel 
genes and molecular pathways involved in asthma development. The approach, 
although effective at identifying genes with large effect sizes, can have limited 
statistical power to detect genes with modest effects, which importantly are the ones 
contributing to complex diseases such as asthma; therefore linkage studies require large 
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sample sizes to achieve the same power
130
. Replication is an important component of 
genetic linkage studies and the lack of it can call in to question the original findings.  
Failure to replicate can be due to a number of reasons including genetic heterogeneity, 
insufficient power of the replication studies, differences in the ascertainment methods or 
inconsistencies in the phenotype definition of the subjects
131
. 
 
1.2.2 Candidate gene-association studies  
The candidate gene approach of complex disease gene identification involves the study 
of groups of cases and controls in which markers of biologically plausible candidate 
genes are examined for their association to a disease. Candidate genes could be 
functional candidates for which biological information suggests that they could 
potentially be involved in asthma development.  The principle is to compare frequencies 
of the alleles between the case and control group and if a genetic association between a 
marker and the trait is identified, the gene is proposed as a candidate susceptibility gene 
for the trait that needs further investigation. A genetic association expresses the 
tendencies of two characters, such as a disease trait and a marker allele to occur together 
at non-random frequencies. Unlike linkage, the association is not a genetic phenomenon 
88
. If a positive association is found using either the population-based or family-based 
approach, it can be the result of identifying the real causative variant. Linkage 
disequilibrium between the studied allele and the real causative mutation is the most 
common goal of an association study and expresses the statistical association between 
marker alleles at loci that they are linked to as part of the same ancestral haplotype in 
the population. 
Although the study design is somewhat more straightforward there are nevertheless 
factors which need to be taken into consideration, such as the method to test the 
association, the selection of the markers and the population to study
132
.  
Candidate-gene association studies can be either population-based or family-based. In 
the first instance cases and controls from the same population need to be selected 
carefully and well-matched for age, sex and ethnicity to avoid population stratification 
in which a spurious association result can be found due to the presence of genetically 
distinct subsets within the population
133
. Family-based association uses the transmission 
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disequilibrium test (TDT) principle in which the transmission of specific alleles from 
the parents to affected probands is followed and the evidence of an increased 
transmission is tested
134,135
. TDT detects both genetic association and linkage and the 
results are unaffected by population stratification. 
Candidate gene approaches have resulted in the identification of several genes 
conferring susceptibility to asthma or asthma-related phenotypes such as bronchial 
hyper-responsiveness and levels of total serum IgE. Variants located in the promoters 
and the coding regions of more than 200 asthma candidate genes have been examined in 
over 600 studies
94,136
. 
A recent defining review of the state of genetics of asthma by Vercelli et al., utilised an 
excellent classification system to group the large variety of asthma candidate genes into 
4 key groups: 1) genes involved in innate immunity and immunoregulation, 2) genes 
associated with Th2- cell differentiation and effector functions, 3) genes associated with 
epithelial biology and mucosal immunity and 4) genes associated with airway 
obstruction and airway remodelling
94
. Group 1 contains genes connecting innate 
immunity to the immune response causing the immune response triggering events 
referred to as pattern recognition receptors (PRRs).  PRRs are expressed by a number of 
cell types providing evidence of the strong link between microbial exposure and 
reduced susceptibility to asthma. Several single nucleotide polymorphisms (SNPs) in 
CD14 
137
, TLR2 (Toll-like receptor 2) 
138
, NOD2 (Nucleotide-binding oligomerization 
domain 2) 
97
, TIM1 (T-cell immunoglobulin domain and mucin domain-1) 
139
  have 
shown association to asthmatic phenotypes revealing the importance of microbial 
recognition genes in the aetiology of the disease. 
The second group includes genes involved in the promotion of the Th2-cell 
inflammation phenotype which is prominent in asthma. Genes contributing in the Th2-
cell switch such as GATA3
140
 and its inhibitor transcription factor T bet
141
, IL-4
142
, IL-
4RA
143
, IL12B
144
 and STAT6
145
 have been reported to be associated with asthma and 
asthma-related phenotypes. Interleukin-13 (IL-13) has been extensively studied due to 
its fundamental role in Th2-cell mediated responses. Animal studies have shown that 
IL-13 can promote airway hyperresponsiveness, mucus hypersecretion and airway 
remodelling; all characteristics of Th2-cell inflammation
146,147
. IL-13 is highly 
expressed in the asthmatic airways
148
.  Several polymorphisms have been found to be 
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associated with asthma including a coding SNP IL13+2044GA which results in the 
substitution of arginine with glutamine  and influences the biological activity of the 
protein
97,149
.  The same SNP has also been shown to be associated with levels of total 
serum IgE
150
. A promoter SNP in the gene, IL13-1112CT, that has been shown to 
regulate the transcription of IL-13 and its secretion by mitogen-stimulated mononuclear 
cells, has also been found to be associated with asthma
151,152
. Another gene within this 
group of variants which have shown robust and replicated associations to asthma traits 
is the β chain of the high affinity receptor for IgE 129,153,154. A splice variant of the β 
gene was also found to regulate FcεRI surface expression levels which in turn could 
have an impact on epithelial inflammation 
155
. Further asthma-associated genes involved 
in Th-2-cell inflammatory responses are IL-5 and IL-5RA
156
.  
The third group of asthma candidate genes are expressed in airway epithelial cells. 
Epithelial-cell surface events are very important in asthma manifestations since these 
cells have a central role in the inflammatory-cell infiltration of the airways by attracting 
T cells and eosinophils through chemokines release. Uteroglobin/Clara cell (CC16) and 
eotaxin (CCL11) are two examples of chemokines found to contribute to the asthmatic 
phenotype
157,158
. Filaggrin (FLG), a recently identified gene expressed in the epidermis, 
oral and nasal mucosa has been associated with atopic dermatitis and eczema
159,160
, and 
also found to influence asthma
161,162
. FLG is a member of the epidermal differentiation 
complex in chromosome 1q21 and was initially investigated in atopic dermatitis due to 
FLG mutations causing ichthyosis vulgaris, a rare recessive Mendelian skin disease
163
. 
The association between asthma and FLG variations are found to be dependent of atopic 
dermatitis, suggesting that the epidermal skin barrier could be important in the 
development of asthma.  
Asthma severity, airway remodelling and airway obstruction are the key features of the 
fourth group of asthma candidate genes. One of the most studied and replicated genes in 
asthma pathogenesis is the β2-adrenergic receptor gene (ADRB2). Consideration of 
relevant drug pathways and the fact that beta-adrenergic receptor agonists are 
commonly prescribed for the treatment of asthma, has resulted in variants in the ADRB2 
gene being studied and found to be significantly associated with clinical asthma. The 
mechanism by which these variants regulate the receptor‟s activity however, remains to 
be elucidated 
164,165
.  
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Other candidate genes that have been investigated include HLA 
166
 and tumour necrosis 
factor (TNF) genes
167
  within the MHC on Chromosome 6p, the glutathione-S- 
transferases, GSTP1 and GSTM1
97,168
, thromboxane A2 receptor (TBXA2R)
169
, 
leukotriene C4 synthase (LTC4S)
170
, lymphotoxin-alpha (LTA)
167
 and arachidonate 5-
lipoxygenase (ALOX5)
171
.  
The major issue in these investigations is the replication of the findings across different 
studies to confirm their robustness. Therefore, similar to linkage/positional cloning 
studies, factors affecting the consistency of the results are true genetic heterogeneity and 
differences or limitations in the study design, which include an insufficient number of 
subjects, limited statistical power or multiple testing errors. Association analysis 
therefore has two key disadvantages. Because this approach is based on linkage 
disequilibrium or on testing the potential functional polymorphisms, the number of 
polymorphisms that need to be scanned in the entire genome is very high (>100,000). 
The second disadvantage is the diminishing power that occurs with high genetic 
heterogeneity due to population structure
172
. 
Case-control association studies have been used to study the role of the positional 
candidate genes identified by linkage studies, confirming the complementary role of 
these two types of genetic mapping approaches. The whole-genome linkage study 
strategy provides the unbiased hypothesis-free generation of data and the association 
study strategy provides the straightforward and powerful method to test these findings 
in multiple populations.  ADAM33 is a good example of a gene identified by a linkage 
study followed by replication of its association to asthma or related-phenotypes in 9 
subsequent genetic studies
136
. 
 
1.2.3 Genome Wide Association Studies (GWAS) for asthma 
The next step in the genetic mapping investigation was the launch of whole-genome 
association studies based on the original idea published by  Risch and Merikangas in 
1996
130
. The development of the strategy resulted from recent advances in genetics and 
genomics research. The completion of the Human Genome Project and the HapMap 
Project
173
 made the selection of the markers and the study design feasible since the 
common variations and their patterns across the genome is known. Simultaneously, the 
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development of genotyping platforms and the generation of marker chips covering the 
whole genome and the progress in statistical tools and bioinformatics have enabled the 
realisation of this type of study. Genome-wide association studies combine the 
advantages of whole genome scan linkage analysis and the robustness of association 
studies. The method involves genotyping a dense map of markers (SNPs) across the 
genome using the available commercial platforms in order to identify loci associated 
with the disease
174
. The strategy will be described in detail in Chapter 3, Section 3.1.1. 
The first whole-genome association study was conducted in Type II diabetes in 2007
175
. 
The first whole-genome association study for asthma was published in 2007
176
. More 
than 317,000 SNPs were genotyped in family and case-control panels including 994 
patients with childhood-onset asthma and 1,243 non-asthmatics as controls. A highly 
significant association on 17q21.1 was initially identified and this was replicated in an 
independent group of 2,320 German children as well as in 3,301 subjects from the 1958 
British Cohort study. Genome-wide gene expression data generated from the children of 
families in the original study revealed that transcript levels of the ORMDL3 gene were 
highly associated with a number of markers on the 17q21.1 locus. The identified 
markers were the same SNPs that had showed association with asthma suggesting that 
ORMDL3 could be the gene of importance at this locus. 
The initial chromosome 17q21.1 finding has been subsequently replicated in studies 
involving ethnically diverse populations including French-Canadian family trios
177
, 
Mexican and Puerto-Rican family trios 
178,179
, North American white subjects
180
, 
Scottish children and young adults
181
, Chinese
182
 and Japanese children
183
. Variants on 
17q21 chromosome were mainly reported to contribute to childhood asthma. A study by 
Bouzigon et al. confirmed the role of 17q21 locus in early-onset asthma and it also 
showed that environmental tobacco smoke exposures in early-life can enhance the risk 
of asthma 
184
. 
The second whole-genome association study conducted for asthma investigated the 
association of a SNP in the gene encoding the chitinase-like protein YKL-40 (gene 
annotation CHI3L1) and the asthmatic phenotype in a European founder population, the 
Hutterites 
185
. The results showed that a promoter SNP (-131C→G) in the CHI3L1 gene 
was highly associated with increased serum levels of the YKL-40 protein (P=1.1x10-
13), asthma (P=0.047) and bronchial hyperresponsiveness (P=0.002). The SNP was 
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shown to alter the transcription of CHI3L1 gene by disrupting the binding of 
transcription factors. The association was present when independent case referent panels 
were genotyped for the marker. YKL-40 serum levels were 15% higher in asthmatics 
and 10% higher in patients with bronchial hyperresponsiveness compared to controls. 
Serum levels of YKL-40 have been previously investigated in severe asthma and were 
found to be increased in asthmatics, proposing a role for the YKL-40 protein as a 
biomarker for asthma
186
. 
Both genome-wide studies shared common features essential for a successful and 
convincing outcome
187
. These included well-characterised population samples which 
allowed the researchers to identify genetic factors in a group of subjects with common 
genetic background of the disease; the populations were of sufficient size or 
homogeneity to allow replication of results and genome wide significance; independent 
case referent populations were used for testing the replication of the results and finally, 
the genetic association with asthma or asthma-related phenotypes was reinforced by 
studies confirming the functional role of these genes. 
Importantly, these genome-wide association studies highlight the need of collaborative 
schemes among research groups to obtain a sufficient number of well-characterised 
population samples thus providing statistical power to detect true causal loci. These 
newly identified asthma genes could contribute to different asthmatic phenotypes and 
they require further functional investigation to explain their specific role in the 
development of the disease
188
.   
Genome-wide association studies (GWAS) could be supported by genome-wide 
expression studies measuring global transcript levels and seeking association with 
particular loci. The idea is supported by the proposed theory that many variants 
associated with disease susceptibility cause a change in gene expression levels. 
Transcription, messenger RNA stability and maturation, splicing or translation are all 
stages that may be affected by a variant-induced expression changes within a gene. 
Therefore, cell-specific or tissue-specific whole-genome expression analysis can 
identify susceptibility variants
189
. Complex disease phenotypes can be regarded as 
quantitative traits themselves or relevant types of cells can be used for gene expression 
experiments, such as lymphocytes for asthma. In addition, gene expression levels can be 
used as surrogate and handled as quantitative traits, termed expression quantitative trait 
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loci (eQTLs), as it has been reported that they correlate with disease traits in 
families
96,190
. 
The first GWAS study
191
 for asthma is an example of the application of gene expression 
data in conjunction with a whole-genome association study. The transcript levels of 
Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines from asthmatic 
children were measured
176
 and examined in combination with genome wide SNP 
genotyping results. The consistent and strong association of the ORMLD3 transcript 
levels with the same markers that showed association with asthma on 17q21.1 was 
supportive of ORMDL3 as the novel asthma susceptibility gene in the region.  
 
1.2.4 Gene- environment and gene-gene interactions in asthma 
The effect of genetic and environmental factors is not independent and it is currently 
acknowledged that there is a great amount of interaction between them, modifying their 
distinct effects.  
In a genetic study examining the effect of variations in the genes of the IL-4 and IL-13 
pathway, it was found that the combined effect of polymorphisms in the IL-13, IL-4, IL-
4Rα and STAT6 genes resulted in an increased risk for high serum IgE levels and 
childhood asthma of 10.8-fold and 16.8-fold respectively
192
. These findings stress the 
significance of studying the combined effects of genetic factors rather than focusing on 
single genes. Investigating genomic interactions could elucidate novel pathways 
involved in both the development and progression of a complex disease like asthma.  
The heritability of asthma varies between 37 to 80%, leaving a remaining 20 to 60% for 
the influence of environmental factors (Section 1.1.7)
193,194
. Studies have also proposed 
that the effects of environmental and genetic factors are equal
195
. It is highly likely that 
interactions exist between the genetic and environmental factors described in paragraph 
1.1.4. An example of a potential gene x environment interaction came from a study 
exploring the effect of environmental exposures and the direction of association with 
asthma of CD14 poymorphisms
196
. Interestingly, it was found that direction of 
association of CD14/-260 C-->T SNP to levels of both total and specific serum IgE to 
aeroallergens was the opposite between children raised in contact with pets compared to 
children raised in contact with stable animals. The CD14 polymorphisms have been 
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widely studied in relation to exposure to different environmental factors and the 
diversity of observed results could be explained by the variable effect of the different 
exposures
94
.  
As increasing numbers of genes and important environmental factors are identified, it 
presents the opportunity to examine genetic x genetic and genetic x environmental 
interactions and explain their effects in asthma development. 
Although much has been learnt about the genetic mechanisms underlying asthma in the 
last decade, it is estimated that less than 30% of the genetic susceptibility factors have 
been identified so far 
197
.  Further investigation is therefore warranted in order to fully 
understand the disease.  
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1.3 Severe or “difficult/therapy-resistant” asthma  
Asthma might not be one single disease but rather a syndrome encompassing discrete 
pathological conditions
198,199
.  
Severe or “difficult/therapy-resistant” asthma refers to asthma that is poorly controlled 
in terms of persistent symptoms, episodic exacerbations and persistent and variable 
airway obstruction despite the use of high doses of inhaled corticosteroids, long-acting 
bronchodilators and short β2 agonists 
200
. This form of asthma represents less than 10% 
of the disease but it is related to substantial economic burden due to the significant 
morbidity among these patients (Section 1.1.4).  
Different guidelines have been formed to facilitate the consensus definition of severe 
asthma in the scientific community. The Global Initiative for Asthma (GINA)
201
 and the  
National Asthma Education and Prevention Program (NAEPP) 
70
 have proposed 
guidelines for the definition of the disease severity according to the use of short-acting 
bronchodilators, nocturnal symptoms, baseline pulmonary function measurements and 
frequency of the exacerbations (Table 1.1). 
The American Thoracic Society (ATS) workshop in 2000
202
 formulated a definition of 
severe asthma which includes both major and minor criteria related to not only regular 
use of inhaled corticosteroids but also health care utilization. It was concluded that 
severe asthmatics should meet 1 or 2 major criteria and 2 of the 7 minor criteria (Table 
1.2).  
Studies showing that the classification strategies accounting for the health care 
utilization of the severe asthmatic patients are very powerful, including the NAEPP with 
physician assessment in The Epidemiology and Natural History of Asthma: Outcomes 
and Treatment Regimens (TENOR) cohort study
203
 and a study correlated the inpatients 
hospitalisations and emergency hospital visits to physician classification of the severity 
of asthma
204
. 
The pathophysiology of severe asthma when compared to the mild type has two 
prominent characteristics; persistent eosinophilia, that remains unresponsive despite 
high-dose corticosteroid treatment, and the accompanying neutrophilic 
inflammation
68,205-209
. It is also evident from the studies that severe asthma can be 
37 
 
divided into different inflammatory phenotypes which could explain the discrepancy in 
the response of severe asthmatics to corticosteroids.  
 
 
PEF, Peak Expiratory Flow; the speed of the air moving out of the lungs at the beginning of the 
expiration, (lt/sec) 
 FEV1, Forced Expiratory Volume in one second, the amount of air that one can forcibly blow out in one 
second, (lt) 
• The presence of one of the features of severity is sufficient to place a patient in that category. 
• Patients at any level of severity-even intermittent asthma-can have severe attacks. 
 
Table 1.1. GINA asthma classification criteria
210
. 
 
 
 
 
 
 
 Symptoms/Day Symptoms/Night PEF or 
FEV1 
PEF 
variability 
STEP1 
Intermittent 
< 1 time a week 
Asymptomatic 
and normal PEF 
between attacks 
</= 2 times a 
month 
  
>/= 80% 
  
< 20% 
  
STEP 2 
Mild       
Persistent 
> 1 time a week 
but < 1 time a day 
Attacks may 
affect activity 
> 2 times a month 
  
>/= 80% 
  
20-30% 
  
STEP 3 
Moderate 
Persistent 
Daily 
 
Attacks affect 
activity 
> 1 time a week 
  
60%-80% 
  
> 30% 
  
STEP 4 
Severe    
Persistent 
Continuous 
 
Limited physical 
activity 
Frequent 
  
</= 60% 
  
> 30% 
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Major Criteria 
To achieve control to level of mild-moderate persistent asthma 
1. Treatment with continuous or near continuous ( 50 percent of year) oral glucocorticoids 
2. Treatment with high-dose inhaled glucocorticoids: 
Beclomethasone >1260 mcg/day 
Budesonide >1200 mcg/day 
Flunisolide >2000 mcg/day 
Fluticasone >880 mcg/day 
Triamcinolone >2000 mcg/day 
Minor criteria 
1. Requirement for additional daily treatment with a controller medication, eg, long-acting -
agonist, theophylline, or leukotriene antagonist 
2. Asthma symptoms requiring short-acting -agonist use on a daily or near daily basis 
3. Persistent airflow limitation (FEV1 <80 percent predicted; diurnal peak expiratory flow 
variability >20 percent) 
4. One or more urgent care visits for asthma per year 
5. Three or more oral glucocorticoid bursts per year 
6. Prompt deterioration with 25 percent reduction in oral or inhaled glucocorticoid dose 
7. Near-fatal asthma event in the past 
 
Table 1.2. The American Thoracic Society workshop consensus criteria for the 
definition of severe refractory asthma
202
. 
 
Additional highlighted factors in the characterisation of the severe asthmatic phenotype 
include the age of onset and the differences between childhood and adult severe asthma, 
the corticosteroid insensitivity and the chronic airway obstruction.  
Interestingly in cases of severe asthma that have emerged later in life (late-onset 
asthma) the duration of the obstruction is significantly shorter despite the same or a 
worse degree of airway obstruction observed 
211,
 
68
. Also, these patients had a smaller 
degree of atopy by skin prick test and lower IgE levels compared to patients with age-
onset in childhood.  
Lung function tests such as FEV1 do not allow distinction between steroid-sensitive 
severe and difficult/therapy resistant severe asthma 
212
. The steroid-insensitive patients 
also presented >30% variability in their FEV1, a measure of airway limitation. 
Differences in the molecular pathways and glucocorticoid-related genes possibly 
generate specific inflammation types causing the lack of responsiveness to 
corticosteroids
213,214
.   
39 
 
Persistent airway obstruction is not present in all severe asthmatics even though it is one 
of the criteria for severe asthma definition. Different biomarkers have been shown to be 
involved in severe asthma with and without low FEV1. Blood eosinophilia, bronchial 
wall thickening and exhaled nitric oxide (NO) has been shown to be higher in severe 
asthmatics with severe airway limitation although this was only observed for patients 
who were older with a longer disease duration
200
. The disease duration, older age and 
sputum eosinophilia were also associated with persistent airflow limitation in studies 
implying that eosinophilic inflammation in the airways could be implicated in the 
severe airway limitation and can be used for the identification of specific severe 
asthmatic phenotypes
68,215
.  
The high degree of variability in defining the severe asthma compared to mild asthma 
and/or moderate asthma could propose that this asthmatic sub-phenotype has distinctive 
genetic basis than the other asthmatic phenotypes. The identification of relevant 
biomarkers would be the optimal solution for the characterisation of the asthmatic sub-
phenotypes and the assignment of the appropriate treatment as mentioned above. 
 
1.3.1 Severe asthma used as the extreme differentiated phenotype for genetic 
mapping studies 
Selecting individuals representing the extreme phenotype, such as severe asthma, can 
increase the probability of sampling a genetic variant influencing the trait of interest. 
Genetic studies including individuals with this extremely differentiated phenotype could 
potentially offer a very efficient strategy for isolating the genetic features associated 
with the disease, since these patients have a greater chance of carrying the characteristic 
genetic determinants. Indeed, the study can include even a small number of severely 
affected subjects and retain high statistical power. This strategy has been used in 
dissecting the genetic basis of other complex diseases such as obesity where severely or 
morbidly obese probands were selected to enrich the study for susceptibility loci
200,216
.   
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1.4 Aims of the Thesis 
To carry out a case-control study including severe asthmatic children and adults (cases) 
and mild asthmatics and healthy individuals (controls) testing the GWAS
191
 findings in 
childhood asthma. To further investigate the findings by using fine mapping genotyping 
strategies in the candidate loci. To examine the functional role of the asthma-associated 
variations by utilising molecular biology techniques and eQTL analysis data.  
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Chapter II: General Methods and Materials 
 
2.1 Materials 
2.1.1 Solutions and reagents 
  
All solutions and reagents for DNA extraction, whole-genome amplification and 
TaqMan
®
 SNP genotyping assays were provided by the manufacturers.  
 
Cell culture solutions 
Dulbecco’s Modified Eagles Medium (DMEM) (Sigma) 
DMEM was supplemented with 2mM L-glutamate (Sigma) and heat-inactivated 10% 
Foetal Bovine Serum (FBS – supplier PAA) under aseptic conditions and kept at 4o C 
until required. 
 
RPMI1640 media (Sigma)  
RPMI1640 was supplemented with 2mM L-glutamate (Sigma) and heat-inactivated 
10% Foetal Bovine Serum, FBS, (PAA) under aseptic conditions and kept at 4 
o
C until 
required.  
Trypsin-EDTA (10X) 
5.0g porcine trypsin and 2.0g EDTA were added to 1 litre 0.9% sterile sodium chloride 
(NaCl, Sigma) under aseptic conditions in a flow hood. 
For use the solution was diluted 1:10 with Hanks Balanced Salt Solution (HBSS, 
Sigma).  
Cell Freezing Medium-DMSO 
Dimethylsulfoxide (DMSO) (Sigma) was mixed with heat-inactivated FBS (PAA) 1:10 
dilution under aseptic conditions in a flow hood and stored at -20
o
C until required.  
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Table 2.1.Cell lines used and their culture specifications 
 
 
 
 
 
 
 
 
 
 
 
Cell 
line 
Media Supplements Culture 
conditions 
Cell 
properties 
Cell type 
A549 DMEM 10% FBS 
2mM L-
Glutamate 
37
o
C, 5% 
CO2 
Adherent Epithelial 
Daudi RPMI1640 10% FBS 
2mM L-
Glutamate 
37
o
C, 5% 
CO2 
Suspension B cell 
Jurkat RPMI1640 10% FBS 
2mM L-
Glutamate 
37
o
C, 5% 
CO2 
Suspension T cell 
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2.2 Methods 
This section provides detailed information on the practical laboratory procedures carried 
out for this thesis.  Unless otherwise stated all practical work was carried out by the 
author. 
 
2.2.1 Clinical collections  
Severe asthmatic adults and severe asthmatic children were recruited from severe 
asthma clinics within the UK. The first set of samples (Set 1) consisted of extracted 
DNA samples from 241 severely affected adults and 39 severely affected children 
provided by Professors Fan Chung and Ian Adcock (National Heart and Lung Institute, 
Imperial College & Royal Brompton Hospital, London). Additionally, DNA samples 
from 111 mild asthmatic adults were obtained. For all patients, asthma was physician 
diagnosed, FEV
1
 (the amount of air that one can forcibly blow out in one second [L]) 
Table 2.2. Total number of asthmatic subjects in the study. 
 
was measured before and after inhaling 400 μg of salbutamol from a metered-dose 
inhaler of >12% of baseline FEV
1
 and bronchial hyperresponsiveness to methacholine 
was also measured. Asthma was defined as severe according to the ATS criteria
202,217
. 
The major criterion for entry in the study was determined by their use of either 
continuous oral corticosteroids or high dose inhaled corticosteroids or both in order to 
  SUBJECT SET  
1 
SUBJECT SET 2 TOTAL 
Severe asthmatic 
adults 
240 157 397 
Severe asthmatic 
children 
39 77 116 
Mild asthmatic 
adults 
111 - 111 
TOTAL 390 234 624 
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achieve control of asthma to a level of mild-moderate persistent asthma. These patients 
were also required to present 2 or more of the minor criteria (Chapter I, Section 1.3).   
The next set of subjects, Set 2 included 157 severely asthmatic adults from Glenfield 
Hospital adult clinic recruited by Prof Chris Brightling, University of Leicester and 77 
severely affected children from the Royal Brompton paediatric clinic recruited by Prof 
Andrew Bush, NHLI. For the severe asthmatic adults from Glenfield Hospital clinic a 
full patient characterisation was available according to a specialised protocol that 
included parameters of airway inflammation, airway physiology and quality of life and 
control symptoms
218,219
.For severe asthma definition in the paediatric clinic the GINA 
criteria were followed
210
. Severe asthma was defined as Step 4 severe/persistent asthma 
which includes patients with continuous symptoms during the day, frequent during the 
night and FEV1</= 60% (Chapter I, Section 1.3).  
For Set 2 samples whole blood was collected into EDTA vacutainers from both children 
and adults by standard venepuncture and stored at -80ºC prior to DNA extraction. In 
some cases collection of a blood sample from the asthmatic children was not possible 
and instead a saliva sample was obtained using the Oragene collection system. Genotek 
(http://www.dnagenotek.com/) vials containing the Oragene·DNA solution were used 
and stored at room temperature (RT) until DNA extraction. 
In total, 397 severe asthmatic adults and 116 severe asthmatic children were included in 
the study, Table 2.2 shows the number of severe, moderate and mild asthmatics of Set 1 
and Set 2 as subdivided in adulthood and childhood asthma. In the severe asthmatics 
adult group, mean age, yr (SD
a
) was 47.17 (13.85) and sex ratio (male:female) was 1:2. 
For 240 subjects the atopic status according to skin prick tests was known and FEV% 
pre-agonist measurements were available. Also, IgE measurements were available for 
157 subjects. In the children group, mean age, yr (SD
a
) was 11.96 (2.69) and sex ratio 
(male:female) was 3:2. Table 2.3 summarises the phenotype information of the 640 
subjects. 
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Table 2.3. Phenotypic description of the subjects in Set 1 and Set 2 sample panels. 
 
For the genotyping study (Chapters III and IV) extracted DNA from individuals of the 
MRC-A panel of families, previously recruited by the Molecular Genetics Group, 
NHLI, Imperial College, was also used
220
.  The MRC-A panel consists of 207 families 
that were recruited through a proband with severe asthma (Step III) asthma or worse 
according to British Thoracic Society guidelines
5
 (Table 2.4). Probands had to have 
more than one hospital admission for asthma in the last 5 years and use maintenance-
inhaled steroids (Table 2.5). For all subjects, skin prick testing was carried out to the 
common allergens Dermatophagoides pteronyssinus, (House Dust Mite - HDM) 
Phleum pratense (Timothy Grass pollen - Grass), Felis domesticus (cat dander - Cat), 
Aspergillus Fumigatus (Mould - Asp), Cladosporium Herbarum (Mould - Clad) and a 
negative control.  Additionally, total serum IgE and specific IgE measurements for 
HDM and grass and total eosinophilic counts had been performed. Asthma was defined 
as a positive response to the question „Has your doctor ever told you that you have 
asthma?‟.The sex ratio for adults was male:female, 1:1 and the mean age in yr, (range) 
was 41 (24-64). For the children the sex ratio was male:female, 2:3 and the mean age in 
yr (range) was 11 (2-39).  
 Severe asthmatic adults Severe asthmatic children Mild 
asthmatic 
adults 
 Sample 
Set 1 
(N= 240) 
Sample 
Set 2 
(N=157) 
Combined 
(N=397) 
Sample 
Set 1 
(N=39) 
Sample 
Set 2 
(N=77) 
Combined 
(N=116) 
Sample 
Set 1 
(N=111) 
Mean age, 
yr (SD
a
) 
44.41 
(13.69) 
51.45 
(13.01) 
47.17 
(13.85) 
11.30 
(3.15) 
12.4 
(2.55) 
12.05 
(2.80) 
29.49 
(8.10) 
Sex ratio 
(F:M) 
2:1 3:2 2:1 1:2 3:4 2:3 3:4 
FEV%, % 
(SD
a
) 
64.3 
(19.6) 
- - - 
76.8 
(18.49) 
- 90.0 (13.2) 
Atopic/No
n-atopic 
(%) 
46:54 - - - 74:26 - 43:56 
IgE, IU/lt 
(SD
a
) - 
258.6 
(464.9) 
- - 
1204 
(2829.6) 
- 
-  
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Table 2.4. Ascertainment criteria for the probands of the MRC-A panel.  
 
 
Table 2.5. The MRC-A panel subjects. 
 
2.2.2 DNA extraction  
2.2.2.1 DNA Extraction from whole blood 
DNA was extracted from whole blood samples using the Wizard
®
 Genomic DNA 
Purification Kit (Promega). The kit can be applied to DNA isolation from white cells, 
tissue culture cells, animal and plant tissue, yeast, Gram positive and Gram negative 
bacteria with typical yield depending on the specific type of the sample. For human 
whole blood, the yield depends on the quantity of the white blood cells present and it 
can therefore range from 250 to 500μg from 10ml of starting material. 
The DNA extraction procedure involves a four-step process 
221
: In the first step of the 
protocol, depending on volume of blood obtained either 3ml or 9ml was transferred to a 
sterile 15ml or 35ml tube containing 3X volumes of the Cell Lysis solution.  After 
Inclusion Criteria 
 The patient must be on maintenance inhaled steroids 
 The patient must have had one hospital admission in the last 5 years or receiving 
“STEP 3” asthma management 
 The patient must be between 5 and 25 years of age 
 The patient must have at least 1 sibling 
 Both parents must be alive 
Exclusion Criteria 
 Presence of cystic fibrosis, bronchiectasis, chronic lung disease 
 Asthmatic Non-asthmatic Total 
Probands and siblings 321 140 461 
Parents 130 291 421 
Total 451 431  
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thorough mixing the tube was incubated at RT for 15 minutes to lyse the red blood cells 
after which samples were spun at 3,750rpm for 10 min at room temperature. The 
supernatant was removed and discarded and the pellet was vortexed vigorously for 30 
seconds to re-suspend the white blood cells. This step was repeated to remove the 
remaining red blood cells and the pellet appeared white. In the next step, 3ml or 9ml 
Nuclei Lysis Solution was added to the tube and after mixing it was incubated at 37
o
C 
for at least 3 hours or more ideally overnight. After incubation and allowing the samples 
to cool, 1ml or 3ml (depending on original whole blood sample volume) Protein 
Precipitation solution was added to the nuclear lysate and after vortexing the solution 
was centrifuged at 3,750rpm for 10 min at room temperature. The supernatant 
containing the DNA was transferred to either a 15ml or 50ml sterile tube and the DNA 
precipitated by the addition of 3ml or 9ml isopropanol followed by gentle mixing. DNA 
was then pelleted by centrifugation for 10 minutes at 3,750rpm at RT, washed with 70% 
ethanol and re-pelleted as before. The supernatant was carefully discarded and the tube 
allowed to air dry for 30 min. Depending of the volume of the blood samples DNA 
Rehydration Solution was added to the DNA pellet for re-suspension. The samples were 
initially incubated at 4
o
C for 2-5 days to rehydrate and then stored at -20
o
C until 
required. 
 
2.2.2.2 DNA extraction from saliva 
The Oragene
®
·DNA collection system (DNA Genotek) was used to collect saliva for 
DNA extraction from asthmatic children. The Oragene·DNA kit can capture a median 
yield of DNA of 110μg from 2ml of saliva. After the saliva collection, DNA is 
stabilized by mixing with the Oragene·DNA solution allowing storage at RT. For DNA 
extraction, the Oragene·DNA/saliva sample was thoroughly mixed by inverting the vial, 
and incubated at 50
o
C in an air incubator. After 2 hours, 500μl of the sample was 
transferred to a 1.5ml microcentrifuge tube and 20μl of the Oragene·DNA Purifier was 
added to the tube. The tube was vortexed for 20sec and incubated on ice for 10min. The 
sample was then centrifuged at 13,000rpm RT for 5min after which the supernatant was 
carefully transferred into a fresh microcentrifuge tube containing 500μl of room-
temperature 100% ethanol to allow DNA precipitation. After centrifugation at 
13,000rpm RT for 2min, the supernatant was discarded and the DNA pellet was washed 
with 500μl 70% ethanol and it was centrifuged at 13,000rpm. The supernatant was 
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discarded and the pellet was dissolved in 100 μl TE (10 mM Tris-HCl, 1 mM EDTA, 
pH 8.0) (Sigma). The samples were initially incubated at 4
o
 C for 2-5 days for 
rehydration followed by storage at -20
o 
C until required. 
 
2.2.2.3 DNA quantitation 
DNA samples were quantified using NanoDrop
® 
ND-1000 UV-Vis 
Spectrophotometer.
222
. The NanoDrop
®
 Spectrophotometer uses fiber optic technology 
and surface tension to hold a drop of 1 μl of DNA sample between two optical surfaces, 
which defines the path length for the measurement. The surfaces were initially wiped 
with 70% ethanol followed by pipetting 2μl of RNase-free water (Qiagen) onto the 
lower optical surface. The lever arm of the NanoDrop
®
 was closed to allow cleaning of 
both optical surfaces. The water was wiped and the NanoDrop
®
 software was opened 
selecting the nucleic acid measurement module. The spectrophotometer was initialized 
by placing 1μl of RNase-free water and the surfaces were wiped once again. A blank 
measurement was performed by loading 1 μl of RNase-free water. After this, the 
spectrophotometer was ready to perform the DNA concentration measurements by 
loading 1 μl of each sample. Once the measurement was complete the optical surfaces 
were cleaned with 70% ethanol. 
 
2.2.3 Whole-Genome amplification by REPLI-g 
In this study, whole genome amplification was performed for 163 DNA samples since 
their concentrations were low and not optimal for the subsequent genotyping steps. 
Acquiring the adequate amount and quality of DNA in a genotyping study is a pre-
requisite since it determines genotyping success rate.  
 
In the past, different whole genome amplification methods have been used.  These have 
been  based on degenerate oligonucleotide primed PCR 
223
 modifications thereof
224,225
 
primer extension pre-amplification
226
 and improved extension pre-amplification 
227
. A 
commercial kit, REPLI-g by Qiagen was used in this study which applies a simple 
isothermal reaction called the multiple displacement amplification (MDA) method 
228
.  
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The REPLI-g kit allows uniform amplification of whole genomic DNA from small 
samples. The yield obtained does depend on the quality of the initial template but using 
the REPLI-g Mini kit and a reaction volume of 50μl it is possible to obtain a minimum 
of 10μg of DNA. The whole genome amplification method uses the highly processive 
φ29 DNA polymerase and random exonuclease-resistant primers in an amplification 
reaction
229
 (Figure 2.1). The enzyme, derived from Bacillus subtilis phage φ29 contains 
an inherent „3 to 5‟ exonuclease activity that enables proofreading capability and thus 
increases the fidelity of the method 
230
. Due to the strand displacement capability of 
φ29, the reaction does not require repetitive cycles of denaturation and annealing, and 
consequently the longevity and activity of the polymerase during the reaction is 
increased
231
 
232
.  Another advantage of the method is the use of potassium hydroxide 
KOH alkali denaturation which is more efficient in creating potential priming sites than 
the classic thermal denaturation step used by other DNA amplification methods.  
The MDA method has been tested in terms of production of sufficient amounts of DNA 
necessary for large-scale genotyping, genome coverage and accuracy of genotyping 
calls 
233
. The MDA technique has been shown to produce robust and representative 
DNA suitable for use in a variety of experiments including TaqMan
®234-237
, short 
tandem repeat analysis
129,234,236,238
, bead array assays
239
, mass spectrometry
240
, 
GeneChip
®241-243
, single-stranded conformation polymorphism
226
, comparative genome 
hybridization array 
226,244
, pyrosequencing
237,245
, DNA sequencing
237,246
 and gel 
analysis
247
. Compared to standard PCR-based methods it was shown to introduce the 
lowest amplification bias 
248
.  
 
 
 
Figure 2.1 Schematic Representation of REPLI-g Amplification:  Phi 29 DNA 
polymerase moves along the DNA template strand displacing the complementary 
strand. The displaced strand becomes a template for replication allowing high yields of 
high-molecular-weight DNA to be generated. (red bar:original DNA strand, small grey 
and red bars:the primers, pale red bar: the new generated original stand). 
(http://www1.qiagen.com/products/genomicdnastabilizationpurification/replig/repligmi
nimidikits.aspx#Tabs=t1. 
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2.2.3.1 REPLI-g whole-genome amplification protocol  
For each REPLI-g reaction, 5μl of each of the template DNA samples (>10 ng) was 
denatured by adding 5μl Solution B-denaturation buffer (0.4 M KOH,10 mM EDTA) in  
microcentrifuge tubes. After mixing by vortexing and a brief centrifugation, the samples 
were incubated at RT (15-25
oC) for three min. 10μl of Stop Solution (1:10 dilution of 
Repli-G Solution B) was then added to the incubated reactions. A solution consisting of 
29 μl REPLI-g Mini Reaction Buffer and 1 μl of REPLI-g Mini DNA Polymerase was 
prepared and added to the 20μl of denatured, neutralized genomic DNA samples. After 
mixing the samples were incubated at 30°C for 14 hours. The samples were then heat 
inactivated at 65°C for 10 min and then transferred into 96-well plates for storage at -
20
o
C until required. NanoDrop
® 
ND-1000 UV-Vis Spectrophotometer was used to 
establish DNA concentrations of the samples prior to their use in downstream 
genotyping (Sections 2.2.2.3 and 2.2.4). 
 
2.2.4 Agarose gel electrophoresis and DNA visualisation 
 
DNA was visualised and DNA fragments were separated using agarose gels 
electrophoresis. The method is based on the migration of negatively charged DNA 
through the agarose matrix in an electric field. Shorter DNA molecules move more 
quickly and migrate further than the longer products. DNA fragments ranging from 50 
bp to several megabases can be separated by this method. Visualisation of the DNA 
fragments was achieved by adding ethidium bromide (EtBr) to the agarose gel. EtBr is a 
DNA intercalating factor which fluoresces under ultra violet (UV) light.  
 
A 100ml agarose gel was prepared by mixing 90ml of ddH2O, 10ml of 10X Tris- Borate 
EDTA, TBE (Sigma) and the appropriate amount of agarose (Sigma) in grams (g) 
depending on the desired agarose gel concentration (e.g. for a 2% w/v agarose gel, 2 g 
of agarose were added). The solution was brought just to the boil in a microwave oven 
(Sharp Rotisserie, Jet & Grill Microwave Convection Oven) to dissolve the agarose. It 
was then left to cool down to about 60
oC at room temperature and 4 μl of 10mg/ml EtBr 
was added and mixed by stirring. The agarose solution was poured into a gel tray and a 
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well comb was inserted. The gel was left to cool down and become solid at room 
temperature. 
 
The combs were removed and the rack with the gel was put into an electrophoresis tank 
containing the running buffer consisting of 800 ml of 1X TBE. The DNA samples were 
prepared by mixing 5 μl of each sample with 5 μl of loading dye Blue/Orange 1X 
(Promega). They were then loaded on the gel. A DNA ladder was also loaded in the gel, 
1μl of 0.5μg/ μl, to allow an estimation of the size of DNA fragments (New England 
Biolabs No. N3231S, Figure 2.2).The gel was run at 95 Volts
 
(V) for approximately 1 
hour. Following electrophoresis the gel was visualised under a UV Illuminator 
(FirstLight
®
 UV Illuminator, UVP). 
 
 
Figure 2.2. 100 bp DNA Ladder visualized by ethidium bromide staining on a 1.3% 
TAE agarose gel. Mass values are for 0.5 µg/lane (Image taken from 
http://www.neb.com/nebecomm/products/productN3231.asp).  
 
 
2.2.5 Quality test PCR reaction 
 
A test PCR was conducted to assess the quality of DNA. The method has been used for 
a number of years by the Molecular Genetics Group. The test PCR amplicon  (184bp) 
included a 15 bp deletion on the 3‟UTR of the regulator of chromosome condensation 
and BTB (PDZ) domain containing protein 1 (RCBTB1) gene.  
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PCR reactions were set up with appropriate reagents  and the primers: 
5‟-GGAACACCATAATTTTGGTG-3‟   Forward primer 
3‟-TCTTCAAGTCAACCCTCTTA-5‟    Reverse primer 
The PCR reaction consisted of 5μl of DNA 10ng/μl mixed with 1X Reaction buffer 
(BIOLINE), 2mM dNTPs (BIOLINE), 5pmol/μl of both primers (MWG), 2mM MgCl2 
(BIOLINE) and 0.4 U BIOTAQ
TM 
in final volume of 10μl. The PCR cycling conditions 
were 31 cycles of 95
o
C for 1min, 50
o
C for 1 min and 72
o
C for 45sec (PTC-225,MJ 
Research, Peltier Thermal Cycler,  http://www.gmi-
inc.com/BioTechLab/mjresearchptc100.htm).  
 
2.2.6 TaqMan
® 
Genotyping Assays 
2.2.6.1 Assay principle 
TaqMan
®
 genotyping relies on the 5‟ nuclease activity of the Thermus aquaticus (Taq) 
polymerase used to amplify and detect specific SNP alleles in purified DNA samples. 
Each TaqMan
®
 assay contains two primers for amplifying the sequence of interest and 
two TaqMan
®
 Minor Grove Binder (MBG)
249
 probes for detecting the alleles. The 
presence of two probe pairs in each reaction allows genotyping of the two possible 
variant alleles at the polymorphic site. The genotyping assay determines the presence or 
absence of a SNP based on the change in fluorescence of the two dyes associated with 
the allele-specific probes.  
 The TaqMan
®
 MGB probes are 13-20bp long and are designed to be perfectly 
complementary to the DNA region containing the SNP site. A reporter dye (VIC
®
 or 
6FAM
™) is conjugated to the 5‟ end of each probe allowing discrimination between the 
two SNP alleles. In addition, a non-fluorescent quencher (NFQ) is included at the 3‟ 
end of the probe. When the probe is intact, the proximity of the quencher dye to the 
reporter dye eliminates the reporter fluorescent signal caused by fluorescent resonance 
energy transfer (FRET)
250
. During the PCR reaction AmpliTaq Gold DNA Polymerase 
Ultra Pure (UP) cleaves only the probes that are hybridised to the target site. Due to the 
probe degradation, the reporter separates from the quencher thereby generating a 
fluorescence signal. The primers amplify the sequence containing the SNP and each 
fluorescently labelled probe hybridises and reports the presence of the specific allele. 
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The signal is therefore amplified in every PCR cycle and when measured it indicates 
which specific allele is present in the sample (Figure 2.3).  
The minor grove binding ability of the fluorescent probes provides an efficient allelic 
discrimination, because the MGB stabilises the binding of probe to the template, 
thereby increasing the melting temperature (Tm) of the probe length without increasing 
probe legth
249
. The mismatch discrimination between shorter probes is increased and as 
a result the allele specificity is enhanced. Also, the signal-to-noise ratio of the assays is 
increased because the reduced distance between the fluorophore bound on the 5‟ of the 
sequence and the quencher bound to the 3‟ of the sequence is reduced resulting in a 
more efficient quenching of the intact probe.   
        
2.2.6.2 Allele calling and results visualisation 
The results from the TaqMan
®
 SNP Genotyping Assays are read at the endpoint of the 
reactions rather than in real-time. DNA samples laid in 96-well plates are genotyped 
simultaneously and the allele calls for each individual is indicated by plotting the 
normalised intensity of each of the reporter dyes in each reaction well on a Cartesian 
plot. The data analysis software algorithm assigns individual sample data to a particular 
genotype cluster, either one of the two homozygote clusters or the heterozygote cluster. 
The genotyping data can be then exported in an excel file. 
 
2.2.6.3 Advantages of the TaqMan
®
 SNP genotyping method 
Among the advantages of the TaqMan
®
 SNP genotyping method is its simplicity since it 
requires a single enzymatic step for all the assays without post-PCR processing by using 
universal reactions and thermal cycling conditions. The design of the primers and the 
probes in the region including the SNP is fairly flexible and insertion/deletion 
polymorphisms can be also genotyped. The workflow is simple involving the mixing of 
a Universal Master Mix with the assay and the DNA sample followed by PCR and 
endpoint detection. 
There are 4.5 million pre-designed TaqMan
® 
SNP assays available including 3.5 million 
HapMap SNPs
226
, 70,000 cSNPs and 160,000 validated assays. It is also possible to 
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order the design of any possible SNP in any organism by providing a 300 bp sequence 
including the SNP after validation with File Builder Software v3.1. Prior to the use of 
File Builder, the sequences are evaluated bioinformatically to determine whether the 
sequences were unique within the human organism. This would ensure that the designed 
primers and probes would bind efficiently to the target regions most conserved between 
individuals. Public Databases such as the Basic Local Alignment Search Tool 
(BLAST)
221
 http://www.ncbi.nlm.nih.gov/blast/ are used to detect regions with 
similarities to the sequences in question. The RepeatMasker
251
 program 
http://www.repeatmasker.org/ is used to identify and mask common repetitive elements 
within the sequences. The SNPs should not be included in any masked repetitive areas; 
finally the sequences are entered into the File Builder software for qualification, probe 
design and direct ordering from Applied Biosystems. 
 
 
Figure 2.3.Overview of the TaqMan
®
 SNP Genotyping Chemistry.  
Adapted from www3.appliedbiosystems.com/cms/groups/mcb_support/ 
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2.2.6.4 TaqMan SNP Genotyping procedure 
The DNA samples were diluted with DNase-free, RNase-free water in 96-well 
MicroAmp
™
 reaction plates at 20ng final quantity and 11.25μl final volume. Each plate 
included wells containing DNA samples of known genotypes as positive controls and 
wells with RNase-free water as negative controls. The master mix containing 12.5μl 
(2X) Universal TaqMan
® Genotyping Master Mix and 1.25μl (20X) TaqMan® 
Genotyping assay mix was prepared and added to each of the wells in the plate with a 
multi-channel pipette resulting in a final reaction volume of 25μl. The plate was 
covered with a MicroAmp
™
 Optical Cap, briefly vortexed and centrifuged to spin down 
the contents and eliminate any air bubbles from the solutions. PCR was performed 
using the Applied Biosystems 7300 Real-Time PCR System under the specified 
conditions of 40 cycles of 10 min at 95
o
C, 15 sec at 92
o
C and 1 min at 60
o
C.  After 
PCR amplification an endpoint plate read was performed on the Real-Time PCR 
instrument and an allelic discrimination plate read document was created (SDS 
software). The plate read document was then analysed and the genotyping results were 
verified with results from checking the positive and negative controls. 
 
2.2.7 Cell lines and cell culture 
All cell culture work was conducted in a Class 2 microbiological safety cabinet (Biomat 
Class II) within a designated tissue culture laboratory under standard aseptic conditions. 
Cell lines A549 (alveolar epithelium), Daudi (B lymphoblast) and Jurkat (T 
lymphoblast) were obtained from the American Type Culture Collection (ATCC, 
http://www.lgcstandards-atcc.org/). The frozen aliquots were revived by rapidly 
thawing in a 37
o
C water bath and then added to 12 ml of the appropriate 37
o
C pre-
warmed media (Section 2.1.1, Table 2.1). The di-methyl Sulphoxide (DMSO) present in 
the cryoprotectant medium was removed from the samples as it is toxic for many cells. 
This was achieved by centrifuging the media containing the cells for 3min at 1200rpm 
(Heraeus
®
, Labofuge
®
 400 R, Centrifuge, Thermo Scientific), the supernatant was 
removed and the cell pellet was resuspended in a T75 (Falcon) flask with 12 ml fresh 
pre-warmed media. The cells were incubated at 37
o
C with 5% CO2. 
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The A549 cell lines were passaged when the confluence of the cells was approximately 
80%. First, the media was discarded and the cell lines were washed with Hanks 
Balanced Salt Solution (Sigma) pre-warmed at 37
o
C. The washing solution was 
discarded and the cells were treated with 1ml Trypsin-EDTA diluted in 9ml HBSS for 6 
minutes at 37
o
C to ensure full detachment of the cells from the tissue culture flask 
surface. Next, 10ml of culture media (Section 2.1.1) was added to the flask containing 
the cells and 10ml of diluted Trypsin-EDTA and the contents decanted into a 50 ml 
Falcon tube and spun at 1500rpm for 5 min. After discarding the supernatant, the cell 
pellet was resuspended in 20ml of culture media and 2 ml of this was then added into 
new T175 flasks each containing 20ml pre-warmed media.  Passage number was kept 
below 47 and was typically between 40 to 47. 
The Daudi and the Jurkat cell lines were passaged when they reached 1 x 10
6
 cells/ml. 
A viable cell count was performed before splitting and the cells were suspended to 3-5 x 
10
6
 cells/ml with pre-warmed media (Section 2.1.1). The cell count was performed by 
mixing 15 μl of suspension cells with 15 μl Trypan Blue (Sigma) and pipetted to a 
haemocytometer (Figure 2.4). The number of viable cells in two diagonal large squares 
(A and D) was counted under a microscope (Olympus CK2) and the concentration of 
the viable cells/ml was calculated by multiplying the number of cells in the two squares 
times 10
4
. To allow culture expansion, fresh 37
o
C media was added following 
calculation by the following equation: 
(Density of cells ÷ Desired cell Density) x Culture Volume = Desired Final Culture 
Volume.       
To maintain the same culture volume, the following equation was used: 
(Desired cell Density ÷ Density of cells) x Culture Volume = Desired Final Culture 
Volume  
Passage number was for Daudi cells used were 3 to 10 and for the Jurkats 1 to 6.   
For long-term cryopreservation of the cell lines, a number of cell aliquots were prepared 
and stored frozen under liquid nitrogen.  Prior to cryopreservation, cells from the A549 
line were left to reach 80% confluence whilst the suspension cell lines (Jurkat and 
Daudi) cells were left to reach a density of 1 x 10
6
 cells/ml. Cells of each type were first 
counted, then pelleted as described for passaging above and then the pellets resuspended 
57 
 
in a sterile solution of 10% DMSO and 90% FBS. Aliquots of 1ml were prepared 
containing 5 x 10
6
 cells and the tubes were transferred to a polystyrene box and placed 
at -80
o
C for 24-48 hours to allow them to freeze slowly thereby minimizing the 
formation of ice crystals which are undesirable as they can render cells unviable. After 
storage at -80
o
C, the cell aliquots were transferred to liquid nitrogen (later vapour phase 
nitrogen) for long-term storage.   
 
 
 
Figure 2.4. Diagram showing the haemocytometer layout when viewed under a light 
microscope (image adapted from 
http://www.ruf.rice.edu/~bioslabs/methods/microscopy/cellcounting.html.)  
 
 
 
 
 
   A    B 
   C    D 
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Chapter III: Genome Wide Association Study for Asthma:  
Investigation of Findings in Severe Asthma 
3.1. Introduction 
3.1.1 Genome Wide Association Studies (GWAS) 
Genetic mapping studies are continuously evolving due to the advances in analytical 
tools and capabilities in high-throughput genotyping and statistical interpretation of the 
findings. These advances, alongside the release of the commercial platforms for 
performing economically viable genome-wide genotyping, have led to a new phase in 
human medical genetics. Now, it is possible to establish a standardised platform for all 
genome wide association studies
252
. The initial HapMap Project data had a central role 
in the development of methods for the design and analysis of genome-wide association 
studies as it provided detailed information about patterns of genetic variation in four 
different population samples. The HapMap projects aimed to identify how human 
genetic variation is organised in local blocks, called haplotypes and discover the single 
nucleotide polymorphisms which uniquely characterise these haplotypes blocks.  A 
haplotype defined as a set of alleles on the same chromosome which tend to be 
transmitted as a block through pedigrees or populations can provide information on 
interactions or combined effects of multiple SNPs located on the same haplotype block. 
This could be explained by the fact that haplotypes could possibly define functional 
units of a gene and the presence of the haplotype structured human genome give the 
haplotype analysis considerable value in investigating the true causal variant in a 
genomic region
253
. These informative SNPs termed as tag SNPs can serve as proxies for 
much of the remaining common variation to which they are correlated with.  
 The HapMap project study included a total of 270 DNA samples; 30 trios of two 
parents and an adult child from a US Utah population with Northern and Western 
European ancestry (Centre d‟Etude du Polymorphisme Humain, CEPH, CEU) 30 family 
trios from Yoruba, Ibadan, Nigeria (YRI), 45 unrelated Japanese in Tokyo, Japan (JRT), 
and 45 unrelated Han Chinese in Beijing, China (CHB). The HapMap Project was 
launched in 2002 when the genotypes of more than one million sequence variants, their 
frequencies and the degree of association between them were determined in the four 
population groups
173
. The aim of the project was to genotype at least one common SNP 
every 5 kilobases (Kb) across the euchromatic regions of the human genome in the 270 
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individuals. Apart from its central role in GWAS design, the completion of Phase I 
HapMap also provided information about the structure and causes of recombination hot-
spots
254,255
, the prevalence of structural variation
256,257
 and the genes that have 
undergone recent adaptive evolution
255
. 
  
Phase II HapMap included the characterisation of over 3.1 million human single 
nucleotide polymorphisms (SNPs) which were genotyped in the same 270 individuals
226
 
. It is estimated that 25-35% of the 10 million (approx.) common SNPs (with minor 
allele frequency (MAF) ≥ 0.05) in the human genome were genotyped, resulting in a 
HapMap SNP density of one per kilobase. The SNP map constructed in the Phase II 
HapMap is considered to capture untyped common variation with an average maximum 
r
2
 of between 0.9 and 0.96 in the various population groups. r
2
 is a measurement of 
„correlation‟ or linkage disequilibrium between two SNPs whose values range from 0 to 
1 (r
2
 of one indicates complete LD). The value is derived from both allele frequencies 
and recombination between the two SNPs.  
 
Differences in linkage disequilibrium structure were also revealed when Phase II data 
was compared to Phase I HapMap results. The results demonstrated that 10-30% of 
pairs of individuals in a population sharing at least one region of extended genetic 
identity derive from the recent ancestry and up to 1% of all common variants are not 
tagged because they lie within recombination hotspots. Phase II, in general, included a 
better representation of rare variation than Phase I. The gain in both resolution and 
outline of SNP density could improve the power of association studies.  
 
Another application of the HapMap data involves the haplotype phasing of genotype 
results and the genotype inference from new samples by using the high-quality 
haplotype information available from the database. In this way, the HapMap haplotypes 
provide a way of in silico genotyping Phase II SNPs that were not included in the 
project.  
 
Following the assumption that the human genome is clustered into haplotypes, the 
majority of the variation can be accurately sampled with as few as 300,000 carefully 
chosen single nucleotide polymorphisms (SNPs).  
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There are commercial platforms available supplied by Illumina® and Affymetrix® for 
whole-genome genotyping, which employ different combinations and number of SNPs 
from the Phase II HapMap
258,259
. In all published studies, it was estimated that the 
available coverage of these products performs well in CEU and CHB+JRT and some 
perform well in YRI population groups. Arrays of approximately 500,000 SNPs capture 
68-88% of all HapMap Phase II polymorphisms with r
2≥0.8 in CEU.  
 
These advances in genotyping and the increased understanding of the human genome 
structure has now made it feasible for GWAS, examining 100s of thousands SNPs using 
either family or case-referent panels, to be designed for a variety of complex human 
diseases. The genome-wide mapping approach was proposed by Risch and Merikangas 
in 1996
130
 and ten years on, a number of genome-wide association studies in complex 
diseases including Type I
49,260
 and Type II diabetes
175,224,261-264
, inflammatory bowel 
disease
207,265-268
, prostate cancer
185,269-273
, breast cancer
274-276
, coronary heart disease
277-
279
 and a study exploring the genetics of seven common diseases
280
  have been 
published. Similarly to the previously applied linkage mapping studies (Chapter I, 
Section 1.2) the GWA approach can identify novel loci for diseases and their 
quantitative traits. The GWAS, simultaneously retain the high statistical power of the 
hypothesis-based candidate gene association studies by detecting high-frequency, small-
effect polymorphisms believed to contribute to the predisposition in common diseases 
according to common disease common variant hypothesis
174,281
. The statistical power of 
a genetic study is determined by the sample size, the magnitude of the genetic effect and 
the allele frequency and this can be controlled by the ascertainment of a large 
population study group adequate to detect  common variants of an effect size OR<1.5. 
Collaborative approaches and formation of consortia are therefore key in bringing 
together large population groups which allow GWAS to be statistically powerful
282
. . 
 
3.1.2 GABRIEL Phase I: Genome Wide Association Study for Asthma 
The GABRIEL project is a multidisciplinary study combining the genetics, 
epidemiology and immunology research fields to identify the genetic and environmental 
factors of asthma in European countries (http://www.gabriel-fp6.org/project/index.htm). 
Founded by the EC Framework 6 grant it includes collaborations of more than 150 
scientists from 14 European countries.  
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As part of the GABRIEL project, the first GWAS for asthma was carried out 
220
. The 
study included a group of 207 predominantly (99%) nuclear families recruited through a 
proband with Step 3 severe childhood onset asthma (MRC-A) (Chapter 2, Section 
2.2.1). In total, the panel consisted of 295 sib pairs, 11 half-sib pairs and 3 singletons. A 
second panel of 437 non-asthmatic Caucasian UK subjects (UK-C) was also included. 
To increase power of the GWAS, a case-control group of 728 German school children 
with physician-diagnosed asthma recruited as part of the Multicentre Asthma Genetics 
In Childhood Study (MAGICS) study and 694 reference children recruited in the 
International Study of Asthma and Allergies in Childhood (ISAAC)
197
 were also 
genotyped.  Genotyping was performed using the Illumina Sentrix Human-1 
Genotyping BeadChip (109,000 SNPs, 100K) and the Illumina Sentrix HumanHap300 
Genotyping BeadChip (317,000 SNPs, 300K) for all populations groups listed in 
(Figure 3.1). 
 
For the 100K BeadChip the markers are gene centric including gene-regulatory regions, 
whereas the 300K chip employs tag SNPs based on HapMap Phase II. More specifically 
for the Illumina 100K bead array system 30% of the markers are based on genes or 
within 10 Kb of the coding region and the remaining markers are uniformly spaced 
across the genome, with preference in highly conserved non-coding regions.  
The analysis revealed multiple markers on chromosome 17q21 were strongly and 
repeatedly associated with childhood onset asthma in both the family and case-control 
panels of subjects with a combined P-value of P<10 
-12
 
220
. The direction of the allele 
transmission examined to the affected probands by family-based association test in the 
MRC-A group was consistent to the results in the case-control study, supporting that the 
results were not affected by population stratification. The results were replicated in an 
independent study of 2,320 German children (P=0.0003) and in 3,301 subjects from the 
British 1958 Birth Cohort (P=0.0005)
220
. A forward stepwise regression analysis 
showed that three SNPs (rs7216389, rs11650680, rs3859192) lying between 34.5 and 
36.0 Mb on 17q chromosome were jointly associated with asthma (P<10 
-12
) but also 
had statistically independent effects, raising the possibility that more than one 
functional SNP may be located in the region. 
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Figure 3.1. The study design of the Gabriel Phase I GWAS. Children and parents in the 
MRC-A panel were genotyped with Illumina Sentrix Human-1 Genotyping BeadChip. 
All children were genotyped with Illumina Sentrix HumanHap300 Genotyping 
BeadChip. Gene expression was measured in lymphoblastoid cell lines (EBVL) from 
the MRC-A affected and unaffected children (Figure taken from Moffatt, M. F. et al. 
Nature 448, 470-3 (2007)
220
). 
 
 
In addition, for one of the UK panels (MRC-A) Epstein-Barr virus-transformed (EBV) 
lymphoblastoid cell lines for all children (400 in total) had been made, allowing global 
gene expression arrays to be run for the purpose of expression Quantitative Trait Loci 
(eQTL) analysis. Associations among 408,273 genotyped SNPs and 54,675 transcripts 
representing 20,599 genes were identified 
226
. Both cis and trans associations were 
reported with LOD scores between 3.68 and 59.1. Global gene expression was 
measured with the Affymetrix Human Genome HG-U133 plus 2.0 chip. The obtained 
data could reveal dysregulated genes and gene clusters present in the airway epithelium, 
taking part in processes like the initiation and maintenance of inflammation at the 
epithelium, a central event in asthma development. 
In combination with the eQTL analysis data, the SNPs strongly associated with 
childhood asthma on the 17q21 region were shown to be significantly associated (P<10
-
22
) with the transcripts levels of ORMDL3 gene. These data provide strong evidence that 
the expression of ORMDL3 gene, a member of a gene family that encodes trans-
membrane proteins anchored in the endoplasmic reticulum
283
 is controlled by 
determinants conferring susceptibility to childhood asthma.  Since the GWAS, the 
chromosome 17q21 associations have replicated by a number of independent studies 
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involving both Caucasian populations as well as groups of subjects of other ethnic 
origins (Chapter I, Section 1.2.3). 
In the original GWAS
220
 in addition to the chromosome 17q21 associations other 
markers  showed associations to asthma at a slightly lower level of significance (False 
Discovery Rate FDR=5%) indicating that additional susceptibility loci with smaller 
effects than those on chromosome 17q21 existed 
220
.  
The original GWAS for asthma did not include individuals having the most severe 
phenotype (Chapter I, Section 1.1.8). Severe asthma is the extreme phenotype included 
within the top ten percent of the population distribution of the trait. Therefore, 
recruitment of severe asthmatics can increase the power to detect genetic associations 
and the homogeneity of the population sample. For these reasons, severe asthmatics 
were collected for a case-referent genetic study exploring the factors underlying asthma. 
The aim of this chapter was to examine the results from the GWA and eQTL studies 
focussing on the results for the UK dataset in order to first draw up a listing of specific 
SNPs and to then investigate these SNPs for their role in the aetiology of severe asthma. 
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3.2. Materials and methods  
3.2.1 Selection of SNPs for genotyping 
Genotyping data from the asthma GWAS has previously been assembled into a web 
based database, the GABRIEL Genome Scan Browser 
(http://gabriel.well.ox.ac.uk/gsb/wwwqtl.cgi). The browser provides information sorted 
by the different subject panels genotyped, the chromosomes and the specific 
chromosomal position. Information provided (scan type) includes minor allele 
frequency (MAF) figures, genotype data or P-values of genetic association tests 
expressed in a logarithmic scale (lop). The output of each of the scans is available in 
both a plot and a text form in which the lop (-log10[P-value]) for each of the genotyped 
SNPs is also included. Additionally the browser supplies information on the SNPs that 
are within genes or in regulatory regions of genes with links to other key genome 
browsers, such as the University of California Santa Cruz (UCSC-
http://genome.ucsc.edu/cgi-bin/hgGateway) and ENSEMBL 
(http://www.ensembl.org/index.html) (Figure 3.1).  
 
 
Figure 3.1. Snapshot of the GABRIEL Genome Scan Browser. 
(http://gabriel.well.ox.ac.uk/gsb/wwwqtl.cgi). 
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Using the GABRIEL Genome Scan Browser, the results from the various subject panels 
were examined and all markers with a lop greater than 2 (≡P-value<0.01) identified, 
collated and summarised per chromosome in independent spreadsheets. 
 A second database was also used, the SNP Browser V 1.0 
(http://www.sph.umich.edu/csg/liang/asthma/).  This database provides a graphic 
interface for browsing the association results between the 408,273 genotyped SNPs and 
the 54,675 transcripts included in the eQTL analysis
176
. For each transcript the browser 
displays graphically the LOD scores of all SNPs with a P-value ≤0.001 across the 
genome. It also provides detailed information for the association results providing the 
effect, the heritability (H
2
), the P-values for each of the SNPs and the probe information 
from Affymetrix. Data for the average expression of the probes in each gene is also 
available (AVG_GENE). For example on Figure 3.2 the results for PRKCE gene are 
shown, in which 236459_at probe expression is highly associated with a number of 
SNPs on chromosome 2. 
           
Figure 3.2. The SNP Browser V 1.0 (http://www.sph.umich.edu/csg/liang/asthma/). 
The graph shows the association results between the Affymetrix expression probes and 
the markers across the genome. The top red line on the graph designates the Bonferroni 
adjusted critical value for all SNPs at 0.05 level, LOD=6 and the bottom red is the 
baseline, LOD=2.  
Threshold 
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Focusing on the UK families panel data (100K array), information for all markers with 
a P-value≤0.01 (-log10(P-value)≥2) was compiled for each chromosome, including the 
results from the genome scan browser and the SNP browser. The family-based 
association analysis results were preferred since they are free from population 
stratification and present more robust associations
284
. Spreadsheets were designed to 
include the chromosome position and the name of the gene where the associated SNPs 
are located, the association results given as  -log 10(P-value), in each panel for the 
markers and also the eQTL analysis results. Additional information about previous 
linkage or association studies on specific regions and genes and functional information 
about the genes was added where appropriate. This resulted in a summary of results per 
chromosome for the top hits from the GWA study. Table 3.1 gives an example for 
chromosome 6. 
CHROM GENE 
LOCA
TION 
lop (MRC-A) lop COMB lop UK lop D eQTL 
6 C6orf54 168,1 2,13072 1,42404 3,06621 1,11694 NO 
6 RPS6KA2 166,8 2,73053 1,30324 2,836 1,89364 NO 
6 FNDC1 159,5 2,70476 1,10094 1,34416 0,613434 NO 
6 ARID1B 157,5 2,34819 1,44189 2,05722 0,9354 YES+T7 
6 RBM16 155,5 2,23093 1,58603 2,0718 2,1203 NO 
6 CNKSR3 154,8 2,90897 1,42149 1,81738 1,95242 NO 
6 C6ORF97 151,9 2,06573 1,15675 1,6061 1,35486 NO DATA 
6 UTRN 144,7 2,26969 1,06074 1,88136 2,27714 NO 
6 LAMA2 129,2 2,47846 2,49217 1,81936 1,66362 NO 
6 CF075  126,3 2,10407 0,641061 1,7159 0,451317 NO DATA 
6 IBRDC1 125,3 2,50015 2,02317 1,69601 1,42914 NO 
6 TCBA1 124,1 2,08515 1,89118 2,41137 2,00856 NO 
6 SMPDL3A 123,1 2,13967 0,481856 0,508416 0,783152 NO 
6 SLC35F1 118,6 2,01465 2,47982 1,91326 1,74152 NO 
6 CD164 109,8 2,48179 0,051814 0,342695 0,350361 NO 
6 ARMC2 109,3 2,37334 1,22777 2,86192 0,777379 NO 
6 ATG5  106,7 2,2461 0,940923 2,03534 1,19104 NO 
6 FBXL4 99,4 2,17255 1,35229 0,405737 1,46987 NO 
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6 B3GAT2 71,6 3,63997 1,40871 2,10334 1,10361 NO DATA 
6 GLULD1 64,1 2,66334 0,084567 0,189252 0,03605 NO 
6 GCLC(5') 53,4 2,29756 3,89722 2,37789 3,0779 NO 
6 CLIC5 46 1,82749 1,63615 1,54073 1,69103 T5 
6 NFKBIE 44,3 2,36855 1,06343 0,543722 1,32651 NO 
6 BTBD9 38,3 2,01221 1,81985 1,64864 1,4597 NO 
6 C6orf89 37 2,78439 0,677353 0,273844 0,601033 NO 
6 CPNE5 36,8 2,16966 2,0183 1,65223 3,15739 NO 
6 TCP11 35,2 3,70333 2,01099 2,836 0,656254 NO 
6 ANKS1A 35,1 3,68445 1,82175 3,60067 0,730775   
6 BTN2A1 26,6 2,57199 1,93285 2,05479 0,251944 YES 
6 HIST1H3G 26,4 2,19911 no marker no marker no marker NO 
6 NEDD9 11,4 1,77935 2,00856 1,15146 2,2579 NO 
6 ENSG00000203564 2,38 3,24818 1,60359 0,918788 1,00121   
6 NP_001034981.1 0,15 2,51515 0,214585 0,566915 0,161682   
        
 
Table 3.1. Spreadsheet for the results on Chromosome 6. lop (MRC-A): family data 
results (100K array), lop COMB: combined results for the MRC-A children, UK-C and 
MAGICS case/referent panel (300K array), lop UK: UK case/referent results (300K 
array), lop D: German case/referent results (300K array), eQTL: YES/NO for a 
significant/non significant result in eQTL analysis respectively (March 2006 human 
reference sequence, NCBI Build 36.1). 
 
The top 10 genome wide hits were selected for further investigation in the severe 
asthmatic samples both childhood onset and adult onset (Section 3.2.2) to establish 
whether they were important genetic factors underlying the extreme disease phenotype 
The ORMDL3 top hit, SNP rs7216389, from the combined analysis of the family and 
the case-control panels was also included in the study (Table 3.2). 
 
 
68 
 
 
 
 
 
 
 
 
 
   
 
 
Table 3.2. SNPs selected for genotyping. The GWAS result for the MRC-A dataset 
shown as –log10(P). 
 
 
 
3.2.2 Subject sets  
The 11 SNPs selected were genotyped in 397 severe asthmatic adults and 94 severe 
asthmatic children available at this time point (Chapter 2, Section 2.2.1). The reference 
group included data from the MRC-A panel of subjects which was available from the 
original GWAS.  
 
3.2.3 Genotyping  
Whole genome amplification using REPLI-g (Chapter 2, Section 2.2.3) was necessary 
prior to genotyping for 163 DNA samples that had insufficient DNA or DNA of low 
concentration.  Post whole genome amplification, an aliquot was visualised on an 
agarose gel (2%) to check that the amplification had been successful.  In addition a test 
Assay 
No. 
SNP dbSNP   
Allele 
Gene Chromosome -log10(P) 
1 rs1401107 A/G Genomic 2 5.920996 
2 rs10270097 A/C DGKI 7 5.239727 
3 rs481297 T/C ST8SIA5 18 5.091034 
4 rs2243603 C/G SIRPB1 20 4.327575 
5 rs1356847 A/G Genomic 2 4.154707 
6 rs12715305 G/C DLEC1 3 4.029505 
7 rs11097415 G/A SHROOM3 4 4.014328 
8 rs6656822 T/C SLC19A2 1 4.003518 
9 rs6585018 G/A PDCD4 10 4.702323 
10 rs248944 C/G ZNF506 19 4.228808 
11 rs7216389 T/C ORMDL3-
GSDML 
17 4.300000  
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PCR was performed using an aliquot of the amplified genomic DNA and results of the 
PCR visualised on agarose. Genotyping of the 11 SNPs (Table 3.2) was done using 
TaqMan
®
 SNP Assays (Chapter 2, Section 2.2.6).  Severe asthmatics Subject Set 1 was 
obtained first and genotyping was initially conducted in these 39 samples (Chapter II, 
Table 2.2). Additionally, when 55 samples from Subject Set 2 were acquired, 
genotyping was performed in the samples and the data were combined for the 94 
samples in total. For inclusion in subsequent statistical analyses, genotype data for each 
SNP had to have a >90% call rate and the positive and negative controls called 
correctly. Positive controls were reactions with DNA samples of known genotypes and 
negative controls were reactions containing H2O instead of DNA. 
 
3.2.4 Statistical analysis 
 
For each SNP, deviation from Hardy-Weinberg equilibrium (HWE) was checked by chi 
square tests. Genotype and allele frequencies were compared between cases and 
controls by Fisher‟s exact test and logistic regression conducted using SPSS 
(http://www.spss.com/)
285
. The 5% False Discovery Rate adjustments for multiple 
testing were calculated at Qvalue
286
 software in R language environment. 
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3.3 Results  
3.3.1 Whole genome amplification results 
The 163 stock DNA sample (Chapter II, Section 2.2.3) concentrations prior to whole 
genome amplification varied between 1-50ng/μl. After using the REPLI-g kit the 
resulting yields were mean, μg (range), 20.37 (5.7 - 28.9) with the concentrations mean, 
ng/μl (range), 407.41 (150-580) using NanoDrop® DNA quantitation (Chapter II, 
Section 2.2.2.3). In Figure 3.3 a histogram depicts the concentration results for the 163 
DNA samples that underwent whole genome amplification, organised into nine classes. 
The samples before and after whole genome amplification were run in a 2% agarose gel 
(Figure 3.4).  If amplification is successful, a characteristic high molecular weight 
smear should be seen on the gel. 
 
 Figure 3.3. A histogram summarising the REPLI-g DNA amplification results. 
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                                 1       2      3      4      5      6      7       8       9    10 
 
Figure 3.4. DNA samples before and after whole genome amplification with REPLI-g. 
Lane 1 is the DNA ladder (NEB N3231S) whilst lane 2 contains high yield genomic 
DNA sample for comparison.   Lanes 3 to 6 contain samples post whole genome 
amplification.  Lanes 7 to 10 contain aliquots of the same samples prior to whole 
genome amplification.   
 
Next to check that the whole genome amplified DNA would work robustly in 
subsequent PCR based analyses, a test PCR for DNA quality was carried out (Chapter  
II Section 2.2.5).  Success of the PCR was assessed by running the products out on 
1.5% agarose gel (Figure 3.5).    
             1   2    3     4    5    6    7   8     
  
1,517bp - 
1,000bp - 
500bp - 
 
200bp-
100bp -  
1,517bp - 
1,000bp - 
 
500bp - 
 
200bp-
100bp -  
500bp- 
200bp- 
10 bp 
Figure 3.5. Example of the 
results obtained following the 
test PCR of REPLI-g whole 
genome amplified DNA 
samples.  Lane 1 contains the 
DNA ladder (NEB N3231S) 
whilst Lanes 2 to 6 contain test 
samples.  Lane 7 contains a 
positive genomic DNA control 
whilst Lane 8 is the negative 
PCR control. 
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3.3.2 Genotyping Call and Quality Control results 
The genotyping results for the 504 samples from adults and children were assembled 
and a call rate for each of the assays was calculated. All but one assay (Assay 1) had a 
call rate >90% (Table 3.3). Assay 1 was therefore not included in subsequent statistical 
analyses. No significant deviation from HWE was observed for any of the SNPs (Table 
3.3). The positive and negative controls included in each genotyping experiment 
produced the anticipated results for all assays. Figures 3.6a and b include the cluster 
plots for rs481297 and rs2243603 SNP assays. 
 
 
 
 
 
 
 
 
 
Table 3.3. Genotype call success rates and HWE test results for the TaqMan SNP 
assays.  
 
 
 
 
 
 
 
 
Assay 
No. 
SNP Alleles 
(Minor/Major) 
Call Success rates HWE (χ2 P value) 
1 rs1401107 A/G 85%  
2 rs10270097 A/C 96.3% 0.375 
3 rs481297 T/C 95.2% 0.103 
4 rs2243603 C/G 95.9% 0.370 
5 rs1356847 A/G 94.8% 0.978 
6 rs12715305 G/C 96.3% 0.999 
7 rs11097415 G/A 98.3% 0.945 
8 rs6656822 T/C 91.5% 0.927 
9 rs6585018 G/A 99.6% 0.952 
10 rs248944 C/G 94.8% 0.969 
11 rs7216389 T/C 96.6% 0.766 
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a. SNP rs481297 
 
 
b. SNP rs2243603 
 
 
Figure 3.6. The allelic discrimination plots for 2 SNP assays on the first 90 DNA 
samples. Samples containing one of the homozygote genotypes are depicted with blue 
and red symbols, whereas those with heterozygote genotypes are depicted with green 
symbols. The grey squares represent the negative controls (water). 
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3.3.3 Statistical analysis results for SNP rs7216389 
The chromosome 17q21 ORMDL3-GSDML SNP which gave the highly significant 
result in the GWA study
191
 was genotyped in severe asthmatics (Chapter II, Table 2.2). 
The SNP was included in the 300K array but not in the 100K, therefore no genotyping 
data for the adult controls were available (Figure 3.1). Genotype frequencies of 
rs7216389 from healthy British adults, therefore, were obtained from the 1958 British 
Cohort Study
287
 (http://www.b58cgene.sgul.ac.uk/). Comparing genotype frequencies 
between cases and controls in children using Fisher‟s test gave not significant result 
(P=0.452), whereas a highly significant difference was shown in the adults (P=5.4x10
-
05
). To investigate further the association in adults, logistic regression analysis was used 
for this group and the Odds Ratio (OR) for this association was OR (95% CI): 1.42, 
(1.21-1.67), P=1.8x10
-5
 under the additive model (Table 3.4).  
Subjects were separated according to the age-onset of the disease to explore if the 
genetic effect of the variations is present in both groups. Childhood asthma-onset was 
present in 114 samples and adulthood asthma-onset in 112 subjects. A significant 
association between SNP rs7216389 and severe asthma was reported only in the 
childhood onset asthmatics (OR 2.02, CI: 1.53-2.68, P=4.5x10
-6
) (Table 3.5b). 
Interestingly, the frequency of the T allele was 67%, similar to the figure reported by 
Moffatt et al.
191
 Adult-onset of the disease did show any significant associations for this 
SNP (P=0.853) and minor allele frequency (T allele) was 49% comparable to the one in 
the control group (47%) (Table 3.5a). 
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a) 
 
 
Table 3.4. Genotype frequencies and statistical results for rs7216389 for a) child severe 
asthmatics and b) adult severe asthmatics (MAF : Minor Allele Frequency). 
 
 
 
 
 
 
 
 
 
Children 
 
Genotype frequencies (N) 
  
rs7216389(C/T) CC TC TT MAF  P value 
Asthmatics 0.211 (19) 0.455 (41) 0.333 (30) 0.561  0.452 
Controls 0.21 (24) 0.53 (60) 0.25 (29) 0.521   
 
 
b) 
Adults 
 Genotype frequencies (N)    
rs7216389(C/T) CC TC TT MAF  P value              OR (95% CI) 
Asthmatics 0.179 (69) 0.519 (200) 0.301 (116) 0.56  5.4x10-05           1.42, (1.21-1.67)  
Controls 0.283 (405) 0.487 (696) 0.229 (328) 0.47    
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a) 
 
b) 
 
 
 
 
Table 3.5. Genotype frequencies and association test results for rs7216389 in a) 
adulthood onset severe adult asthma susceptibility and b) childhood onset severe adult 
asthma susceptibility 
 
 
 
 
 
 
 
Adults with adulthood onset asthma 
   
 
Genotype frequencies (N) 
   
rs7216389(C/T) CC TC TT MAF P value OR (95% CI) 
Asthmatics 0.259(29) 0.500 (56) 0.241 (27) 0.49 0.853 1.07, (0.78-1.47) 
Controls 0.283 (405) 0.487 (696) 0.229 (328) 0.47 
  
 
Adults with childhood onset asthma  
   
 
Genotype frequencies (N) 
   
rs7216389(C/T) CC TC TT MAF P value OR (95% CI) 
Asthmatics 0.089 (11) 0.482 (59) 0.429 (44) 0.67 4.5x10
-6 2.02, (1.53-2.68) 
Controls 0.283 (405) 0.487 (696) 0.229 (328) 0.47 
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3.3.4 Statistical analysis results for the 9 genome-wide top hits 
The genotype frequencies between the severe asthmatic adults and children were 
compared to the genotype frequencies in the control groups using Fisher‟s exact test for 
9 markers. Subject Set 1 results were initially analysed and two of the SNPs, 
rs10270097 and rs6585018 shown to have significantly different genotype frequencies 
between cases and controls in the children group (P=0.01 and P=1x10
-4
 respectively). 
The results remained significant when genotyping data from Set 2 samples were added 
in the analysis (P=6.1x10
-5
 and P=3.4x10
-7
). The control data was the MRC-A GWAS 
data for both the adults and the children. 
 
 Table 3.6. Statistics results for all 9 markers after applying Fisher‟s exact test. The 
results for Set 1 and Set 1 and 2 combined are shown. Data from children and adults 
groups combined and children group alone are shown. 
 
For both SNPs the significant results were observed in the children groups but not the 
adults groups (data not shown).  In SNP rs10270097 there was a decrease in the 
frequency of the A minor allele and in SNP rs6585018 an increased frequency of the 
minor allele C was reported. For the adults groups no significant association was found, 
with P-values P=0.158 for rs10270097 and P=0.65 for rs6885018 (Tables 3.7-8). 
Genotyping data from both severe asthmatic adults and children groups were combined 
and compared to MRC-A non-asthmatics. The results were significant for SNPs 
rs10270097 and rs6585018 in combined Set 1 and Set 2 analysis (P=0.007 and 
Assay 
No 
SNP Set 1  Sets 1 and 2 Combined 
  Fisher’s exact test P-value Fisher’s exact test P-value 
  Severe 
Asthmatic 
Adults+Children 
Cases:Controls 
234:394 
Severe 
Asthmatic 
Children 
Cases:Controls 
39:134 
Severe  
Asthmatic 
Adults+Children 
Cases:Controls 
492:394 
Severe 
Asthmatic 
Children 
Cases:Controls 
94:134 
2 rs10270097 0.071 0.01 0.007 6.1x10
-5                
3 rs481297 0.467 0.808   
4 rs2243603 0.092 0.382   
5 rs1356847 0.441 0.402   
6 rs12715305 0.855 0.601   
7 rs11097415 0.619 0.487   
8 rs6656822 0.562 0.735   
9 rs6585018 0.32 1x10
-4 0.027 3.8x10-7 
10 rs248944 0.895 0.128   
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P=0.026), but no increase in significance was seen indicating that the association result 
was observed in the children group. The results remained significant when adjusted for 
FDR 5% (data not shown). 
a) 
 
 
 
Asthmatics 0.861 (81) 0.138 (13) 0.0 0.069  6.1x10-5 
Controls 0.992(132) 0.007(1) 0.0 0.003   
b) 
Adults 
 Genotype frequencies (N)   
rs10270097(C/A) CC AC AA MAF  
Fisher’s 
exact test 
P value 
Asthmatics 0.861 (329) 0.125 (48) 0.013 (5) 0.076  0.158 
Controls 0.885(232) 0.114(30) 0.0 0.057   
c) 
Children + Adults 
 Genotype frequencies (N)   
rs10270097(C/A) CC AC AA MAF  
Fisher’s 
exact test    
P value 
Asthmatics 0.861 (410) 0.128 (61) 0.01 (5) 0.074  0.007 
Controls 0.921 (363) 0.078 (31) 0.0 0.039   
 
Table 3.7. Genotype frequencies and P-values for rs10270097 in a) children, b) adults 
and c) combined children and adult groups (MAF : Minor Allele Frequency).  
 
Children 
 Genotype frequencies (N)   
rs10270097(C/A) CC AC AA MAF 
Fisher’s 
exact test 
P value 
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a) 
Children 
 Genotype frequencies (N)   
rs6585018(T/C) AA GA GG MAF 
Fisher’s 
exact test 
P value 
Asthmatics 0.776 (73) 0.212 (20) 0.010 (1) 0.107  3.4x10-7 
Controls 0.993 (133) 0.007 (1) 0.000(0) 0.003   
b) 
Adults 
 Genotype frequencies (N)   
rs6585018(T/C) AA GA GG MAF  
Fisher’s 
exact test 
P value 
Asthmatics 0.928 (366) 0.069 (27) 0.002 (1) 0.037  0.65 
Controls 0.922 (237) 0.077 (20) 0.0 0.039   
c) 
Children + Adults 
Genotype frequencies (N) 
rs6585018(T/C) AA GA GG MAF  
Fisher’s 
exact test    
P value 
Asthmatics 0.899 (439) 0.096 (47) 0.004 (2) 0.050  0.026 
Controls 0.946 (371) 0.054 (21) 0.0 0.003   
 
Table 3.8.Genotype frequencies and P-values for rs6585018 in a) children, b) adults 
and c) combined children and adults groups (MAF : Minor Allele Frequency).  
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3.4 Discussion 
A substantial amount of information was available after the completion the GWAS. The 
GWAS results were initially assessed and prioritised to select the findings for further 
interrogation. Focusing on the UK family data, the 10 most significantly associated 
markers to childhood asthma in the GWAS were selected to be typed in severely 
affected children and adults. The top hit result SNP rs7216389 from the GWAS was 
also included in the study. Severe asthma represents the extremely differentiated 
asthmatic phenotype that could contribute in increased statistical power to detect genetic 
associations.  Prior to genotyping a subset of the DNA samples available (N=163) 
underwent successful whole-genome amplification as assessed by the quality control 
tests that were performed (Section 3.3.1). The full complement of DNA samples have 
been genotyped for the 11 selected SNPs and genotyping data for 10 SNPs passed QC 
and have been analysed for their associations with severe asthma.  Three of the ten 
SNPs showed significant associations to the disease phenotype. 
In this study, no significant association was found for the chromosome 17q21 SNP 
rs7216389 marker and the most severe asthma phenotype in children. Interestingly 
however, a highly significant association was found to severe asthma in the childhood-
onset asthma (P=4.5x10
-06
) with the direction of the association the same as that 
observed in the original GWA, but not in the adult-onset asthma (P=0.853).  
In the original GWAS asthmatic children on minimum Step 3 asthma
210
, were 
examined. The present study examined the effect of the highly associated SNPs from 
the GWAS in the most severely affected group of asthmatic patients. This study had as 
a main prospective not to replicate the GWAS findings, but to examine the effect of 
these markers in the specific subphenotype, severe „difficult/therapy resistant‟ asthma. 
The non-significant association reported in the severe asthmatic children for this SNP 
could reveal the important ascertainment differences between the two asthmatic groups 
of children. The results highlight also the differences in the genetic component between 
childhood and adulthood asthma-onset and the necessity to control for the age-of onset 
in the genetic studies investigating the predisposition to a complex disease like asthma. 
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Findings for rs7216389 were reported which showed consistency in ethnically diverse 
populations (Chapter I, Section 1.2.3). The current study reports the implication of 
17q21 locus in the development of childhood-onset adulthood asthma in the UK 
population and in combination with the recent published studies in ethnically diverse 
populations it confirms the importance of the 17q21 region in the development of the 
disease.  
SNP rs10270097 showed significant association with severe childhood asthma 
(P=6.1x10
-5
) with the minor allele, A, having a decreasing frequency in the asthmatic 
children, revealing a potentially protective effect. No significant association was found 
for the adult group shown (P=0.158). The SNP, on chromosome 7q33, is located within 
intron 16 of the gene that encodes diacyl-glycerol kinase iota (DGKI), a cytoplasmic 
protein that regulates the intracellular concentration of diacyl-glycerol (DAG) and is 
possibly involved in glycerolipid metabolism, glycerophospholipid metabolism and 
phosphatidylinositol signalling system pathways
288
. The kinase could be involved in 
biochemical signalling pathways of allergic reactions present in the asthmatic responses, 
where DAG acts as a second messenger to conduct extracellular signals into the 
intracellular environment. 
The SNP rs6585018 also was found to be significantly associated to severe asthma in 
children (P=3.4x10
-7
).  In this case the minor allele was increased in the asthmatics 
(10%) compared to healthy children (0.03%). The SNP showed no association with 
severe adult asthma (P=0.65). rs6585018 is located within the predicted promoter of the 
programmed cell death protein 4 (PDCD4) gene, a tumour suppressor on chromosome 
10q24 that down-regulates the expression of MAP4K1 inhibiting events important in 
driving invasion 
289
. Its function as a transcription regulator and its high expression in 
lymphocytes could imply that it is involved in the transcriptional regulation of genes 
important in the asthmatic responses
290
.  
The 9 SNPs selected to be investigated in this study appeared with the most significant 
associations in the GWAS but only 2 of these found to be significantly associated to 
severe childhood asthma. These variations could represent the asthma-implicated loci 
potentially shared by severe asthma and moderate/severe phenotype used in the original 
GWAS. Differences in phenotypic definition and subject ascertainment, however, could 
account for the diverse results between the GWAS and the present genetic study. 
82 
 
Asthma has been recognised as a heterogeneous disease with different 
subphenotypes
291
, although common guidelines such as the GINA or the ATS criteria 
have been proposed, variability is expected to be present in different recruitment 
strategies. Differences in the genetic background and the environmental effects could 
also contribute to the observed genetic heterogeneity. If two different studies follow 
strictly identical definition criteria in determining the phenotypes and there is no 
heterogeneity due to genetic architecture there may be true differences in the aetiology 
of the disease.  
A more comprehensive genetic investigation for severe asthma is warranted but in order 
to be able to conduct a GWAS for severe asthma – both childhood and adult separately 
and combined– a large number of samples are required to ensure power of the study.  
For the adulthood asthma, the AUGOSA project examining the genetic factors in severe 
asthma is already in progress (personal communication M.F. Moffatt) but remains to be 
done for childhood.   
Nonetheless the present study has generated some very interesting findings which 
warrant further investigation. 
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Chapter IV: Fine mapping of the PDCD4 locus 
4.1 Introduction 
 In Chapter III, the markers with the most significant association results from the 
Genome Wide Association Study in childhood asthma
220
 were genotyped in two 
different disease groups, one consisting of adult cases of severe asthma and the other 
consisting of childhood cases of severe asthma. From the study, two SNPs were found 
to be associated with severe asthma, rs10270097 (P=6.1x10
-5
) and rs6585018 
(P=3.4x10
-7
). The SNP most strongly associated to asthma in the GWAS analysis 
(rs7216389), positioned in the 17q21 genomic area, also showed a highly significant 
association to childhood-onset asthma (P=4.5x10
-06
). 
Fine mapping studies focus on the selection of a set of markers in a genomic region for 
genotyping to refine the association signal and identify the true causal variant. A genetic 
polymorphism may act by directly affecting the expression of a candidate gene. This 
could happen by altering the regulation of expression of the gene if it is located on a 
regulatory element such as a promoter or enhancer or by changing the composition and 
function of the protein if it causes the replacement of an amino acid or changes the 
splicing sites of the gene. If a SNP changes the amino acid in the polypeptide sequence 
it is a non-synonymous SNP and if not due to the degeneracy of the genetic code it is 
called a synonymous SNP. Non-synonymous SNPs could also create a premature stop 
codon resulting in a non-functional polypeptide. 
 Marker rs10270097 is located within intron 16 of the diacylglycerol kinase iota (DGKI) 
gene on chromosome 7q33. DGKI is 457 kb in size and consists of 35 exons, with the 
start codon in exon 2, and encodes a 117 kDa protein consisting of 1065 amino acids. 
DGKI participates in the regulation of intracellular pathways by phosphorylating the 
second messenger, diacylglycerol (DAG) and producing phosphatidic acid
288
. The 
expression of DGKI is tissue specific and Northern blots and RT-PCR analyses showed 
that transcripts of the gene are found in brain and retina
292,293
.  Following its physical 
mapping on chromosome 7q33 by Fluorescence In Situ Hybridization (FISH)
288
, it was 
hypothesized that DGKI could be a candidate gene for a form of retinitis pigmentosa by 
producing phosphatidic acid in the retina
294
. Although it would be interesting to follow 
this finding for further investigation, it was not included in the subsequent steps of the 
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study, since it was located on an intron of the relatively large DGKI gene (~500 kb) and 
it presented lower results of significance compared to PDCD4 marker (Chapter III). 
Additionally, PDCD4 was a more convincing functional candidate as it will be 
described in the next paragraphs. 
Marker rs6585018 is located 5‟ upstream of the Programmed Cell Death 4 (PDCD4) 
gene on chromosome 10q24. The gene is 28 kbp in size and consists of 12 exons with 
two starting codons that result in the production of two different protein isoforms. The 
469-amino acid protein is an acidic protein with a calculated molecular mass of 51.7 
kDa. It contains two overlapping GxGxxG nucleotide-binding motifs, which are 
characteristic of protein kinases, although it does not have a kinase catalytic domain
295
. 
Yeast two-hybrid, in vitro binding and in vitro pull-down assays have shown that 
PDCD4 isoforms can interact with eukaryotic initiation factor 4G (EIF4G), ribosomal 
protein S13 (RPS13) and thus may regulate EIF4G-dependent translation through 
interaction with these two proteins in senescent fibroblasts
296
. It was subsequently 
reported that PDCD4 can function as a tumour suppressor by inhibiting the helicase 
activity of the translation initiation factor EIF4A preventing the expression of many 
proteins
297
. PDCD4 contains two tandem MA3 domains on the middle and carboxyl end 
area formed by conserved alpha helices, through which it binds to EIF4A producing a 
stable complex that displaces EIF4G and RNA from EIF4A during translation 
initiation
290
. MA-3 domains consist of more than 120 amino acids and they are present 
in a number of translation initiation factors, such as eIF4G, plant eIF(iso)4F and an 
isoform of eIF4G, DAP-5/NAT/p97
298
. The MA3 domains are believed to be involved 
in the interactions of the initiation factors, although their specific role is unknown. 
PDCD4 protein is highly expressed in lymphocytes and the epithelial cells of the 
mammary gland 
295,299
.  
rs6585018 is located 385 bp upstream of the start of the PDCD4 gene within the 
predicted promoter region of the gene, rendering this SNP an interesting variation for 
further investigation. The promoter of PDCD4 was identified and described for the 
chicken homologue Pdcd4 but not for the human gene
300
. The chicken Pdcd4 gene was 
shown to include Myb-inducible regulatory elements
301
. Human PDCD4 also contains 
recognition sites for Myb transcription factor (Appendix, Figure A1) suggesting that the 
human gene could be under the Myb-transcription regulation. 
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Any polymorphic marker located within the regulatory elements of a gene such as the 
promoter could potentially influence directly gene transcription by altering the 
recognition sites of transcription factors that bind to sequences within the promoter or 
regulatory regions. The association of the marker to the disease could therefore reflect 
differing expression levels of the gene product which in turn may influence disease 
aetiology. Equally the marker may not be the key variant causing the disease but could 
be in linkage disequilibrium with the real causative alleles. Consequently, the critical 
next step would be to conduct fine mapping of the association to establish which variant 
is causing disease. The key to fine mapping is the investigation of the linkage 
disequilibrium of the gene region by genotyping further markers in the sample sets.  In 
addition novel variants should be explored by gene re-sequencing in selected 
individuals and then genotyping of any new markers identified. In this way an extensive 
picture of the LD of the region can be constructed ideally resulting in the key causative 
variant being pinpointed.  
As the association with rs6585018 was the most significant found (Chapter III) and the 
variant was within a key regulatory region of the PDCD4 gene, a fine mapping of the 
PDCD4 gene region will be conducted to further dissect the association seen in order to 
establish whether rs6585018 was the key variant or to identify the causative SNP. 
 
4.1.1 Fine mapping methods 
For fine mapping, it is essential to comprehend and explore the gene area with the 
functional identified elements and the way they affect the expression of the gene. Many 
software programs are publicly available and could be used to enrich the already 
published information about the position of the regulatory regions such as the promoters 
and the enhancers. Polymorphic sites are more commonly found in inter-genic regions 
and introns, areas of less functional interest than the exons and the regulatory regions, 
since natural selection would deplete genotypes with a detrimental effect to an 
individual. 
Prior to the completion of the Human Genome Project
29,239
, genome-wide scans using 
microsatellites identified regions of genetic linkage, which extended for several Mb. 
Fine mapping strategies were used in conjunction with linkage studies following 
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positional cloning to identify candidate genes in these wide chromosomal regions. The 
identification of PHF11 and DPP10 as important genes underlying asthma were a result 
of genetic linkage being found followed by positional cloning incorporating fine 
mapping
96,97
. Fine mapping including saturation genotyping was also performed in the 
candidate gene approach studies to determine the specific functional variant within a 
gene. GWAS should be also followed by fine mapping strategies to ensure that a variant 
within or close to the gene is the key functional disease associated SNP.  
Examples include a common mis-sense variant located in the glukocokinase regulatory 
protein gene (GCKR). This variant was found to be associated with metabolic 
phenotypes such as measurements of glucose homeostasis following fine mapping after 
a genome-wide association approach and association studies in 12 independent 
cohorts
302
. A non-synonymous polymorphism of the nicotinic acetylcholine receptor 
subunit gene (CHRNA5) was identified as the variant with the strongest association in 
lung cancer through fine mapping following once more a GWAS and a replication 
study
50
. A fine mapping study of hepatocyte nuclear factor (HNF1B) on chromosome 
17q12, resulted in the discovery of two independent loci, separated by a recombination 
hot spot, associated with prostate cancer 
269,303
. A number of candidate functional SNPs 
in the breast cancer susceptibility gene fibroblast growth factor receptor 2 (FGFR2)
274
 
were evaluated in a fine-scale mapping study and a single variant located on a DNase I 
hypersensitive site was isolated as significantly associated with breast cancer
304
.  
The first step prior to SNP selection is to obtain all the relevant genomic information for 
the particular candidate gene area. This includes the identification of all the SNPs in the 
area, the sorting of these SNPs according to their functionality and the construction of 
the LD map of the area using public databases such as Ensembl, UCSC Genome 
Browser
305
 and HapMap. Although SNPs located within known functional elements 
could be viewed as more likely to be causal variants, it is best to select SNPs evenly 
spaced across the region of interest as most variations are not well characterised and 
could be potentially contributing to the function of the gene
306
. A good alternative is to 
select tagSNPs; that is SNPs that could serve as proxies for the rest of the SNPs in the 
area depending on the haplotype structure of the region
307
.  
For fine mapping a lower quantity of genotyping is usually required as opposed to the 
hundreds of thousands of SNP that are examined by GWA studies.  Again many of the 
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low level genotyping platforms are PCR- based but nonetheless array technology can 
still be used with companies like Affymetrix (http://www.affymetrix.com) and Illumina 
(http://www.illumina.com/) offering custom arrays with a lower number of features 
allowing investigation of a few hundred SNPs simultaneously. These types of arrays 
however only become cost effective if one is looking to genotype a substantial number 
of individuals.   
In addition to genotyping SNPs included in public databases e.g. HapMap, sequencing 
can also be used to identify rare novel variations that tend not to be in the public 
databases 
308,309
. GWA studies focus on SNPs of high frequency that are informative. 
Less frequent SNPs can be more important in disease aetiology when dealing with a 
complex disease and therefore once a region has been identified by GWAS it is 
important to characterise and genotype these less frequent variants. Multiple rare non-
synonymous sequence variants, for example, were found to contribute significantly to 
low plasma HDL-C levels
310
 and to be enriched in individuals with reduced sterol 
absorption and plasma low-density lipoprotein levels
311
. At present sequencing for 
identification of novel variants has had to focus on re-sequencing a limited number of 
individuals. With the development of high throughput ultra-deep sequencing and the 
next generation sequencers, at present rather costly technology, one can anticipate that 
SNP discovery strategies will evolve and have in fact already begun to do so with 
projects like the 1000 genomes (http://www.1000genomes.org/)
112,312,313
.  
Sequencing can be used in combination with restriction fragment length polymorphism 
(RFLP) mapping, to detect polymorphisms in DNA sequence by using restriction 
endonucleases that recognise a specific DNA fragment containing the possible 
polymorphism
314
. 
Areas of low complexity due to repetitive elements are prone to produce errors during 
genotyping or sequencing, therefore, it is also important to include redundant SNPs (or 
a set of SNPs) in high LD (r
2
>0.8) with the initial finding in the original study.  
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4.1.2 PDCD4 and fine mapping 
For PDCD4 a number of markers not included in the GWA study but identified from 
public databases and informed by HapMap data, will be selected and typed in the severe 
asthmatic and healthy children used in the previous genotyping steps (Chapter III). The 
PDCD4 area will be analysed bioinformatically and regions of potential functional 
relevance will be chosen for re-sequencing in a number of asthmatic children to identify 
novel/rare SNPs. Any interesting SNPs will be subsequently genotyped in all samples. 
Additionally, a group of mild asthmatics will also be genotyped for comparison to 
severe asthmatics, in order to assess if the underlying association seen relates to therapy 
induced steroid-resistance in the severe asthmatics.  
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4.2 Materials and Methods 
4.2.1 Selection of SNPs 
4.2.1.1 The Genome Browsers-Visualizing the genomic information for the PDCD4 
gene 
Public databases including The University of Santa Cruz (UCSC) Genome Browser, 
Ensembl, HapMap genome browser and the SNP database dbSNP were used for 
accessing an overview of the PDCD4 gene area. The UCSC Genome Browser providing 
a portal to the ENCyclopedia Of DNA Elements (ENCODE) Project
150
 includes 
functional information, assemblies for a collection of genomes and information on gene 
expression, homology and DNA variation
315
 (http://genome.ucsc.edu/ ). 
Ensembl is a cooperative scheme between the European Bioinformatics Institute and the 
Wellcome Trust Sanger Institute (http://www.ensembl.org). Initially launched in 1999, 
the database subsequently in combination with the Human Genome project
29,239
 aims to 
display genomic data from humans and other vertebrates by generating graphical views 
of the genes and their features
233
. Similarly to the UCSC browser, Ensembl provides 
information on genetic variation but additionally provides data from comparative 
genomics alignments for orthologous and paralogous genes. Detailed images of 
transcript and protein structures are also available on the database. 
Another useful tool to navigate through the genomic areas and also gain access to 
genotyping data is the HapMap genome browser (http://www.hapmap.org/). Through 
the browser it is possible to download the analysis datasets as well as gain interactive 
access to the database. 
An alternative for acquiring detailed SNP information is the SNP database dbSNP  
(http://www.ncbi.nlm.nih.gov/sites/entrez) of the National Centre for Biotechnology 
Information (NCBI)
316
.dbSNP is a repository for information on single nucleotide 
polymorphisms, short deletion and insertion polymorphisms but does not contain 
extensive information on the relationships between the SNPs. 
All four data resources, the UCSC, the Ensembl, the HapMap browsers and the dbSNP 
database share connections and tracks with each other and many forms of data are being 
integrated from one browser into the other.  Each database as indicated above has 
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explicit characteristics and the analysis of a candidate region is therefore invariably 
more powerful if information from each one is used in combination (Table 4.1).  Data of 
selected regions, including the genotype listings and allele frequencies can be exported 
from the browser for use in planning fine mapping studies.   
PDCD4 was loaded in the USCS and the Ensembl browsers and the largest splice 
variant (ENST00000280154) was chosen for analysis since it is transcribed from a 
larger proportion of the gene and it entirely contains the second splice variant. Using the 
UCSC Genome browser, SNPs and their LD patterns were visualised as well as 
regulatory elements, such as CpG islands, transcription binding sites and microRNAs 
sites in the region. To relate variation relative to the protein structure of PDCD4 the 
Ensembl browser was used. In both domains, the SNPs lying across the PDCD4 area 
were entered to identify those found on regulatory regions or specific domains of the 
protein.  
A list of all SNPs in the genomic area was created combining all the characteristic 
information obtained from the 2 browsers. In addition, the PDCD4 region was loaded 
into dbSNP database as well as the Applied Biosystems (ABI) search engine. dbSNP 
enabled examination of information in relation to SNP validation whilst the ABI search 
engine was performed to determine if SNP TaqMan
®
 assays exist for the SNPs of 
interest. The area including the gene, chr10:112,621,586-112,649,754, was entered at 
the „Landmark or Region‟ textfield on the HapMap Project Data Browser. To capture 
any upstream or downstream regulatory elements, 10 Kb were added at both the start 
and the end of the region (NCBI Build 36.1). Data from the combined Phase I, II and III 
HapMap Project (Chapter III, Section 3.1.1) were used in the analysis. Genotype data 
for all the SNPs on the area were retrieved from the browser and were run using the 
Haploview program
317
 to view the LD and haplotype structure of the region.  
 
Haploview can be used to comprehend the LD structure by providing a means of 
haplotype analysis of different datasets. The test and methods include marker quality 
statistics, LD information, haplotype blocks, population haplotype frequencies and 
single marker association statistics.  
 
Pairwise LD is calculated by D‟ or r2 and a plot representing the values is created. The 
LD values, LD display spacing
307,318
, colour scheme and the number of the markers can 
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be adjusted by the user. Haplotypes can be constructed and their frequencies in the 
population are calculated. The association between different haplotypes is described by 
Hedrick‟s multiallelic D‟, which represents the LD between two blocks by addressing 
them as single markers. 
 
Haplotype-based association testing and evaluation of significance using permutation 
testing can be also generated for manipulating unprocessed genotyping data. Tagger 
program is used to select tagSNPs and calculate the degree of correlation between 
different markers. The data presented in different tabs are analysed in real time and the 
user has the opportunity to customise nearly all options of the analysis. 
 
For the PDCD4 SNPs HapMap genotyping data for the CEU population with Western 
European ancestry were imported in Haploview and haplotypes were constructed. By 
using the Tagger program the degree of coverage of the selected tagSNPs was 
measured
319
. Visualization of the selected tagSNPs was performed by running the data 
on the Goldsurfer2 platform
320
. 
Finally, the list of SNPs chosen for genotyping was compared with the list of SNPs 
included in the GWAS. A number of SNPs were included in the 1958 British Cohort 
study
287
 and this information was also included in the SNP list. SNPs additional to those 
on the GWAS arrays and SNPs included in the 1958 British cohort study were selected. 
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4.2.1.2 Selection of areas of functional interest for sequencing in the PDCD4 gene 
 
The PDCD4 gene area was bioinformatically analysed using the Ensembl and UCSC 
browsers to search for regulatory regions or other domains with particular importance in 
the expression and function of the protein. Areas of the PDCD4 gene poorly covered by 
SNPs on the genome wide SNP arrays were identified as well as areas of particular 
interest in relation to gene expression and protein function. These regions were re-
sequenced (Section 4.2.1.3) to search for novel variations not present in public 
databases such as the dbSNP and to evaluate reported SNPs in dbSNP that were not 
validated.  
The PDCD4 protein contains two MA3 domains formed by conserved alpha helices 
(Section 4.1) in the middle and carboxyl end regions of the protein, through which it 
binds to EIF4A exerting its translation suppression ability. EXPASY is a protein 
analysis system which provides information on protein sequences and structures from 
the protein knowledgebase UniProt/Swiss-Prot (http://www.expasy.ch/) in collaboration 
with the European Bioinformatics Institute 
321
. Using EXPASY and dbSNP databases, 
the gene areas encoding for the MA3 were examined to see if they included variations 
and whether the variations were validated or included in the original GWAS
191
.  
The putative promoter area of the human gene extending 5‟ of PDCD4 gene was 
examined for known variations using the Ensembl, USCS databases, MethPrimer 
(http://www.urogene.org/methprimer/index1.html) and the CpG Island Finder 
(http://cpgislands.usc.edu) online software tools to search for CpG islands. CpG islands 
are genomic regions of 300-3000 bp, which are characteristically rich in CpG sites and 
present in approximately 40% of promoters of mammalian genes
322
. The programs 
predict CpG islands by searching the sequence base by base and evaluating the 
segments by the GC content ≥50%, the length of the region greater than 200 bp and an 
observed/expected ratio of CG greater of 0.6 approximately. The CpG count performed 
represents the actual number of CG di-nucleotides in the island and the percentage CpG 
is the ratio of CpG present in the region.  
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4.2.1.3 Sequencing of PDCD4 gene regions 
For the predicted promoter and exons 6 and 10 of PDCD4 sets of primers (Invitrogen) 
were selected (Appendix, Table A1) using the Primer3 software 
(http://frodo.wi.mit.edu/primer3/). For exon 6, the genomic area starting from 
112,637,234 to 112,637,621 bp (NCBI Build 36.1) was re-sequenced whilst for exon 10 
the genomic area spanning 112,644,093 to 112,644,444 bp was examined. Two sets of 
primers were selected in the promoter to amplify regions 112,621,625 to 112,622,006 
and 112,622,164 to 112,622,604 (NCBI Build 36.1). Details of the primers used for 
PCR amplification and sequencing of each region are detailed in Table 4.2. 
Region Product 
size 
Primers 5’ to 3’  Tm 
(
o
C) 
GC% 
Promoter_1 381 bp CCCCGTGTTACTGGGTAGAA 59.85 55.00 
GCTCAGAAAGAGGGAACCAG 59.01 55.00 
Promoter_2 440 bp GGCTGGACTGAAATCCTGTG 60.66 55.00 
ACCCCATGTACGTTACAGCA 58.93 50.00 
Exon 6 387 bp GCACAGGGAAAGGTGTGTTT 60.01 50.00 
GGAGTATCCAGTGCTAATTCAGG 59.17 47.83 
Exon 10 351 bp GGTGCATTTTAGGAGCAGTTTC 60.14 45.45 
AATGGTTGCAAAAGGTTCAAA 59.48 33.33 
 
Table 4.2. Primer3 selected oligos for re-sequencing of key PDCD4 gene regions 
 
For the sequencing methods, samples were selected with regard to the rs6585018 
genotype. The rs6585018 SNP was associated with asthma in the original study and the 
case control study in severe asthmatics (Chapter III). In this part of the study sequencing 
of samples carrying the alternative rs6585018 alleles could reveal whether rs6585018 
effects express the association with asthma of a rare and novel variant in LD with 
rs6585018
64
. Fifteen of the samples were chosen to be homozygote for the A allele 
(AA) and 10 samples were chosen to be heterozygote (GA) for the SNP rs6585018. 
Homozygotes for the G allele were not available as they were extremely rare in the 
group of severe asthmatic children (1 sample in 116 samples in total). PCR reactions 
were set up with the four sets of primers using 25 DNA templates from the severe 
asthmatic children group.  
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For the Promoter_1 region the PCR reaction contained 100ng of DNA, 200μM dNTPs 
(Roche), 1.2X KCl buffer (Roche), 800nM of each of the primers, 0.75 units of 
AmpliTaq Gold (Roche) and 1.5mM MgCl2 (Roche) up to a final volume of 15μl. The 
PCR conditions for the Promoter_1 region were 95
o
C for 15min, followed by 33 cycles 
of 95
o
C for 1min, 59
o
C for 1min, 72
o
C for 1min and a final cycle of 72
o
C for 10min. 
For the Promoter_2 region the PCR reactions were set up containing 100ng of DNA, 
200μM dNTPs (Roche), 1X KCl buffer (Roche), 800nM of each of the primers, 0.75 
units of AmpliTaq Gold (Roche) and 1.5mM MgCl2 (Roche) to a final volume of 15μl. 
The PCR conditions for the Promoter_2 region were 95
o
C for 15min, followed by 33 
cycles of 95
o
C for 1min, 58
o
C for 1, 72
o
C for 1min and a final cycle of 72
o
C for 10min. 
For the Exon 6 region the PCR reactions contained 50ng of DNA, 200μM dNTPs 
(BIOLINE), 1X KCl buffer (BIOLINE), 200nM of each of the primers, 0.5 units of 
BIOTAQ
TM
 and 1.5mM MgCl2 (BIOLINE) to a total volume of 10μl. The PCR 
conditions for the Exon 6 region were 32 cycles at 95
o
C for 1min, 55
o
C for 1min and 
72
o
C for 1min. 
For the Exon 10 region, the PCR reactions contained 50ng of DNA, 200μM dNTPs 
(BIOLINE), 1X KCl buffer (BIOLINE), 200nM of each of the primers, 0.5 units of 
BIOTAQ
TM
 and 1.5mM MgCl2 (BIOLINE) to a total volume of 10μl. The PCR 
conditions for the Exon 6 region were 95
o
C for 1min, 56
o
C for 1min and 72
o
C for 1min 
for 32 cycles. 
All reactions were first optimised for MgCl2 concentration, buffer concentration, 
enzyme units, the amount of DNA, annealing temperature and number of cycles of 
PCR. 
Products of PCR reactions were run on 2% agarose gels (Chapter II, Section 2.2.4) to 
ensure the reactions had been successful. 
Post successful PCR, the amplified products were purified using QIAquick
®
 (Qiagen) 
following the manufacturer‟s instructions (http://www1.qiagen.com/). Purified products 
were quantified using the Nanodrop
®
 and 100ng of DNA of each of the samples were 
then sent for sequencing by MWG EUROFINS 
(http://www.eurofinsdna.com/home.html). 
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The sequencing results were assembled and visualised using the CodonCode Aligner 
software Version 2.06 (http://www.codoncode.com/). The software enables sequence 
assembly editing but also mutation detection.  
 
4.2.1.4 Restriction Fragment Length Polymorphism (RFLP) for the amplified fragments 
on the PDCD4 putative promoter 
The variations identified by sequencing on PDCD4 putative promoter fragments were 
verified by using the Restriction Fragment Length Polymorphism (RFLP) method. The 
RestrictionMapper website (http://www.restrictionmapper.org/) was used to analyse the 
fragments and construct mapping sites for restriction enzymes.  
For the variation in the Promoter_2 region, BsrBI restriction endonuclease was found 
appropriate for RFLP mapping. The enzyme recognises the sequence: 
 
 
From the virtual digestion available on the RestrictionMapper website, it was shown 
that a Promoter_1 region including the mutation would not be digested by BsrBI whilst 
the Promoter_1 region containing the wild type variation would be digested by BsrBI 
resulting in two products 294 and 86 bp in size. 
For the variation identified within the Promoter_2 region, the HpaII restriction enzyme 
was selected for RFLP mapping as it recognises the palindromic sequence: 
 
 
The virtual digestion on RestrictionMapper showed that when the mutation was present 
in the Promoter_2 region the digestion products would be 105, 98, 78, 60, 52, 15, 12, 
12, 8 bp in size. When the Promoter_2 region contains the wild type variation the 
products would be 98, 78, 69, 60, 52, 36, 15, 12, 12, 8 bp in size. The two alleles of the 
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variation could therefore be distinguished by the 105 bp fragment present in the mutant 
type and the 69 bp and 36 bp fragments present in the wild type. 
For the digestion reactions, 10μl of PCR product was incubated at 37oC for 3 hours with 
3μl 10X buffer (NEB) and 10 units of restriction enzyme up to a final volume of 15μl. 
The results were visualised in a 4% agarose gel (Chapter II, Section 2.2.4). 
 
4.2.2 Sample characteristics  
The selected SNPs were typed in the 94 severe asthmatic children (Chapter II, Section 
2.2.1, Table 2.2) included in the first stage of genotyping (Chapter III). An additional 
twenty-two severe asthmatic children were recruited and included at this point. These 
children were genotyped for all the selected SNPs in addition to the original SNP that 
showed association, rs6585018. In total 116 severe asthmatic children were genotyped 
for the selected PDCD4 SNPs. The MRCA family (Chapter II, Section 2.2.1, Table 2.5) 
panel which includes 295 asthmatic children (probands), 119 asthmatic adults, 145 
healthy children and 268 healthy adults were also genotyped, with children being typed 
for any PDCD4 SNPs not on the Illumina Sentrix Human-1 Genotyping BeadChip 
(100K) or Sentrix HumanHap300Genotyping BeadChip (300K) GWA Illumina arrays, 
whilst their parents (adults) were genotyped for any PDCD4 SNPs not on the 100K 
GWA array. The healthy children from the MRCA panel were used as controls for 
comparison to the 116 severe asthmatic children. In addition, 111 mild asthmatic young 
adults (Chapter II, Section 2.2.1, Table 2.2) were genotyped for the selected PDCD4 
SNPs. These individuals were also used as controls to be compared to the 116 severe 
asthmatic children. The phenotypic description of all the sample sets is detailed in 
Chapter II Section 2.2.1. 
 
4.2.3 Genotyping using TaqMan
®
 SNP Assays 
For all the selected SNPs TaqMan
®
 assays were available and ready to order from 
Applied Biosystems (www.appliedbiosystems.com/). The custom TaqMan
®
 assay for 
rs6585018 previously designed (Chapter II, Section 2.2.6) was used for the 9 new 
samples in the severe asthmatic child group not previously genotyped. TaqMan assays 
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were run as previously described (Chapter II, Section 2.2.6). Each genotyped SNP prior 
to association analyses had to pass the quality control criteria of a >90% call rate and 
conformance with Hardy-Weinberg equilibrium (see Section 4.2.4). 
 
4.2.4 Statistical analysis 
Deviation from Hardy-Weinberg equilibrium was calculated for the allele frequencies 
for both cases and controls by a χ2 test. SNPs with genotype frequencies presenting a 
significant deviation from Hardy-Weinberg equilibrium were excluded. For the SNPs 
not included in the GWAS a family-based test (the Transmission Disequilibrium Test, 
TDT) was performed for the MRCA panel. Genotype and allele frequencies were 
compared between severe asthmatic children (cases) and MRCA healthy children 
(controls) by Fisher‟s exact test and Odds Ratios (OR) and relative risks were calculated 
for mutant variants. The same tests were applied for mild asthmatics (controls) versus 
severe asthmatic children (cases). Haplotype analysis was performed for the cases and 
the controls in severe asthma versus non-asthma and severe asthma versus mild asthma 
study designs. 
 
4.2.4.1 Transmission Disequilibrium Test (TDT) for MRCA families 
Family-based tests of linkage and association emerged from the necessity to use internal 
and for this reason well-matched controls that can overcome the population 
stratification problem
133
. Well-matched cases and controls can also overcome this 
problem, but a good alternative would be to use family-based association tests that 
utilise simplex family triads consisting of an affected child and its two parents. The 
transmission of a particular allele from the parents to the offspring is tested against the 
transmission of the alternative allele that forms a “control” which is perfectly matched 
with the observed case. In the case of no association between the disease and the marker 
then the parental genotypes are random in the population. In the case of no linkage the 
transmission of the marker allele from the parents to the offspring is independent to the 
transmission of the disease.  
99 
 
In the classic Transmission Disequilibrium Test (TDT) each parent from the family trios 
is classified according to the marker allele they transmit to the proband (the affected 
child) and the allele not transmitted. The data is presented in a 2 x 2 table and a 
McNemar‟s test statistic for paired data is calculated. The test has an approximate χ2 
null distribution with 1 degree of freedom
135
. TDT is fundamentally a test of association 
since it is handling alleles and loci but can also detect linkage if linkage disequilibrium 
is present. 
 
4.2.4.2 Case control statistical analysis 
Fisher‟s exact test was used to compare the genotype frequencies between the cases and 
the controls. Severe asthmatic children were compared to healthy children from the 
MRCA panel and also to healthy subjects from the 1958 British Cohort Study if SNP 
data was available. The OR and the relative risks for the mutant allele were calculated 
and the same analysis was followed when severe asthmatics was compared to mild 
asthmatics. For correction of multiple testing, 5% False Discovery Rate adjustments 
were calculated using Qvalue
286
 software in R language environment. 
 
4.2.4.3 Haplotype analysis 
Haplotype analysis is often used to obtain additional information on the genetic 
associations to a specific trait. For the haplotype analysis, Haploview software was used 
to analyse and visualise patterns of linkage disequilibrium and perform association tests 
for both haplotypes and single SNPs
317
 (Figure 4.1). The haplotype association test is 
performed on the set of blocks constructed by the program. Additionally, permutation 
tests for association significance are available. 
Using the genotype data, haplotypes were generated for controls (MRCA healthy 
children and mild asthmatic adults) and cases (severe asthmatic children) and tests of 
association for both single marker and haplotype were conducted. 
For the correction of the significance due to multiple testing, 1,000 permutations tests 
were used in both the single-markers and the haplotypes. 
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4.3 Results 
4.3.1 Selection of PDCD4 SNPs 
 4.3.1.1 Sequencing and identification of CpG islands results in PDCD4 region 
Sequencing methods (Section 4.2.1.3) were used to identify novel variations within the 
PDCD4 gene area and to verify the existence of un-validated reported SNPs (from the 
dbSNP database). 
First, the MethPrimer and the CpG Island Finder program were used to identify any 
CpG islands in the PDCD4 genomic region (Section 4.2.1.2). The results from the 
MethPrimer showed that there are two CpG islands in the predicted promoter area 765 
bp and 369 bp in size with GC contents of 60% and 73% respectively (Appendix, 
Figure A2). The first CpG island was in close proximity to the SNP rs6585018. CpG 
Island Finder program presented one CpG island of 1745bp with GC% content of 
61.6%, overlapping with MethPrimer 2 predicted CpG islands (Appendix, Figure A1). 
Three parts of the gene were selected for re-sequencing, the putative promoter and 
exons 6 and 10. The predicted promoter area was selected due to the possible presence 
of regulatory elements and because the SNP rs6585018 that had showed highly 
significant association with severe asthma (Chapter III, Section 3.3.4) is located within 
the region. The identification of the CpG island in the region raised the possibility of the 
presence of regulatory elements and the promoter of the gene.  
Two pairs of primers were designed to amplify two products encompassing the whole 
promoter region whilst one pair of primers for each of the exons 6 and 10 were used to 
amplify single products for re-sequencing (Section 4.2.1.3). SNPs requiring validation 
and located within the promoter area were rs36023770, rs11548766, rs61864563, 
rs7897957, rs6585019, rs7901359, rs12219468. For exon 6, only a single SNP 
rs41292600 required validation (based on data currently in dbSNP) whilst for exon 10 
there were two SNPs rs41292602 and rs41292604 (Figure 4.1). 
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4.3.1.2 Sequencing results for the putative promoter region 
After successful PCR amplification of fragments Promoter_1 and Promoter_2 (Figures 
4.2 and 4.3 respectively) for 24 of the 25 selected individuals  the PCR products were 
purified, sequenced and the sequence readings were assembled using CodonCode 
software (for one sample the sequencing results were inconclusive and it was excluded 
from the analysis).  
     
 
Figure 4.2.Fragment Promoter_1 PCR results (2% agarose gel). Lane 1 DNA ladder 
100bp (New England Biolabs), lane 2 and 3 are PCR reactions containing 100ng of 
DNA and lane 4 is the negative control.  Expected amplicon size 381bp. 
 
 
Figure 4.3.Fragment Promoter_2 PCR results (2% agarose gel). Lane 1 DNA ladder 
100bp (New England Biolabs), lane 2-5 are PCR reactions containing 100ng of DNA 
and lane 6 is the negative control.  Expected amplicon size 440bp. 
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For the Promoter_1 fragment one individual (sample ID SCR80) was found to have an 
insertion of a single adenine (-/A) at position 112,621,649bp (NCBI Build 36.1) 
(Figures 4.4 and 4.5). For the Promoter_2 fragment the previously un-validated SNP 
rs12219468 (A/G) was found to be present with twelve samples heterozygous (AG), 5 
samples homozygous for the A allele and 3 samples homozygous for the G allele 
(Figures 4.6 and 4.7). One more sample was shown to include an additional variation in 
the Promoter_2 fragment at position 112,622,323bp (NCBI Build 36.1) A single 
individual (sample ID SCR63) was an heterozygote (AG) for this variation (Figures 4.8 
and 4.9).   
 
 
Figure 4.4. Assembling sequencing results on CodonCode software for the Promoter_1 
fragment. Aligned sequence traces for 6 individuals are shown with the identified A 
insertion highlighted in sample ID SCR80. 
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Figure 4.5. Aligned sequencing results for a section of Promoter_1 fragment for 23 
individuals. The second sequence belongs to individual sample ID SCR80. 
 
 
Figure 4.6. Sequence trace alignments for a fragment of the Promoter_2 amplicon in 6 
individuals (assembled using CodonCode software. SNP rs12219468 G↔A is 
highlighted in the red square. 
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Figure 4.7. Aligned sequencing results for a section of the Promoter_2 amplicon 
fragment for 24 individuals. SNP rs12219468 is highlighted across all the sequences 
with a blue line.  
 
 
Figure 4.8. Sequence traces aligned for Promoter_2 fragment with the base change 
observed in individual sample ID SCR63 highlighted with a red circle. 
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Figure 4.9. Aligned sequences for Promoter_2 fragment for 17 individuals highlighting 
base change in individual SCR63 with a blue line.  
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4.3.1.3 Sequencing results for exons 6 and 10 of the PDCD4 gene 
Using the same set of individuals investigated for the promoter region, PCR 
amplifications of exons 6 and 10 were performed and purified amplicons sent for 
sequencing (Figure 4.10). No novel variations were identified in either exon for the 24 
individuals examined. 
 
 
Figure 4.10.Fragments exon 6 and exon 10 PCR results (2% agarose gel). Lane 3 
includes the DNA ladder 100bp (New England Biolabs), lanes 1 and 2 the PCR 
reactions of 100ng of DNA for fragment exon 10 (351 bp) and lane 4 the PCR reaction 
of 100 ng of DNA for fragment exon 6 (387 bp). Lane 5 was the negative control. 
 
4.3.1.4 RFLP mapping of the novel variations  
PCR-RFLP was used to verify the presence of the novel variations discovered by 
sequencing described in Sections 4.3.1.1 and 4.3.1.2 to exclude the possibility of a Taq 
polymerase error. Four PCR reactions were set-up for fragment Promoter_1 from 
sample SCR80 and the samples were subsequently digested with BsrBI and were run in 
a 2% agarose gel with the original undigested fragment included as a control (Figure 
4.11). The results showed that the PCR products were digested by the enzyme since 
bands of 294 and 86 bp were present in all SCR80 PCR products. This was consistent 
with the wild type digestion pattern as described in Section 4.2.1.4, indicating that 
SCR80 contained the wild type variation on position 87 bp. The novel polymorphism 
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identified in sample SCR80 by sequencing could be therefore explained as a sequencing 
artefact and not a true variation. 
 
 
 
Figure 4.11. Digestion results with BsrBI restriction enzyme. Lane 1 is the 100bp DNA 
ladder (NEB), lanes 2-4 different PCR products of sample SCR80 and Well 5 was the 
undigested Promoter1 fragment. 
 
 
To verify the presence of the variation present at position 221 bp in the Promoter_2 
fragment detected in individual sample ID SCR63 an HpaII digestion of the amplicon 
was performed (Section 4.2.1.4). At the same time digests were performed for 
individuals SCR80, SCR20, SCR22, SCR24 and SCR56 that had also undergone re-
sequencing and digests from all samples were run on the same agarose gel (Figure 
4.12). The pattern of the digest products between the SCR63 and the rest of the samples 
clearly differed. For SCR63 samples a double band was observed at 100bp band size 
(lane 2, Figure 4.12). This double band included the 105 and 98 bp digestion fragments 
matching the digestion products pattern when the variation was present, as described in 
Section 4.2.1.4. The double band of 100bp size was not observed for the PCR-RFLP 
results from samples SCR80, SCR20, SCR22, SCR24 and SCR56 (lanes 4-9, Figure 
4.12). For these samples a single band was observed at this size, which corresponded to 
the 98 bp band, matching the digestion pattern expected for the wild type samples 
(Section 4.2.1.4).  
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The fragment was amplified for sample SCR63 and sent for sequencing and the result 
was the same (Figure 4.13). This suggests the Promoter_2 fragment for sample SCR63 
contains a novel variation, named Prom_2_SNP_2. More specifically sample SCR63 is 
a heterozygote (AG) at position 221 bp from the first bp of the fragment Promoter_2. 
 
 
 
Figure 4.12. Digestion results with HpaII restriction enzyme in a 4% agarose gel. Lane 
1 is the 100 kb DNA ladder (NEB), lanes 2-3 different PCR products of sample SCR63, 
lanes 4-5 different PCR products of sample SCR80 and lanes 6,7,8,9 PCR products of 
samples SCR20, SCR22, SCR24, SCR26. 
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Figure 4.13. Digestion results with HpaII restriction enzyme in a 4% agarose gel. Lane 
1 is the 100 kb DNA ladder (NEB), lanes 2,3,4 different PCR products of sample 
SCR63. 
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Table 4.3 summarises the sequencing results of the 24 samples sequenced for 
Promoter_1 and Promoter_2 fragments and the genotypes of each sample for 
rs6585018.  
 
  Promoter_2 Promoter_1 
SAMPLE NO rs6585018 rs12219468 Prom_2_SNP_2 Prom_1_SNP_1 
SCR1 AA AG GG - 
SCR2 AA AG GG - 
SCR6 GA AG GG - 
SCR11 AA AG GG - 
SCR12 GA AG GG - 
SCR13 GA AG GG - 
SCR16 AA AA GG - 
SCR18 AA AA GG - 
SCR20 AA AA GG - 
SCR21 AA AA GG - 
SCR22 AA AA GG - 
SCR26 AA AG GG - 
SCR31 GA AG GG - 
SCR45 GA GG GG - 
SCR56 GA GG GG - 
SCR63 GA GG AG - 
SCR72 AA AG GG - 
SCR73 AA AG GG - 
SCR77 GA AG GG - 
SCR78 AA AG GG - 
SCR80 GA  -  - A 
SCR82 AA AG GG - 
SCR88 AA GG GG - 
SCR89 AA AA GG - 
 
Table 4.3. Genotypes of the identified novel variants in the putative PDCD4 promoter 
(Prom_2_SNP_2 and Prom_1_SNP_1) and the SNPs rs6585018, rs11195360 for the 24 
DNA samples studied. 
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4.3.1.4 Prioritising PDCD4 SNPs for fine mapping 
Five SNPs located in the PDCD4 genomic area were selected for fine mapping. The 
first SNP, rs1322997 was found to be in perfect LD with the initial finding (r
2
=1.0), in 
SNP rs6585018. Two of the SNPs, rs11195360 and rs1407696, were intronic SNPs 
located within introns 1 and 2 respectively of the gene. A synonymous coding SNP 
within exon 5, rs34104444, was also included for genotyping as well as a SNP located 
within the 5‟ region of the gene, SNP rs4918605 (Table 4.4). 
In the original GWAS
191
  as well as the SNP rs6585018 there were five further SNPs 
within the PDCD4 gene that were genotyped but showed no significant association. 
These SNPs were a mis-sense coding SNP rs7081726 in exon 3, and four tagSNPs 
rs10787287 in intron 5, rs6585021 in intron 7, rs1410052 in intron 8 and rs10787289 in 
intron 11. None of these SNPs were in LD with the 5 SNPs selected for fine mapping 
(Table 4.4) and they were excluded from the fine mapping due to their prior lack of 
association. Figure 4.14 shows the position of the markers on the PDCD4 gene region 
with the two alternative splice variants shown. The selection of the markers was 
conducted using the longer of the variants (28.17 Kb encoding the 51.7 KDa PDCD4 
protein). 
All five SNPs selected had been previously validated (frequency data available on 
dbSNP http://www.ncbi.nlm.nih.gov/projects/SNP/) and there were Applied Biosystems 
TaqMan
®
 SNP assays available for all SNPs. None of the SNPs were monomorphic and 
three (rs1322997, rs11195360, rs1407696) had previously been genotyped in the 1958 
British Cohort sample set (http://www.b58cgene.sgul.ac.uk/) providing an additional set 
of control genotyping data for comparison with the genotyping data of the severe 
asthmatic samples. 
Genotype data showed that SNP rs12219469 identified by sequencing in Section 4.3.1.1 
on Promoter_2 fragment was in perfect LD with SNP rs11195360 (data not shown) 
therefore it was not investigated any further since it provided redundant information. 
The variation Prom_2_SNP_2 also identified on the Promoter_2 fragment, described in 
Section 4.3.1.1 was not included in the fine mapping genotyping as it was extremely 
rare (one heterozygote was found  in the 24 samples tested in Section 4.3.1). 
Three of the SNPs, rs1322997, rs11195360 and rs4918605 were selected by the Tagger 
program within the Haploview software to provide good proxies (r
2
>0.8) for the 
113 
 
remaining markers lying within the area. Pairwise-Tagger selection used within 
HapMap CEU dataset also indicated SNP rs11195360 as a tag SNP. Using the 
Haploview Tagger program, markers rs11195360 and rs1407696 were also found to be 
in LD (r
2
=0.9) in the CEU HapMap population. 
 
Table 4.4. The PDCD4 SNPs selected for fine mapping method (Het: heterozygosity, 
MAF%: Minor allele frequency %). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No SNP ID Allele  Function Het MAF% TaqMan SNP 
Assay 
Genotyped 
previously in 
B58C 
1 rs4918605 A/G Intergenic 0.499 25 C__28006862_10 NO 
2 rs1322997 A/C 5' near gene 0.129 3 C___7612060_10 YES 
3 rs11195360 C/T Intron 1 0.484 32 C__31264106_10 YES 
4 rs1407696 G/T Intron 2 0.483 31 C___7612059_10 YES 
5 rs34104444 A/G Exon 5/ 
Synonymous 
0.108 5 C__25629716_10 NO 
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Figure 4.14 The PDCD4 gene including its variations from the Ensembl database, 
NCBI Build 36.1) (The marker that showed the original association in the GWAS
191
 is 
highlighted in red). 
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Figure 4.15 Genomic overview of the PDCD4 gene area by UCSC browser (The LD 
structure in the area is shown represented by the blocks depicting the pairwise D′.  The 
different shades of red indicate varying degrees of LD as quantified using D′, with 
higher D′ values represented by a darker shade). 
 
 
 
 
 
 
 
LD structure 
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4.3.2 Genotyping results 
4.3.2.1 Genotyping of severe asthmatic children (SCR), MRCA panel and mild 
asthmatic adults 
The 5 selected SNPs for fine mapping were genotyped (Section 4.2.3) in subjects from 
the MRCA family collection, the severe asthmatic children and the mild asthmatic 
young adults. For SNP rs6585018 the genotyping data of the MRCA family was 
available from the previous GWA study
191
.  
In total, the SNPs were genotyped in 1054 DNA samples consisting of 145 healthy 
children, 268 healthy adults, 295 asthmatic children and 119 asthmatic adults from the 
MRCA family panel (Chapter II, Section 2.2.1,Table 2.5), and 111 mild asthmatics and 
116 severe asthmatic children (termed the SCR panel) (Chapter II, Section 2.2.1,Table 
2.2). All the TaqMan assays had genotyping call success rates greater than 98% and 
SNP genotype frequencies were in Hardy-Weinberg equilibrium as assessed by χ2 test. 
Table 4.5 summarises the genotyping quality control results for all the assays. For SNPs 
rs11195360, rs1407696 and rs1322997 genotyping data from the 1958 British Cohort 
Study (termed B58C) were available and they were included in the downstream 
statistical analyses.  Tables 4.6 to 4.11 include the overall available genotype counts and 
frequencies in all groups for the 6 SNPs genotyped. The data were subsequently used in 
case-control and family-based association tests. For SNP rs6585018 (Table 4.10) 10 
additional samples were typed from the MRCA non-asthmatic children which were not 
included in the GWAS and 22 samples from the SCR panel compared to previous 
genotyping step (Chapter III, Section 3.3.4, Table 3.8). 
 
 
 
 
 
 
Table 4.5. Genotyping results for the 6 selected PDCD4 SNPs. 
SNP  rsID Samples genotyped 
in 1054 total 
subjects 
Call 
rate 
HWE χ2 test 
P value 
rs4918605 1036 98.29% 0.9957 
rs1322997 1045 99.14% 0.5866 
rs11195360 1034 98.10% 0.9527 
rs1407696 1031 97.81% 0.7380 
rs34104444 1039 98.57% 0.9796 
rs6585018 1046 99.24% 0.8855 
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  rs34104444    
 Counts     
Genotype  GG AG AA Total    
Normal children MRCA 130 9 1 140   
Asthmatic children MRCA 253 38 0 291   
SCR 90 21 1 112   
Normal adults MRCA 239 27  0 266   
Asthmatic adults MRCA 108 12 0 120   
Mild asthmatics 104 5 1 110  
        
 Frequencies     
Genotype GG AG AA    
Normal children MRCA 0.930 0.063 0.007    
Asthmatic children MRCA 0.870 0.130 0.000    
SCR 0.803 0.187 0.010    
Normal adults MRCA 0.898 0.102 0.000     
Asthmatic adults MRCA 0.899 0.101 0.000     
Mild asthmatics 0.946 0.045 0.009   
Table 4.6. Genotype counts and frequencies for SNP rs34104444.  
 
  rs4918605    
 Counts     
Genotype GG AG AA Total    
Normal children MRCA 72 58 10 140   
Asthmatic children MRCA 135 129 26 290   
SCR 51 48 16 115   
Normal adults MRCA 115 123 29 267   
Asthmatic adults MRCA 69 44 7 120   
Mild asthmatics 46 45 13 104  
        
 Frequencies     
Genotype  GG AG AA    
Normal children MRCA 0.509 0.420 0.071    
Asthmatic children MRCA 0.466 0.445 0.089    
SCR 0.443 0.418 0.139    
Normal adults MRCA 0.431 0.460 0.109     
Asthmatic adults MRCA 0.575 0.367 0.058     
Mild asthmatics 0.442 0.433 0.125   
Table 4.7. Genotype counts and frequencies for SNP rs4918605.  
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  rs11195360    
 Counts     
Genotype  CC TC CC Total    
Normal children MRCA 71 56 13 140   
Asthmatic children MRCA 127 135 29 291   
SCR 49 49 16 114   
B58C 707 636 137 1480   
Normal adults MRCA 110 123 32 265   
Asthmatic adults MRCA 66 42 12 120   
Mild asthmatics 43 48 13 104  
        
 Frequencies     
Genotype CC TC TT    
Normal children MRCA 0.507 0.400 0.093    
Asthmatic children MRCA 0.436 0.464 0.100    
SCR 0.430 0.430 0.140    
B58C 0.478 0.430 0.092     
Normal adults MRCA 0.415 0.464 0.121     
Asthmatic adults MRCA 0.550 0.350 0.100     
Mild asthmatics 0.413 0.462 0.125   
Table 4.8. Genotype counts and frequencies for SNP rs11195360.  
 
  rs1407696    
 Counts     
 Genotype CC AC AA Total    
Normal children MRCA 73 53 13 139   
Asthmatic children MRCA 130 133 28 291   
SCR 48 46 17 111   
B58C 706 596 128 1430   
Normal adults MRCA 115 120 32 267   
Asthmatic adults MRCA 65 42 12 119   
Mild asthmatics 43 48 13 104  
        
  Frequencies         
Genotype  CC AC AA    
Normal children MRCA 0.525 0.381 0.094    
Asthmatic children MRCA 0.447 0.457 0.096    
SCR 0.433 0.414 0.153    
B58C 0.494 0.417 0.089    
Normal adults MRCA 0.430 0.450 0.120     
Asthmatic adults MRCA 0.546 0.353 0.101     
Mild asthmatics 0.413 0.462 0.125   
Table 4.9. Genotype counts and frequencies for SNP rs1407696.  
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  rs1322997    
 Counts     
Genotype  AA CA CC Total    
Normal children MRCA 133 10 1 144   
Asthmatic children MRCA 255 41 0 295   
SCR 87 23 1 111   
B58C 1343 134 3 1480   
Normal adults MRCA 237 32 0 269   
Asthmatic adults MRCA 108 12 0 120   
Mild asthmatics 99 6 0 105  
        
 Frequencies     
Genotype  AA CA CC    
Normal children MRCA 0.924 0.069 0.007    
Asthmatic children MRCA 0.861 0.139 0.000    
SCR 0.784 0.207 0.009    
B58C 0.908 0.090 0.002    
Normal adults MRCA 0.881 0.119 0.000     
Asthmatic adults MRCA 0.900 0.100 0.000     
Mild asthmatics 0.943 0.057 0.000   
Table 4.10. Genotype counts and frequencies for SNP rs1322997. 
 
  rs6585018    
 Counts     
Genotype AA GA GG  Total   
Normal children MRCA 133 10 1 144   
Asthmatic children MRCA 254 40 0 294   
SCR 88 23 1 112   
Normal adults MRCA 237 32 0 269   
Asthmatic adults MRCA 108 12 0 120   
Mild asthmatics 101 5 0 107  
  Frequencies         
Genotype  AA GA GG    
Normal children MRCA 0.924 0.069 0.007    
Asthmatic children MRCA 0.864 0.136 0.000    
SCR 0.786 0.205 0.009    
Normal adults MRCA 0.881 0.119      0.000     
Asthmatic adults MRCA 0.900 0.100 0.000   
Mild asthmatics 0.944 0.047 0.009   
Table 4.11. Genotype counts and frequencies for SNP rs6585018.  
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4.3.2.2 Case-control study:  Severe asthma versus non-asthma and severe asthma 
versus mild asthma 
The healthy children from the MRCA panel (N=145) were used as controls and their 
genotype frequencies were compared to the severe asthmatic children genotype 
frequencies. A Fisher‟s Exact test was used and Odds Ratios (OR) and relative risks 
(RR) were calculated for the minor alleles of each SNP. First, severe and MRCA 
healthy children where compared as both were collected through hospital clinics 
(healthy children collected because their affected sib was attending the clinic) and it was 
less likely to be an ascertainment bias. For the three SNPs (rs1407696, rs11195360 and 
rs1322997) with data available from the 1958 British Cohort Study, the genotype 
frequencies were also used as controls to compare them against the severe asthmatic 
children genotype frequencies although it was recognised that there was discrepancy 
with regard to age/or that they were not age matched. Therefore the genotype 
frequencies between controls from the B58C and controls from the healthy MRCA 
subjects for SNPs rs11195360, rs1407696 and rs1322997 were compared using Fisher‟s 
exact test. No significant deviation was observed for any of the SNPs (rs11195360: 
P=0.829, rs1407696: P=0.775, rs1322997: P=0.367). Consequently the genotype 
frequency data from both control groups (MRCA healthy children and B58C controls) 
were also used combined for the analysis of these 3 SNPs. SNPs rs34104444, 
rs1322997 and rs6585018 were found to be significantly associated to severe childhood 
asthma (P=0.01, P=0.005, P=0.005) when MRCA control children were used and SNP 
rs1322997 showed a significant association to asthma when 1958 BCS data were used 
(P=0.00015). The Odds Ratios (OR) for the three SNPs were 2.82 (95% Confidence 
Interval (CI) 1.31-6.05), 2.91 (95% CI: 1.41-6.02) and 2.88 (95% CI: 1.39-5.96) 
respectively. The relative risks (RRs) for the mutant alleles in each SNP (A, C, G) were 
2.63, 2.70 and 2.76 respectively. Finally, the OR for rs1322997 when 1958 BCS control 
data were used was 2.53 (95%CI: 1.61-3.97) with a 2.36 RR for allele C. The other 3 
SNPs (rs4918605, rs11195360 and rs1407696) showed no significant associations 
(Tables 4.12 to 4.17). 
When mild asthmatics were used as controls and compared to severe asthmatic children 
similar results were obtained, rs34104444: P=0.0044, rs1322997: P=0.003 and 
rs6585018: P=0.002. The ORs for these SNPs were 3.48 (95% CI: 1.45-8.38), 4.31 
(95% CI: 1.76-10.57) and 3.72 (95% CI: 1.57-8.79) respectively. Similarly, the RRs 
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were calculated for the risk alleles (A, C, G) were 3.23, 3.94 and 3.41 respectively. No 
significant associations were seen for the SNPs rs4918605, rs11195360 and rs1407696 
(Tables 4.12 to 4.17). 
Comparing the genotype frequencies in the three subject groups used, the severe 
asthmatic children (SCR), the non-asthmatic MRCA children and the mild asthmatics it 
was found that for severe asthmatics the frequencies of the minor alleles (A, C, G) were 
increased compared to both non-asthmatics and the mild asthmatics with the two latter 
groups having similar allele frequencies (Tables 4.6, 4.10 and 4.11 for the three SNPs). 
This could be an indication of the importance of the variations and PDCD4 gene in 
asthma therapy control. All the results remained significant when correction for 
multiple testing was conducted using a False Discovery Rate threshold of 5% (Tables 
4.12, 4.16 and 4.17 for the three SNPs). 
 
rs34104444 
 
rs34104444 
 
GROUPS OR (95% CI) RR 
Fishers exact 
test P value 
Fishers exact 
test P value 
corrected 
SCR versus       
MRCA HEALTHY 
CHILDREN 2.82 (1.31-6.05) 2.63 P=0.01 P=0.0214 
SCR versus         
MILD  STHMATICS 3.48 (1.45-8.38) 3.23 P=0.0044 P=0.0125 
Table 4.12. Association test results for SNP rs34104444 (corrected P values were 
adjusted for 5% FDR). 
Table 4.13. Association test results for SNP rs4918605 (corrected P values were 
adjusted for 5% FDR). 
 
rs4918605  
GROUPS OR (95%CI) RR 
Fishers exact 
test P value 
Fishers exact 
test P value 
corrected 
SCR versus  
MRCA HEALTHY 
CHILDREN 1.37 (0.92-2.04) 1.24 P=0.174 P=0.2877 
SCR versus  
MILD ASTHMATICS 1.03 (0.268-3.95) 1.02 P=0.945 P=0.945 
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rs11195360  
GROUPS OR (95% CI) RR 
Fishers exact 
test P value 
Fishers exact 
test P value 
corrected 
SCR versus  
MRCA HEALTHY 
CHILDREN 1.32 (0.878-1.97) 1.21 P=0.348 P=0.435 
SCR versus  
B58C + MRCA 1.25 (0.929-1.68) 1.16 P=0.211 P=0.2877 
SCR versus  
MILD STHMATICS 1.00 (0.95-1.05) 1.00 P=0.88 P=0.9528 
Table 4.14. Association test results for SNP rs11195360 (corrected P values were 
adjusted for 5% FDR). 
 
rs1407696  
GROUPS OR (95% CI) RR 
Fishers exact 
test P value 
Fishers exact 
test P value 
corrected 
SCR versus  
MRCA HEALTHY 
CHILDREN 1.42 (0.953-2.11) 1.27 P=0.211 P=0.2877 
SCR versus 
B58C+MRCA 1.34 (1.00-1.80) 1.22 P=0.072 P=0.135 
SCR versus  
MILD ASTHMATICS 1.02 (0.795-1.31) 1.01 P=0.732 P=0.8446 
Table 4.15. Association test results for SNP rs1407696 (corrected P values were 
adjusted for 5% FDR). 
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rs1322997  
GROUPS OR (95% CI) RR 
Fishers exact 
test P value 
Fishers exact 
test P value 
corrected 
SCR versus  
MRCA HEALTHY 
CHILDREN 2.91 (1.41-6.02) 2.70 P=0.005 P=0.0125 
SCR versus 
B58C+MRCA 2.53 (1.61-3.97) 2.36 P=0.00015 P=0.00225 
SCR versus  
MILD ASTHMATICS 4.31 (1.76-10.57) 3.94 P=0.003 P=0.0125 
Table 4.16. Association test results for SNP rs1322997 (corrected P values were 
adjusted for 5% FDR). 
 
rs6585018  
GROUPS OR (95% CI) RR 
Fishers exact 
test P value 
Fishers exact 
test P value 
corrected 
SCR versus  
MRCA HEALTHY 
CHILDREN 2.88 (1.39-5.96) 2.67 P=0.005 P=0.0125 
SCR versus  
MILD ASTHMATICS 3.72 (1.57-8.79) 3.41 P=0.002 P=0.0125 
Table 4.17. Association test results for SNP rs6585018 (corrected P values were 
adjusted for 5% FDR). 
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4.3.2.3 Transmission disequilibrium test (TDT) results for the MRCA family data 
Genotype data from the MRCA families were used to examine the transmission of 
specific alleles from the MRCA parents to their offspring for the PDCD4 selected 
SNPs. In the original GWAS
191
 the SNP rs6585018 was shown to have a significant 
association to asthma (P=0.00002) when the MRCA family data was tested for 
association using the TDT. The genotype data for the MRCA families for the five fine 
mapping SNPs was therefore tested using the TDT for association with asthma. Table 
4.18 summarises the results. Two of the five markers (rs1322997 and rs34104444) 
showed significant associations, P=0.0002 and P=0.0009 respectively. 
 
No. Name χ2 P value 
1 rs4918605 1.6 0.2059 
2 rs1322997 14 0.0002 
3 rs11195360 0.523 0.4697 
4 rs1407696 1.063 0.3026 
5 rs34104444 11 0.0009 
Table 4.18.TDT results for the MRCA family panel and asthma and the PDCD4 SNPs.  
 
4.3.3 Haplotype analysis 
4.3.3.1 Severe asthmatic children and healthy controls 
Haplotypes were constructed for the severe asthmatic children (SCR) and the healthy 
unrelated children from MRCA samples for all 6 six SNPs using the Haploview 
program.  Although the gene area (28.7 kb) was in high LD, two blocks of LD were 
found. The first block contains SNPs rs4913605, rs1322997 and rs6585018 whilst 
SNPs rs11195360, rs1407696 and rs34104444 are contained in the second block 
(Figure 4.16). The Tagger programme showed that 3 of the 6 SNPs (rs6585018, 
rs1407696, rs4918605) could work as good proxies for all the markers (mean r
2
=0.975) 
(Table 4.19). 
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a)             
  112610 kb                     112620 kb                           112630 kb                        112640 kb           112650 kb 
 
    
 
 
 b) 
Figure 4.16.Haplotype analysis results for the combined groups of severe asthmatics 
and healthy controls a) The LD block structure in the PDCD4 gene area including the 
selected markers after haplotype analysis using Haploview and b) the haplotypes with 
their frequencies. 
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Allele Best Test r2  
rs4918605 rs4918605 1 
rs1322997 rs6585018 1 
rs6585018 rs6585018 1 
rs11195360 rs1407696 0.937 
rs1407696 rs1407696 1 
rs34104444 rs6585018 0.913 
   
Test Alleles Captured 
rs6585018 rs34104444,rs6585018,rs1322997 
rs1407696 rs1407696,rs11195360 
rs4918605 rs4918605 
Table 4.19. The Tagger results calculated for the 6 SNPs (for r
2
>0.8). 
 
Association testing was also performed using the haplotype data and two haplotypes 
were found to be significantly associated to severe asthma (Table 4.20). Haplotype 
ACG from block 1 and haplotype TTA from block 2 (frequencies 0.073 and 0.065) 
were found more frequently with each other than with other haplotypes and there was a 
significant association to severe asthma (P=0.0029 and P=0.0071). After applying 1000 
permutations to the association results for the haplotypes the results remained 
significant (P=0.013 and P=0.022). Single-marker association tests were also performed 
in Haploview as a second test of association and the results (Appendix, Table A2) were 
similar as the ones described in Section 4.3.2.2. 
 
Haplotype Freq. Case, Control  
Haplotype Ratio Counts 
Case, Control 
Frequencies 
χ2 P value P value 
corrected 
Block 1       
GAA 0.688 148.0 : 80.0, 203.0 : 79.0 0.649, 0.720 2.94 0.0864 0.399 
AAA 0.238 54.5 : 173.5, 67.0 : 215.0 0.239, 0.238 0.002 0.967 1 
ACG 0.073 25.5 : 202.5, 12.0 : 270.0 0.112, 0.043 8.859 0.0029 0.013 
Block 2       
CGG 0.673 144.4 : 83.6, 199.0 : 83.0 0.633, 0.706 2.995 0.0835 0.387 
TTG 0.247 57.1 : 170.9, 69.0 : 213.0 0.250, 0.245 0.022 0.8833 1 
TTA 0.065 22.4 : 205.6, 11.0 : 271.0 0.098, 0.039 7.243 0.0071 0.022 
TGG 0.01 2.1 : 225.9, 3.0 : 279.0 0.009, 0.011 0.027 0.8705 1 
Table 4.20. Haplotype association tests performed by Haploview for the PDCD4 
haplotypes for the severe asthmatics versus healthy controls (P value corrected after 
1000 permutations). 
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4.3.3.2 Severe asthmatic children and mild asthmatics 
Haplotypes were also constructed with data from the mild asthmatic group (controls) 
and the severe asthmatic children (cases). The results again confirmed the presence of 
high LD across the region of interest with the same blocks detected previously also 
observed in this analysis (Section 4.3.3.1). Again as seen for the severe asthmatic and 
healthy controls, SNPs rs11195360 and rs1407696 were in higher LD with each 
compared to any other marker (Figure 4.17). The results from Tagger program also 
showed that the same 3 SNPs (rs34104444, rs11195360 and rs4918605) determined 
previously as proxies (Section 4.3.3.1) could also be used as proxies in this analysis 
(mean r
2
=0.956). 
a) 
  
b) 
  
Figure 4.17. Haplotype analysis results for the combined groups of severe asthmatics 
and mild asthmatics a) Haplotype blocks for PDCD4 SNPs and b) haplotypes with their 
frequencies in mild and severe asthmatics group.  
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Association tests for the individual haplotypes were performed and haplotypes ACG 
and TTA with the lowest frequencies (0.071 and 0.062) presented a significant 
association to severe asthma (P=0.0006, P=0.001) (Table 4.21). After applying 1000 
permutations to the tests for the haplotypes the results remained significant. Similarly to 
the previous section (Section 4.3.3.1), single marker-associations were performed as a 
second test of association and the results (Appendix, Table A3) were similar to the ones 
described in Section 4.3.2.2 for the mild asthmatics compared to severe asthmatics.  
 
Haplotype Freq. Case, Control 
Haplotype Ratio Counts 
Case, Control 
Frequencies 
χ2 P value P value 
corrected 
Block 1       
GAA 0.655 148.0 : 80.0, 142.6 : 73.4 0.649, 0.660 0.062 0.8036 1 
AAA 0.275 54.6 : 173.4, 67.4 : 148.6 0.239, 0.312 2.922 0.0874 0.455 
ACG 0.071 25.4 : 202.6, 6.0 : 210.0 0.111, 0.028 11.812 0.0006 0.005 
Block 2       
CGG 0.637 144.3 : 83.7, 138.7 : 77.3 0.633, 0.642 0.04 0.8416 1 
TTG 0.289 57.2 : 170.8, 71.2 : 144.8 0.251, 0.330 3.335 0.0678 0.239 
TTA 0.062 22.3 : 205.7, 5.0 : 211.0 0.098, 0.023 10.754 0.001 0.006 
Table 4.21. Haplotype association tests performed by Haploview for the PDCD4 
haplotypes for the severe asthmatics versus mild asthmatics (P value corrected after 
1000 permutations). 
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4.4 Discussion 
In this chapter PDCD4 gene was selected for further investigation using fine mapping 
methods in order to pinpoint the causal variation underlying the association previously 
seen to severe asthma (Chapter III, Section 3.3.4). It was decided to focus on this more 
significant association (P=3.4x10
-7
) as opposed to the association between severe 
asthma and rs10270097 within DGKI gene (P=6.1x10
-5
) because the SNP was located 
within the predicted promoter area of PDCD4 and also because prior expression data for 
the protein product of the gene shows it is expressed in cells of relevance to the 
inflammatory condition of asthma so could be of significant functional relevance.  
Following bioinformatic analyses and database interrogations, five SNPs within the 
PDCD4 genomic area were chosen to be typed in the severe asthmatic children and the 
MRCA family panel. For three of the SNPs genotypes were available for the B58C 
study and acted as an additional control group.  In total, 3 SNPs, including the original 
associated SNP, within the PDCD4 genomic area were associated to severe asthma in 
children, rs1322997 (P=0.005), rs34104444 (P=0.01) and rs6585018 (P=0.005). The 
association with rs1322997 resulted to a P value of 0.00015 when a number of controls 
were incremented by inclusion of the B58C genotype data. No significant association to 
asthma were found for the three SNPs rs11195360, rs1407696 and rs4918605. 
The ORs calculated for SNPs rs1322997, rs34104444 and rs6585018 were 2.91 (95% 
CI 1.41-6.02), 2.82 (1.31-6.05) and 2.88 (1.39-5.96) showing that the effect of the SNPs 
had a similar magnitude. This was also reflected by the relative risks for the minor 
alleles of each SNP:  2.70, 2.63 and 2.67 respectively.  
 
In the initial GWA study, the TDT revealed a highly significant association in the 
family data (MRCA) between asthma and rs6585018 (represented on the genome-wide 
SNP array) with a P value of 0.00002. TDTs were therefore performed for the 5 fine 
mapping PDCD4 SNPs and the MRCA family data. Significant associations to 
childhood asthma were seen for markers rs1322997 and rs34104444 (P values 0.0002 
and 0.009 respectively).  
 
Mild asthmatics were also used as controls and compared to severe asthmatics to 
examine the effect of PDCD4 in steroid resistance. The same three SNPs, as for the 
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comparisons with healthy controls, showed significant associations rs34104444 
(P=0.0044), rs1322997 (P=0.003) and rs6585018 (P=0.002). The ORs calculated for 
these SNPs were 3.48 (95% CI 1.45-8.38), 4.31 (1.76-10.57) and 3.72 (1.57-8.79).  
 
For all three SNPs the frequency of the homozygotes for the minor allele was increased 
in the asthmatics group compared to controls (Tables 4.6, 4.10, 4.11). Comparison of 
the genotype frequencies across the various subject sets indicated that the rise in the 
minor allele frequencies of the three SNPs in the severe asthmatic children could be due 
a causative effect of these alleles in the disease. 
 
Haplotype analysis using the genotype frequencies from the PDCD4 markers showed 
that the area was in high LD with two distinct blocks.  The three SNPs showing 
association were in strong linkage disequilibrium with one another (Table 4.19). 
Haplotype ACG of Block 1 (SNPs rs4918605, rs1322997 and rs6585018) was found to 
be associated to asthma (P=0.0029). For Block 2, the haplotype TTA (SNPs 
rs11195360, rs1407696 and rs34104444) was significantly associated to asthma 
(P=0.0071). The results could be attributed to the effect of the presence of the minor 
alleles of SNPs rs1322997 and rs6585018 in the ACG haplotype and rs34104444 in the 
TTA haplotype. 
 
To examine if the PDCD4 SNPs were implicated in the severe form of the disease only, 
statistical analyses were performed comparing a group of mild asthmatics to the severe 
asthmatic child group. Significant associations were again seen for both genotype and 
haplotype data indicating that the locus is of importance in the severe form of the 
disease. In addition when mild asthmatics were compared to healthy non-asthmatics no 
significant associations were found (data not shown), suggesting that this locus is not a 
genetic factor predisposing to the mild form of disease and is of importance for the 
severe form.  
 
The mild asthmatics data used were derived from adults, whereas the severe asthma 
group in the study consisted of children. The difference in the effect of the genetic 
variation could therefore be attributable to the heterogeneity of the disease in the age 
groups.  
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As part of the fine mapping exercise, PDCD4 genomic regions were re-sequenced to 
discover novel or rare variations not included in the public databases and to evaluate the 
validity of variations (present in dbSNP) with no genotype information available. Re-
sequencing was performed in individuals with key genotypes (ten of the samples were 
carrying the minor allele for SNP rs6585018) for the marker that showed association 
originally, SNP rs6585018. Targeted regions were the putative promoter area and exons 
6 and 10. The promoter usually includes regulatory elements controlling the expression 
of the gene and exons 6 and 10 encoded for the parts of the protein forming the MA3 
domains essential for the function of PDCD4 protein. No novel variations were found 
within the exon sequences. Previously un-validated SNP rs12219468 was reported by 
the sequencing results, showing that the marker is present in the region. By comparing 
the genotypes for rs12219468 and rs11195360 (data not shown), it was found that the 
markers are in perfect LD. 
 
Two fragments (labelled Promoter_1 and Promoter_2) of the candidate PDCD4 
promoter region were also re-sequenced and exploration of whether novel SNPs 
identified were real and not artefacts was done by PCR-RFLP. For the Promoter_1 
fragment one of the 24 individuals was found to have an insertion of a single adenine (-
/A) by sequencing but testing by PCR-RFLP revealed this to be an artefact most likely 
due to base mis-incorporation during the sequencing PCR (Figure 4.11). It is estimated 
that there is an overall rate of 2.1x 10
-4
 to 3 x 10
-6
 base mis-incorporations per base per 
cycle depending on the polymerase
323
.  For Promoter_2 a novel SNP identified by 
sequencing was validated by PCR-RFLP – SNP Prom_2_SNP_2 (Figure 4.12 and 
Figure 4.13). The variation however was found only in a single individual, suggesting 
that is an extremely rare variant present in 1 sample out of 24 and therefore it was not 
genotyped in the extended datasets.  
Rare variants are found to contribute to phenotype manifestations in a number of 
complex diseases as opposed to the hypothesis of common variant-common 
disease
308,310
. Whole-genome scans currently do not have the sufficient genome 
coverage to examine the presence of rare variations. Strategies including next-
generation sequencing technology could provide the appropriate method to investigate 
all types of variations in the human genome including the very rare ones
312
. High-
throughput PCR-RFLP applications or designed SNP genotyping assays such as the 
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custom TaqMan
®
 SNP assays can also be used for the same purpose. SNP 
Prom_2_SNP_2, however, had a very low frequency (one heterozygote was identified) 
and if it was an important causal variant, it should have been present in more severe 
asthmatics samples carrying the minor allele for rs6585018. 
In conclusion, the results of fine mapping of the PDCD4 region indicate that SNPs 
rs1322997, rs6585018 and rs34104444 appear to be the key variants underlying the 
disease association of the PDCD4 gene to severe asthma in children.  Two of these 
SNPs (rs1322997 and rs6585018) are located within the predicted promoter of the 
PDCD4, a region that could be important for the transcriptional regulation of PDCD4. 
The results suggest that the transcription regulation of PDCD4 could be controlled in 
part by important regulatory sites present 5‟ of the gene. The presence of markers 
significantly associated to severe asthma in the region (rs6585018 and rs1322997) 
could be related to the effect of these variations in the function of the gene and 
ultimately to the role of the PDCD4 protein in molecular pathways influencing the 
manifestation of the asthmatic phenotype. The gene could also be implicated in other 
processes evident in the extreme asthmatic phenotype, such as the persistent 
eosinophilia and neutrophilic inflammation. The next step therefore is to try and 
establish the function of these variations. The functional investigation of these markers 
could provide insights into their specific role in PDCD4 expression and propose a 
mechanism of contributing to the asthmatic phenotype.   
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Chapter V: Functional Analysis of PDCD4 SNPs 
5.1  Introduction  
 
Fine mapping of the PDCD4 genomic area identified three key SNPs, rs1322997, 
rs6585018 and rs34104444 significantly associated to severe asthma (Chapter IV). To 
investigate this finding further the next logical step is to try and establish whether the 
SNPs (in light of their genomic location) have any functional role in the expression of 
the PDCD4 gene.   
Recent evidence shows that although most of the variations in the human genome have 
no contribution to the disease development there is a large amount of variation that 
influences the phenotypes and in a specific genomic context confers susceptibility to 
human disease
324
. Common variation, like SNP variants, which represent the 90% of the 
known human variation, can be located within the coding region of a gene and if they 
alter the amino acid codon (non-synonymous variants) they can affect the folding of the 
protein, the polarity shift, improper phosphorylation or other post-translational 
modifications such as phosphorylation. If they however do not lead to an amino acid 
change (synonymous variants) they do not affect the function of the protein.  
The other location of the variation is the non-coding region of the genome. This type of 
variation although not influencing directly the protein characteristics, can be located 
within regulatory elements, such as promoters, enhancers and insulators
325
. These 
regulatory SNPs can also affect the binding site of transcription factors and thus they 
can affect the transcription of a gene in a number of different ways. If the variant 
changes the transcription factor binding site, it could increase or decrease the binding 
resulting in allelic-specific gene expression. There is also the possibility that a single 
variant can abolish completely the binding site or create a novel one. In all these cases, 
the binding of the transcription factors is changed leading to changes in the expression 
of the gene and ultimately to changes in the phenotype and the physiological responses 
to environmental stimuli. 
The identification and validation of functional SNPs can be performed by both standard 
molecular biology techniques and bioinformatic tools. In this Chapter, PDCD4 asthma-
associated variants from the previous chapter will be examined using both approaches 
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of functional analysis. First the PDCD4 genomic region will be bioinformatically 
analyzed for binding sites of transcription factors and then Electromobility Shift Assays 
will be performed for in vitro investigation of the effect of SNPs on transcription factor 
binding to the promoter region of PDCD4. The expression of PDCD4 protein will be 
also examined in different cell lines and PBMCs by Western blots and 
immunocytochemistry experiments. Finally, using the mRNA SNP browser the 
relationship between the transcription levels of PDCD4 gene in B cell lines and PDCD4 
SNPs will be investigated. 
 
5.1.1 The Programmed Cell Death 4 (PDCD4) gene 
 
5.1.1.1 PDCD4 structure 
Programmed Cell Death 4 protein was discovered when antibodies were used for 
screening a glioma cDNA expression library and a novel protein localized in the 
nucleus was identified which was named H731
295
. The protein was found to be 
accumulated in the nuclei of confluent normal fetal lung fibroblasts and mainly in the 
cytoplasm of cancer cell lines. In situ hybridisation revealed that the human gene is 
located on chromosome 10q24
326
.  
 
There are two PDCD4 isoforms, 1 and 2, consisting of 458 and 469 amino acids 
respectively. They possess one N-terminal domain and one C-terminal basic domain 
with two conserved alpha-helical MA-3 domains. Western and Northern blots reveal 
that the PDCD4 is up-regulated in senescent diploid fibroblasts
296,327
. There are also two 
basic domains present, which could represent nuclear localization signals although the 
data for the sub-cellular localizations of the protein are conflicting
328
. Yeast two-hybrid 
assays were used to determine the interaction of the C terminus of the protein with other 
components in senescent human diploid fibroblasts, which included parts of 40S 
ribosome complex, Ribosomal Protein S13 (RPS13) and Ribosomal Protein L5 (RPL5). 
In vitro assays confirmed the first interaction with RPS13 and in vitro pull down assays 
showed novel interactions of PDCD4 with translation initiation factor 4 G (EIF4G) but 
not with translation initiation factor 4 E (EIF4E). In the same study, PDCD4 was shown 
to be localized to polysome fractions of fractionated HeLa cells
296
.  
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The protein-protein interactions of the translation factors were shown to be formed 
through the MA-3 domains
329
. Co-immunoprecipitation, yeast two-hybrid and confocal 
immunofluorescence microscopy experiments revealed that the interaction between 
PDCD4 and EIF4A resulted to the inhibition of the helicase activity of EIF4A and the 
subsequent initiation of translation
330
. A mutated form of PDCD4 protein, not including 
the MA-3 domains, completely lost the EIF4A binding activity confirming the role of 
the domains in the function of the protein
331
. By x-ray crystallography, NMR and 
surface plasmon resonance it was shown that both MA-3 domains had a similar 
structure and function
290
. 
 
PDCD4 contains a number of phosphorylation sites. Serine 67 and serine 457 were 
shown to be specifically phosphorylated by Akt (protein kinase B) causing a nuclear 
translocation of PDCD4 protein and a decreased activity in the inhibition of AP-
1(activator protein 1) –mediated transcription332. 
  
Dorello et al. (2006) reported that a possible function of the protein could be the 
inhibition of the translation initiation factor EIF4A which possesses the RNA-helicase 
activity essential for the unwinding of secondary structure at the 5‟ un-translated region 
of mRNAs
297
. The PDCD4 protein phosphorylated on Ser67 by the kinase S6K1 in 
response to mitogens, resulted in-targeting by the ubiquitin ligase SCF-β. A mutant 
PDCD4 in which the Ser67 was replaced by alanine, that did not bind the ubiquitin 
ligase SCF-β, inhibited 5‟ cap dependent translation resulting in smaller cell size and 
reduced progression of the cell cycle. The PDCD4 protein therefore was thought to be a 
translation repressor and the regulated degradation of the protein could promote protein 
translation and cell growth.  
The results were confirmed by another study in which PDCD4 levels were reduced after 
phorbol 12-myristate 13-acetate (PMA) treatment, a result of increased proteasomal 
degradation
333
.The degradation was mediated by Akt and S6K1 phosphorylation of 
PDCD4, as well as MEK-ERK signalling pathway.  
 
5.1.1.2 Regulation of expression of PDCD4 
PDCD4 has been found to be up-regulated in apoptotic cells and specifically pro-
apoptotic treatment of the cells with ionomycin, PMA and dexamethasome induced the 
expression of the protein
334
. PDCD4 protein levels were increased by treatment with IL-
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12 and decreased with IL-2 treatment
335
. Although normal tissues appear to express 
PDCD4 ubiquitously, there are conflicting data regarding the sub cellular 
localisation
328
. Reduced levels of PDCD4 have been seen for an extensive range of 
cancers as well tumour lines treated with anti-cancer drugs 
336,337, 338,339
.  
 
A number of studies have shown that transforming growth factor β (TGF-β) is involved 
in the regulation of expression of PDCD4. TGF-β,  an important immunomodulator in 
the airway remodelling observed in the asthmatic airways, it regulates the epithelial 
inflammation and it is a potent therapeutic target for asthma
340-342
. Induction of PDCD4 
expression when hepatocellular carcinoma cells were treated with TGF-β resulted in cell 
apoptosis 
338
. Another study in vascular smooth muscle cells, found TGF-β increased 
the production of microRNAs-21 (miR-21) which in turn resulted in down regulation of 
PDCD4
343
. The effect of miR-21 on PDCD4 production has been found by a number of 
additional studies and bioinformatics analysis of the 3‟UTR of PDCD4 mRNA has 
identified a conserved binding site for miR-21
178,344-346
. Indeed, miR-21 appears to be a 
negative translation regulator of PDCD4, inducer of invasion, intravasation and 
metastasis and the high miR-21 expression in solid tumours revealed an inverse 
correlation in the expression of PDCD4 and miR-21
344
. 
 
At the protein level PDCD4 has been shown to be regulated by Akt and S6K1 
phosphorylation, which mark the protein for proteasomal degradation (Section 5.1.1.1) 
297,333
. The quantity of the PDCD4 protein is also affected by regulation at the level of 
gene transcription. The transcription factor v-Myb appears to be an inducer of PDCD4 
production and Myb knock-out experiments have resulted in reduced PDCD4 
production in a chicken B cell line
301,347
. The PDCD4 gene contains a CpG island 
located 5‟ upstream of PDCD4 putative promoter and methylation was associated with 
reduced PDCD4 mRNA levels in human glioma cells, which was restored after 
blocking methylation
348
. Knock down of DNA methyltransferase 1 in hepatocellular 
carcinoma cells causing DNA demethylation, resulted in higher PDCD4 expression 
levels
349
 confirming the importance of the CpG island. 
 
From the results of the large variety of studies investigating PDCD4, it is evident that 
PDCD4 regulation takes place at a number of levels including transcriptional 
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translational and protein and in addition these are influence by cell type i.e. cell specific 
mechanisms may exist. 
 
5.1.1.3 Function of PDCD4  
PDCD4 acts through the MA-3 domains and inhibits the initiation of proteinosynthesis 
by inhibiting EIF4A
330
. In studies of a mouse epidermal cell line Pdcd4 was identified 
as being able to act as a tumour suppressor possibly through inhibiting AP-1 activation 
in combination with other factors such as enhancing NF-κB activation350,351. 
The inhibition of AP-1 by PDCD4 was shown to be a result of reduced phosphorylation 
of c-Jun by JNK (Jun N-terminal kinase) due to the blocking of the c-Jun 
phosphorylation by interacting with PDCD4
352
. Further studies suggest the mechanism 
of c-Jun inhibition by PDCD4 is due to  PDCD4 inhibiting the expression of a key 
kinase upstream of JNK MAPKKKK (MAPK kinase kinase kinase) or HPK1 
(haematopoietic progenitor kinase 1) leading to consequent inhibition of c-Jun 
activation and AP-1-dependent transcription
353,354
. 
A protein identified as a PDCD4 target by comparing protein expression in mock and 
PDCD4-transfected human embryonic kidney cell line HEK-293 was the carbonic 
anhydrase type II (CA II) which was downregulated in the cells over-expressing 
PDCD4
355
.  
Another PDCD4 target is the urokinase receptor (uPAR) protein which takes part in the 
degradation of extracellular matrix components promoting cell invasion of tumour cells 
and metastasis
356
.siRNA experiments suggested that PDCD4 can result in increased 
uPAR levels. Apart from the tumour development, PDCD4 has been found to have a 
role in cell cycle progression events although results have varied with some studies 
finding PDCD4 indirectly promoting reduced cell proliferation
357
 whilst other studies 
suggesting an involvement in increased cell proliferation and consequently 
tumorgenesis
358
.  
Another different result was obtained in acute myeloid leukaemia cells in which reduced 
PDCD4 levels had no effect in the expression of p21
Waf1/Cip1 359
. Overexpression of 
PDCD4 in neuroendocrine cell line Bon-1 resulted in higher levels of p21
Waf1/Cip1
 and 
lower levels of dUTPase but the effect was not evident in HCT116 cells
360,361.
. The data 
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therefore is very variable depending on the cell type being investigated but certainly 
PDCD4 has been shown to have a role in proliferation. 
A role for PDCD4 in cellular proliferation is also provided by mouse studies. Mouse 
models over-expressing PDCD4 in the epidermis appeared to have a reduction in 
papilloma formation, papilloma-into-carcinoma conversion and carcinoma incidence 
compared to wild type mice
362
. PMA-induced AP-1 activation and ODC (orntithine 
decarboxylase) levels were reduced. In K-ras-null mice and AP-1-luciferase reporter 
mice, PDCD4 treatment caused inhibition of cell proliferation, tumor angiogenesis, AP-
1 activity and promoted apoptosis in the lungs
337,363
.  PDCD4-deficient mice developed 
spontaneous lymphomas as a result of high IL-4 and/or IL-10 secretion from 
spleenocytes
115
. Both IL-4 and IL-10 are key inflammatory cytokines notably in asthma.  
The pdcd4
-/-
 mice were found to have resistance to inflammatory diseases, such as STZ 
(streptozotocin)-induced diabetes showing that PDCD4 might play a role not only in 
tumorgenesis but also in the development of other inflammatory diseases.   
 
5.1.2 Strategies for the Discovery of Functional Regulatory SNPs 
There are two key issues in relation to the investigation of the role of an associated 
potentially regulatory SNP in the function of gene. First, it is very difficult to predict 
whether the variant is the causal one or if it is in linkage disequilibrium to the real 
causal variant due to the poor understanding of the importance of non-coding genomic 
sequences. Second, the experimental verification of a functional SNP requires the use of 
laborious and complex molecular biological techniques to provide the proof for the 
effect of the SNP in the gene expression. 
 
Following the identification of a candidate gene and a candidate regulatory SNP both 
bioinformatics and experimental methods can be applied to the research. Bioinformatics 
aim to identify putative regulatory elements relative to the position of the candidate 
functional SNPs. This includes comparisons of the SNP-containing sequence to a 
database of known transcription factor binding sites. The probability of the predicted 
matches is given and but the results have to be validated by in vitro experiments
364
.  
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Molecular biology methods that assess the effect of a polymorphism in a DNA binding 
motif of a transcription factor include the ElectroMobility Shift Assay (EMSA) , which 
examines in vitro the binding of specific DNA sequences and proteins
365
, fluorescent 
reporters approaches such as Fluorescence resonance energy transfer (FRET), which is a 
high-throughput method of observing the binding of proteins to DNA sequences
366
 and 
chromatin immunoprecipitation (ChIP) assay, an in vivo binding assay in which the 
DNA binding proteins are identified on specific chromatin fragments
367
.  
 
The specific effect of the polymorphism on the gene expression can be investigated by 
promoter reporter constructs, in which the sequence of interest containing a promoter 
SNP is inserted into an expression vector with a reporter gene (for example the 
luciferase gene) and the level of reporter gene expression is measured when the 
different SNP alleles are present
368,369
. The effect of the SNPs in the expression of a 
gene can be assessed in the transcriptional level by measuring the allelic ratios in 
mRNA in heterozygotes providing evidence whether there is a differential transcription 
of alleles in linkage disequilibrium to the regulatory SNPs. The allelic expression can be 
measured by PCR-RFLP analysis, SNP genotyping, mRNA sequencing or mass 
spectrometry-based genotyping
370-373
. Finally, gene expression arrays can be used to 
evaluate the association between gene transcription levels and specific genotypes. 
Several research groups have generated gene expression databases in lymphoblastoid 
cell lines of various populations and analyzed the association of SNPs to mRNA 
levels
176,189,374
.  
 
Ultimately there is an infinite set of experiments that can be conducted and the 
following chapter details a number of experiments that have based on their results, 
enabled some elucidation of the functional role of the key asthma associated PDCD4 
gene SNPs. 
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5.2  Materials and Methods 
 
5.2.1 Solutions and reagents 
Stock solutions 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer, pH 7.9 
1M stock solution was prepared by dissolving 1.19 g of HEPES (Sigma) in 5ml of 
sterile water. The pH was measured using a JenWay pH Meter 3310. 
EGTA (ethylene glycol tetraacetic acid) buffer, pH 8.0 
0.5 M stock solution was prepared by dissolving 1.90g of EGTA (Sigma) in 10ml of 
sterile water. The pH was measured using a JenWay pH Meter 3310. 
KCl (potassium chloride) buffer 
1M stock solution was prepared by dissolving 0.37g of KCl (Sigma) in 5ml of sterile 
water. 
NaCl (sodium chloride) buffer 
1M stock solution was prepared by dissolving 2.922 g of NaCl (Sigma) in 50ml of 
sterile water. 
DTT (dithiothreitol) buffer 
1M stock solution was prepared by dissolving 0.7712 gr of DTT (Sigma) in 5ml of 
sterile water.  
APS (ammonium persulfate) 
10% (w/v) was prepared by mixing 0.01g of APS (Sigma) with 1ml of sterile water. The 
solution was prepared just before the polyacrylamide gel preparation and consequently 
always used fresh. 
 
The solutions were sterilised using Millipore Steritops™ Filter units.  
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Protein extraction solutions 
Buffer A 
Buffer A contained 10mM HEPES (500μl 1M HEPES, pH 7.9), 10mM KCl (500μl 1M 
KCl), 0.1mM EDTA (10μl 0.5M EDTA, pH 8.0, Sigma), 0.1mM EGTA (10μl 0.5M 
EGTA, pH 8.0), 10μl of 1 M DTT and one protease inhibitor cocktail tablet (Roche) 
diluted to a final volume of 50ml by adding sterile MilliQ- water. Both the DTT and the 
protease inhibitor tablet were added to the solution immediately prior to use. 
Buffer B 
Buffer B consisted of 20mM HEPES (1ml 1M HEPES, pH 7.9), 0.4M NaCl (20ml 1M 
NaCl), 1mM EDTA (100μl 0.5M EDTA, pH 8.0, Sigma), 1mM EGTA (100μl 0.5M 
EGTA, pH 8.0), 10μl of 1 M DTT and 1 protease inhibitor cocktail tablet (Roche) 
diluted to a final volume of 50ml by adding sterile MilliQ- water. DTT and the protease 
inhibitor tablet are added to the solution just before use. 
 
EMSA solutions 
EMSA Binding buffer 
The binding buffer was prepared to result in  final concentrations of 12 mM HEPES 
buffer, pH 7.8, 100 mM NaCl, pH 8.0, 1 mM EDTA, pH 8.0, 1 mM EGTA, pH 8.0 and 
12% (w/v) glycerol (Sigma).  
 
Polyacrylamide gel solutions 
The 6% polyacrylamide gel was  prepared by mixing thoroughly 55.5ml of sterile 
MilliQ- water, 15ml Accugel 19:1 acrylamide:bis-acrylamide (Sigma), 3.75ml 10X 
TBE (Sigma), 750μl 10% (w/v) ammonium persulphate (APS) (Sigma) and 60μl 
tetramethylethylenediamine (TEMED) (Sigma). 
Running buffer (1000ml) for the gel was prepared by diluting 10X TBE to 0.5X with 
sterile MilliQ- water. 
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Western blot solutions 
MES (4-morpholineethanesulfonic acid) 
1X MES buffer was prepared by mixing 50ml of 20X MES (Sigma) with 950ml MilliQ-
water. 
Transfer Buffer 
50ml of Tris-Glycine buffer (0.25M Tris, 1.92M glycine, pH 8.3, Sigma) was combined 
with 100ml methanol (Merck ARISTAR
®
), 1ml NuPage antioxidant (Invitrogen) and 
849ml MilliQ-water. 
Blocking Buffer 
For 5% (w/v) milk, 2.5g of milk powder was mixed with 50ml PBS (Sigma) 
Washing Buffer 
For 500ml of 1X PBS-Tween, 25ml of 20X PBS-Tween (Sigma) was mixed with 450ml 
of MilliQ-water. 
Revelation Buffer 
5ml from the two bottles of the Revelation ECL kit (GE Healthcare) were mixed 
together to form the revelation buffer. 
 
5.2.2 Cell lines and cell culture 
The EMSAs, Western blots and immunocytochemistry experiments were performed in 
A549 alveolar epithelium cell lines, Daudi B lymphoblast cell lines and Jurkat T 
lymphoblast cell lines. The expression of the protein was also examined in PBMCs with 
Western blots. The cell lines were cultured as described in Chapter II, Section 2.2.7. 
 
5.2.3 Protein extractions 
For the extractions of cytoplasmic and nuclear proteins, cell culture media was 
replenished for each cell lines 24 hours before commencement of extractions. The 
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protocol used was based on the method of Schreiber (Schreiber et al, Nucleic Acids 
Research (1989) vol. 17 (5), p6419). Cells were pelleted by centrifugation at 1500rpm 
for 5 minutes (Heraeus
®
 Labofuge
®
 400 R Centrifuge, Thermo Scientific). The cell 
pellet was washed with 5ml of ice-cold PBS and a cell viability count performed with 
trypan blue (Chapter II, Section 2.2.7). 5 x 10
6
 cells were aliquoted into pre-cooled 
eppedorfs tubes and each aliquot spun at 1000rpm for 5 minutes at 4 
o
C. Cell pellets 
were re-suspended in 1ml of ice-cold buffer A (Section 5.2.1). The tubes were incubated 
for 15 minutes on ice and then 67μl of IGEPAL 630 (Invitrogen) were added to each 
tube. The tubes were vortexed for 45 seconds, incubated on ice for 5 minutes and then 
10μl of the suspension was taken and mixed with 10μl of trypan blue to be inspected 
under the light microscope to check that complete cell lysis had occurred. If cell lysis 
was incomplete the samples were vortexed for a further 20 seconds and again an aliquot 
re-examined, although for the majority of the time a single vortex was sufficient and 
only occasionally was a second vortex was necessary. The lysed cells were centrifuged 
at 12,000rpm for 30 seconds at 4 
o
C (Hettich, MIKRO 22R) and pellet obtained re-
suspended in 500μl ice-cold buffer A, and then again centrifuged at 12,000rpm for 30 
seconds at 4 
o
C after which the supernatant, containing  the extracted cytoplasmic 
proteins was collected. 20μl volumes of the cytoplasmic protein extracts were aliquoted 
into pre-cooled eppedorf tubes and stored at -80 
o
C if not used immediately in further 
experiments.          
The weight of the remaining pellet (which contains the intact cell nuclei) was measured, 
re-suspended in 3 times volume of ice-cold buffer B (Section 5.2.1) and incubated on 
ice for a minimum of 1 hour with intermittent vigorous vortexing. After incubation the 
samples were spun at 12,000rpm for 5 minutes in 4 
o
C and the supernatant that contains 
the extracted nuclear proteins was collected. 20μl volumes of the nuclear protein 
extracts were aliquoted into pre-cooled eppedorf tubes and stored at -80 
o
C if not used 
immediately in further experiments.  
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5.2.4 Bradford assay 
The Bradford protein assay was used to quantify both  the cytoplasmic and nuclear 
protein extracts 
375,376
. First, bovine serum albumin (BSA, Sigma) standards were 
prepared with concentrations ranging from 0μg to 16μg/μl. For the protein aliquots, 1μl 
of each extract was used for the Bradford assay. All samples were mixed with 200μl of 
Bradford reagent (Sigma) and the absorbance was measured at 595 nm using a 
spectrophotometer (Synergy HT, Biotek
®
). For all samples, standards and protein 
extracts duplicates readings were performed. 
 
5.2.5 Electromobility shift assay (EMSA) 
EMSA is a classic in vitro method of studying the effect of a how a polymorphism 
effects the binding of a protein molecule to DNA (or RNA) and as a result protein-DNA 
(or RNA) interactions
377,378
. By labelling radioactively or chemically the DNA (for 
example), the protein-DNA complexes can be detected after being resolved on 
polyacrylamide gels.  The complexes are separated according to their size, charge and 
shape creating different patterns of shifted bands across the gel compared to a control 
lane which includes just the DNA probe represented by one band. The conditions 
(temperature, pH) are controlled so that the complexes are stable and can migrate 
through the polyacrylamide gel. Quantification of the affinity of the probe to the protein 
can be determined if the concentration of the probe and protein are available. The 
affinity and the specificity of the complexes are can also be tested by conducting 
competition assays using excess quantities of specific and non-specific unlabelled 
probes. Supershift assays can also be used to confirm the presence of a specific protein 
in the formation of the complex. In this case an antibody is added to the EMSA 
reactions and if it binds to the protein-DNA complex it will form a considerably larger 
complex which will migrate slower in the gel electrophoresis or due to the antibodies 
affinity to the protein it may prevent formation of the protein-DNA complex resulting in 
an absence of bands on the polyacrylamide gel. EMSA experiment design is combined 
with in silico analysis of the DNA sequence for the identification of protein binding 
elements. Different labelling strategies have been developed including radioactive, 
fluorescent and biotin labelling molecules. 
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5.2.5.1 Bioinformatics analysis 
DNA sequences surrounding the PDCD4 SNPs were first analyzed for transcription 
binding sites using the online available programs TFSearch
212,379
 
(http://www.cbrc.jp/research/db/TFSEARCH.html) and MatInspector
380,381
 
(http://www.genomatix.de/products/MatInspector/). Both forward and reverse 
sequences were inserted in the programs with analysis performed twice for the differing 
alleles of each SNP. For the TFSearch program, the settings all matrices were used for 
the classification and the default value of 85.0, was used for the threshold. For the 
MatInspector analyses, a core similarity value of 0.90 was used, which expresses the 
matching of the queried sequence to the highly conserved nucleotides on the candidate 
binding site stored in the database. A perfect match is designated by a core similarity 
value of 1.0. 
 
The MatInspector software is a more sophisticated tool for searching transcription factor 
(TF) binding sites. It provides the option of promoter prediction and the TF binding 
sites discovery is achieved by accessing the MatBase, a large transcription factor 
knowledge database. The searching sequences are connected to the genomic databases 
and the results are produced for each allele of the SNP automatically. In addition, a 
comprehensive graphical interactive graphical representation of the analysed sequences 
is available. Information on the identified transcription factors bound to the test 
sequence is also provided.  
 
5.2.5.2 Probe design for EMSA  
After the results were obtained for all the SNPs, probes for both alleles and sense and 
antisense strands were designed for the rs6585018 SNP, shown to alter the binding of a 
transcription factor to the sequence. The probes were designed so that they extend 15-20 
bases 5‟ and 3‟ of the polymorphism and a 4 bp AGCT sequence was introduced at the 
5‟ end of each of the oligonucleotides in order to allow subsequent radioactive labelling 
of the probes using Klenow polymerase. A non-specific probe was also generated to be 
used in the EMSA competition assays. This probe did not include the rs6585018 SNP or 
the binding site including it.  
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5.2.5.3 Creation of radioactive double-stranded EMSA probes 
Double-stranded probes were first generated by mixing 3.5μl of 100pmol/μl sense and 
anti-sense single-stranded probes (stock concentrations of probes diluted in autoclaved 
Milli-Q water to obtain desired concentration) with 193μl of sterile 1X Tris-EDTA (TE) 
buffer. The solution was incubated at 100 
o
C for 5 minutes on a heat-block (Techne 
DRI-Block
®
 DB.2A) and then allowed to cool down at room temperature for at least 1 
hour. The double-stranded probes were then either stored at -20 
o
C or went on to be 
radioactively labelled.  
For the radioactive labelling, the Klenow fragment of DNA polymerase I from 
Escherichia coli (Sigma) was used. The Klenow fragment retains the 5‟-3‟ polymerase 
activity and the 3‟-5‟ exonuclease activity of the holoenzyme, but loses the 5‟ 
exonuclease activity. It therefore has proof reading capability which is essential to 
ensure the nucleotides of the probes are incorporated in the sequence correctly avoiding 
sequence errors. The Klenow fragment requires the 5‟ AGCT overhang included in the 
probe design to initiate the reaction. The radioactive labelling reactions were set up to 
include final concentrations of 0.175pmol/μl of the double-stranded probe, 0.15 mM 
each of dATP, dGTP, and dTTP (New England Biolabs), 5 units of Klenow enzyme 
(Sigma), 1X buffer for Klenow fragment and 2μl α-32P CTP (PerkinElmer®). The 1X 
enzyme buffer was prepared to contain 50 mM Tris-HCl pH 7.5, 100 mM ammonium 
sulphate, 10 mM 2-mercaptoethanol and 1mg/ml bovine serum albumin (BSA, Sigma). 
The reaction was incubated at 37 
o
C for 15 minutes in a heat-block (Techne DRI-
Block
®
 DB.2A) after which it was briefly spun (Hettich Universal 32 Tabletop 
Centrifuge) and diluted 1:2 with 20μl of sterile Milli-Q water. A pre-purification count 
was obtained for 1μl of the radioactively probe by using a mini-I series 900 mini-
monitor (Mini Instruments Ltd.). The rest of the labelled probe solution was purified 
using a MicroSpin™ G-25 column (Amersham Sciences) to remove unincorporated 
dNTPs. Briefly, the column was prepared by vortexing and centrifugation for 1 minute 
at 3000rpm (Hettich Universal 32 Tabletop Centrifuge). The labelled probe was applied 
to the centre of the column and the purified probe was collected at the bottom of 
eppedorf tube following column centrifugation at 3000RPM for 2 minutes (Hettich 
Universal 32 Tabletop Centrifuge). A post-purification count was obtained for   1μl of 
the purified probe. The purified labelled probe was diluted to 40 counts per seconds/μl 
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approximately using sterile water and if not being used immediately in the EMSA 
reactions, it was stored at -20
o
 C. 
 
5.2.5.4 EMSA binding reactions 
EMSA reactions were prepared using nuclear extracts from the human alveolar 
epithelium A549 cell line, the human acute T cell leukaemia Jurkat cell line and human 
the Burkitt‟s lymphoma B cell Daudi cell line (ATCC), since the PDCD4 protein is 
expressed at high levels in both T cells and B cells. Although PDCD4 is moderately 
expressed in the A549 cell line, it was included due to the importance of the airway 
epithelium in asthma. 
For the EMSA binding reactions, nuclear extracts were incubated in independent 
reactions with the set of probes designed and radioactively labelled for each 
polymorphism of interest. Poly(dA-dT) was added to prevent unspecific binding of 
proteins to the binding sites of the probes and by including this reagent potential 
background noise which can obscure signals is reduced. Each EMSA reaction consisted 
of 5-10 μg of nuclear extract, 2-3μl of the radioactive labelled probe (hot probe), 1X 
binding buffer (Section 5.2.1), 0.75 μg poly(dA-dT) (Sigma) and 4% glycerol in a final 
reaction volume of 15μl. Both nuclear extracts and hot probes were thawed only once to 
prevent degradation and consequently poor quality results caused by the frequent 
freeze-thawing cycles. For the competition assays different reactions were prepared 
including 10X and 60X of the hot probe unlabelled specific and 10X and 60X of the 
non-specific probes. 
The reactions were first set up to contain all the reagents with the exception of the hot 
probe and left to pre-incubate for 10 minutes at room temperature. After this time, the 
hot probe was added and the reactions were incubated for 20 minutes at room 
temperature. The reactions were then run on a 6% non-denaturing polyacrylamide gel 
(Section 5.2.1). Prior to loading the reactions, the gel was allowed to set for at least 2 
hours and then  pre-run at 100 V at 4 
o
C for 30 minutes using 0.5X TBE (Sigma) as 
running buffer. After loading the EMSA reactions into the wells of the gel, the gel was 
run for 4 hours at 4 
o
C with 0.5X TBE running buffer.  The gel system used for the 
EMSAs was the Emperor Penguin™ electrophoresis system (Owl Separation Systems).  
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After electrophoresis, the gel was carefully transferred onto 3MM Whatman paper, 
covered with cling film and dried at 80 
o
C for 2 hours under vacuum. The dried gel was 
then exposed to Kodak X-Omat AR film (Sigma) for between 2 to 48 hours at -80 
o
C 
prior to being developed.  
 
5.2.5.5 Supershift Assays 
The supershift assays were set up in the same way as the standard EMSA reaction but 
included 0.3ng of 150μg/ml anti-Myb antibody (Abcam®). 
 
5.2.6 Western blots 
Western blots
382-384
 were used to study the expression of PDCD4 protein in Jurkat, 
A549, Daudi and peripheral blood mononuclear cells (PBMCs). The protein samples 
were prepared by mixing 30μg of extracts with an appropriate volume of lithium 
dodecyl sulfate (LDS, Invitrogen™) to results in a final total volume of 30μl. The 
samples were incubated at 90 
o
C for 5 minutes in a heat-block and then they were 
briefly spun with the centrifuge stopped once 13,000rpm had been reached (Hettich 
Universal 32 Tabletop Centrifuge) reached. NuPage® Bis-Tris Pre-Cast 6% gel was 
prepared following the manufacturer‟s instructions (Invitrogen™). The gel chamber was 
assembled (XCell SureLock™ Mini-Cell, Invitrogen) and the NuPage® MES running 
buffer (Invitrogen™) was added to fill the chamber. The wells of the gel were flushed 
out with 1X MES buffer (Sigma) to remove excess liquid and the protein samples were 
then loaded. Rainbow protein marker (GE Healthcare) was loaded into the first well of 
the gel. The gel was run at 200Volts, 110mA for approximately 1 hour. Whilst gel 
electrophoresis was ongoing, 2 pieces of filter paper (Whatman
®
) were cut 7cm x 8cm 
and transfer buffer was prepared (Section 5.2.1). After electrophoresis, the gel was 
removed and then one piece of Whatman paper was placed into the bottom of the mini-
chamber, then the gel, then the nitrocellulose membrane and then the second piece of 
Whatman. The Whatman paper and nitrocellulose membrane were all pre-soaked prior 
to assembly in transfer buffer. After assembly of the various layers, any air-bubbles 
were removed and the mini-chamber was inserted into the transfer electrophoresis 
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chamber. The chamber was filled with transfer buffer and it was run at 30Volts and 
170mA for 1 hour. After that, the chamber was disassembled and the membrane was 
placed carefully into a tray containing 12ml of blocking buffer (Section 5.2.1) and 
incubated for 30 minutes at room temperature with gently shaking on a rocking 
platform. The membrane was washed 3 times with 1X PBS-Tween (Sigma) for 5 
minutes. A 1:1000 dilution in 1%BSA in PBS of the primary antibody (mouse anti-
PDCD4, Abcam
®
) was prepared and the membrane was incubated overnight in 12ml of 
the antibody preparation in a cold-room on a stirring platform (Gyro-rocker SSL3, 
Stuart
®
). The antibody solution was then removed and the membrane was washed three 
times each time for 5 minutes with 1X PBS-Tween. The membrane was then incubated 
with the secondary antibody (again a 1:1000 dilution in 1% BSA in PBS of goat anti-
mouse (Abcam
®
) for 1 hour at room temperature on a stirring platform. The membrane 
was washed again three times each time for 5 minutes with 1X PBS-Tween, blot dried 
on filter paper and then placed onto cling film. After that, 10ml of revelation buffer (GE 
Healthcare) was added onto the membrane and left for 1 minute, after which the 
membrane was wrapped with the cling film and put inside a chemiluminescence film 
chamber and exposed to an electrochemiluminescence (ECL) film (Amersham 
Hyperfilm™ ECL, GE Healthcare) for 1, 5 or 30 minutes before being developed.  
 
5.2.7 Immunocytochemistry 
For immunocytochemistry experiment, cytospins containing 1 X 10
5
 cells were 
prepared. First cells were pelleted at 1500rpm for 5 minutes (Heraeus
®
 Labofuge
®
 400 
R Centrifuge, Thermo Scientific) counted using trypan blue and diluted to 0.5 X 10
6
 
cells/ml with PBS (Chapter II, Section 2.2.7). For the cytospins, 200μl of the cells were 
applied to each slide. The filters and the slides were assembled for the cytospin 
sandwiches, the first aliquot of 100μl of cells was added and the cytospin assemblies 
were centrifuged at 350rpm for 3 minutes (Shandon, Cytospin 3 Centrifuge). After this 
the cytospins were de-assembled and the slide-filter position was inverted in the 
sandwich. Finally, the cytospins were re-assembled, the second aliquot 100μl of cells 
was added and again the assemblies were centrifuged at 350rpm for 3 minutes. The 
slides containing the cells were then allowed to dry at 4 
o
C. 
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For the immunocytochemistry, the slides were first immersed for 10 minutes with 4% 
(w/v) paraformaldehyde in PBS (pH 7.4; Sigma) after which a 3-minute PBS wash on a 
stirring platform were performed. For the blocking step, 5% (w/v) BSA/PBS was added 
to the slides for 30 minutes. They were again washed with PBS three times as before 
and then incubated with the primary antibody [(rabbit polyclonal anti-PDCD4, Abcam
®
) 
diluted (1μg/μl) in PBS containing 10% (v/v) normal human serum] for 1 hour and 30 
minutes at room temperature. The slides were washed as before with PBS, and then 
incubated with 1:1000 diluted Alexa Flour 488-conjugated goat anti-rabbit IgG 
antibody (Molecular Probes) (diluted in PBS (pH 7.4) containing 10% (v/v) normal 
human serum) for 1 hour at room temperature. The slides were washed with PBS and 
then incubated with 5μM diaminidino phenylindole (DAPI) in Hanks Balanced Salt 
Solution for 3 minutes. After washing with PBS to remove excess DAPI solution the 
slides, they were mounted with 500μl Prolong Gold anti-fade reagent (Invitrogen), 
covered and sealed with cover slides. The slides were examined using a Leica TCS 4D 
confocal microscope (Leica Microsystems) equipped with argon, krypton and 
ultraviolet lasers.  
 
5.2.8 Isolation of PBMCs 
The expression of PDCD4 protein was examined in peripheral blood mononuclear cells 
from normal volunteers. For the PBMCs isolation, three 20ml aliquots of blood 
collected into EDTA (300μl 0.5M) were obtained. The three 20mls were combined and 
mixed with 60ml of 6% Hemohes (B Braun Medical Ltd) and 15ml of 0.9% NaCl 
(Baxter Healthcare) and then left to sediment for 45 minutes at room temperature. The 
PBMC-rich top layer was collected into 50ml falcon tubes containing 15ml of PBS. The 
tubes were centrifuged at 1500rpm for 5 minutes, the supernatant discarded and the 
pellet then washed with PBS and re-pelleted by centrifuging once more. The PBMC 
collecting columns were prepared by mixing 27ml of Percol (GE Healthcare) with 3ml 
of 9% NaCl. Three different Percol dilutions were prepared by adding PBS to achieve 
Percol percentages of 55%, 67% and 81%. In a new 50ml falcon tube, the 81% solution 
was added, the tube was covered with tape and the 67% solution was carefully layered 
onto the 81% solution using a plunge free 2ml syringe to ensure flow of solution was 
very gentle so that layers of different Percol % were retained prior to centrifugation. 
151 
 
The cell pellets were re-suspended in the 55% Percol solution and this was then very 
carefully layered on top of the column. The columns were centrifuged at 2500rpm for 
25 minutes (Heraeus
®
 Labofuge
®
 400 R Centrifuge, Thermo Scientific) at 20 
o
C. After 
centrifugation, the layer between 55% and 67% gradients contained the isolated PBMCs 
and these were carefully removed, washed with PBS as above and the cell pellets after 
spinning were then used for protein extraction (Section 5.2.3). 
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5.3 Results 
5.3.1 Bioinformatics analysis 
Bioinformatic analysis of all the PDCD4 SNPs was conducted in order to establish 
whether any of them had the potential to alter the binding sites of transcription factors 
(Appendix, Figure A1). The SNPs plus the immediate 15 bp flanking sequences from 
either site were examined using the TFSearch and MatInspector programs and the 
results are given in the six tables - Tables 5.1 to 5.6. The tables for each SNP include 
the search results from the two programs, details of which transcription factors could 
potentially bind to the sequence, the strand (sense or anti-sense), the position and the 
sequence of the binding site and the scores which measure the matching of the queried 
sequence to the sequence matrix of the transcription factor. A perfect match is 
represented by 100 in the TFSearch and 1.00 when using MatInspector. The default 
threshold for the scores is set to 80 and 0.80 respectively.  
From the results, it is revealed that for SNPs rs6585018, rs11195360, rs1407696, 
rs34104444, rs4918605 and rs1322997 there are several transcription factors that 
recognize the SNP flanking sequence. For the first 5 SNPs there are transcription factors 
showing allelic-specific binding, whereas this was not found for rs1322997 SNP. For 
example Myb transcription factor only binds to the sequence of rs6585018 only when 
the A allele is present and whilst for rs11195360 Myb binds only when the C allele is 
present. It should be noted that SNP rs11195360 was not significantly associated to 
asthma (Chapter IV), however it was included to build up a more detailed insight into 
the transcription factors potentially binding in the region examined. The alleles of the 
other SNPs (rs1322997 and rs34104444) that had shown a statistically significant 
association to asthma (Chapter IV, Section 4.3.2) also presented allelic-specific binding 
of transcription factors GCR1 and Fork head domain factors respectively (Tables 5.4 
and 5.6). SNP rs6585018 however was the only SNP that showed consistent results by 
both TFSearch and MatInspector, as the allelic-specific effect on Myb transcription 
factor was identified by both softwares (Table 5.1). 
Interestingly, rs6585018 had been found to be the SNP with the highest association to 
asthma (Chapter 4, Section 4.3.2) and previously the Myb transcription factor has been 
found to be important in the regulation of the transcription of the PDCD4 gene although 
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this data was generated within a chicken cell line
300,301
. The marker is located in 
proximity to the predicted PDCD4 promoter area, proposing a possible role in the 
regulation of the expression of the gene. In light of these findings it was decided to 
focus on SNP rs6585018 and conduct EMSA experiments.  Details of the probes 
designed are given in Table 5.7.  
 
 
Allele Program TF Strand Position Sequence Score 
rs6585018_A TFSearch HSF + 8-12 AGAAAG 100.0 
v-myb + 12-20 AGCAACGGC 92.0 
c-myb - 10-27 AAAGCAACGGC 
CAGAGGG 
87.6 
ADR + 25-29 GGGAG 86.2 
MatInspector Cellular and 
viral myb-like 
transcriptional 
regulators 
+ 13-25 GCAACGGCCAGAG 0.985 
rs6585018_G TFSearch HSF + 8-12 AGAAAG 100.0 
ADR + 25-29 GGGAG 86.2 
MatInspector - - - - - 
Table 5.1. Results from the analysis of the rs6585018 SNP sequence for transcription 
factor binding sites. (The SNP position is indicated in red. The bases in bold on the MatInspector 
results are the core binding sites for the transcription factors). 
 
Allele Program TF Strand Position Sequence Score 
rs11195360_T TFSearch SRY - 10-16 TCTGTTT 90.0 
MatInspector Fork head 
domain factors 
- 7-23 GAATCTGTTTAGTTG
TGTG 
0.903 
rs11195360_C TFSearch Cap + 15-22 TCAGTTGT 93.2 
HSF - 13-17 GTTCA 86.3 
MatInspector 
 
Cellular and 
viral myb-like 
transcriptional 
regulators 
- 11-23 CTGTTCAGTTGTG 0.883 
Core promoter 
initiator 
elements 
+ 13-23 GTTCAGTTGTG 0.983 
Table 5.2. Results from the analysis of the rs11195360 SNP sequence for transcription 
factor binding sites. (The SNP position is indicated in red. The bases in bold on the MatInspector 
results are the core binding sites for the transcription factors). 
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Allele Program TF Strand Position Sequence Score 
rs1407696_T TFSearch CdxA - 4-10 TATAAAT 100.0 
CdxA + 8-14 AATTATA 98.6 
HSF + 20-24 AGAAT 95.4 
Cap - 11-18 TATACTGA 90.5 
Cap - 19-26 GAGAATGT 88.0 
CdxA + 1-7 ATATATA 87.1 
CF2-II + 1-9 ATATATAAA 85.9 
CdxA + 11-17 TATACTG 85.0 
MatInspector Vertebrate 
TATA binding 
protein factor 
+ 1-17 ATATATAAATTATAC
TG 
0.920 
Distal-less 
homeodomain 
transcription 
factors 
- 3-21 ATATAAATTATACTG
AGAG 
0.910 
rs1407696_G TFSearch CdxA - 4-10 TATAAAT 100.0 
CdxA + 8-14 AATTATA 98.6 
HSF + 20-24 AGAAT 95.4 
Cap - 19-26 GAGAATGT 88.0 
CdxA + 1-7 ATATATA 87.1 
ADR1 + 14-19 ACGGAG 86.2 
CF2-II + 1-9 ATATATAAA 85.9 
MatInspector 
 
Vertebrate 
TATA binding 
protein factor 
+ 1-17 ATATATAAATTATAC
GG 
0.920 
Distal-less 
homeodomain 
transcription 
factors 
- 3-21 ATATAAATTATACGG
AGAG 
0.910 
Table 5.3. Results from the analysis of the rs1407696 SNP sequence for transcription 
factor binding sites. (The SNP position is indicated in red. The bases in bold on the MatInspector 
results are the core binding sites for the transcription factors). 
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Allele 
Program TF Strand Position Sequence Score 
rs34104444_G TFSearch PBX-1 + 4-12 ACCAATCAT 92.2 
CdxA + 7-13 AATCATA 86.4 
NF-Y + 2-12 ACACCAATCAT 86.4 
HSF + 16-20 GGAAT 86.3 
GATA-1 - 4-13 ACCAATCATA 85.3 
MatInspector CCAAT 
binding factors 
+ 1-15 AACACCAATCATACA 0.943 
Human and 
murine ETS1 
factors 
+ 8-28 ATCATACAGGAATAT
TTTGAGC 
0.869 
rs34104444_A TFSearch HSF + 16-20 AGAAT 95.4 
PBX-1 + 4-12 ACCAATCAT 92.2 
CdxA + 7-13 AATCATA 86.4 
NF-Y + 2-12 ACACCAATCAT 86.4 
GATA-1 - 4-13 ACCAATCATA 85.3 
MatInspector 
 
CCAAT 
binding factors 
+ 1-15 AACACCAATCATACA 0.943 
Heat shock 
factors 
+ 4-28 ACCAATCATACAAGA
ATATTTTGAG 
0.844 
Fork head 
domain factors 
+ 10-26 CATACAAGAATATTT
TG 
0.886 
Table 5.4. Results from the analysis of the rs3414444 SNP sequence for transcription 
factor binding sites. (The SNP position is indicated inred. The bases in bold on the MatInspector 
results are the core binding sites for the transcription factors). 
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Allele Program TF Strand Position Sequence Score 
rs4918605_A TFSearch HSF + 11-15 GGAAC 90.9 
Cap - 3-10 CAGGATGA 89.2 
Bcd - 16-23 ATAATCCA 88.6 
GATA-1 + 3-12 CAGGATGAGG 86.1 
CdxA - 15-21 CATAATC 85.7 
MatInspector Human and 
murine ETS1 
factors 
+ 3-23 CAGGATGAGGAACA
TAATCCA 
0.920 
Bicoid-like 
homeodomain 
transcription 
factors 
+ 12-28 GAACATAATCCAAAT
GG 
0.935 
Onecut 
homeodomain 
factor HNF6 
+ 12-28 GAACATAATCCAAAT
GG 
0.873 
NeuroD, Β2, 
HLH domain 
- 19-31 ATCCAAATGGCC 0.943 
rs4918605_G TFSearch HSF + 11-15 GGAAC 90.9 
Cap - 3-10 CAGGATGA 89.2 
Dfd - 11-26 GGAACGTAATCCAAA
T 
86.1 
GATA-1 + 3-12 CAGGATGAGG 86.1 
Bcd - 16-23 GTAATCCA 86.1 
MatInspector 
 
Human and 
murine ETS1 
factors 
+ 3-23 CAGGATGAGGAACG
TAATCCA 
0.928 
PAR/bZIP 
family 
+ 7-23 ATGAGGAACGTAATC
CA 
0.868 
Bicoid-like 
homeodomain 
transcription 
factors 
+ 12-28 GAACGTAATCCAAAT
GG 
0.883 
Onecut 
homeodomain 
factor HNF6 
+ 12-28 GAACGTAATCCAAAT
GG 
0.837 
NeuroD, Β2, 
HLH domain 
- 19-31 ATCCAAATGGGCC 0.943 
Table 5.5. Results from the analysis of the rs4918605 SNP sequence for transcription 
factor binding sites. (The SNP position is indicated in red. The bases in bold on the MatInspector 
results are the core binding sites for the transcription factors). 
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Allele Program TF Strand Position Sequence Score 
rs1322997_C TFSearch HSF - 21-25 GTTCT 100 
GCR1 - 8-16 AAGGAAGCC 90.9 
CdxA - 4-10 CACAAAG 87.2 
MatInspector Human and 
murine ETS1 
factors 
+ 2-22 AACACAAAGGAAGC
CTAAGGT 
0.951 
SOX/SRY-
sex/testis 
determining and 
related HMG 
box factors 
- 3-25 ACACAAAGGAAGCC
TAAGGTTCT 
0.829 
rs1322997_A TFSearch HSF - 31-35 GTTCT 100.0 
CdxA - 4-10 CACAAAG 88.5 
MatInspector Human and 
murine ETS1 
factors 
+ 2-22 AACACAAAGGAAGC
ATAAGGT 
0.954 
Table 5.6. Results from the analysis of the rs1322997 SNP sequence for transcription 
factor binding sites. (The SNP position is indicated in red. The bases in bold on the MatInspector 
results are the core binding sites for the transcription factors). 
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5.3.2 Protein extraction results 
Protein extractions were performed for both cytoplasmic and nuclear fractions of A549, 
Jurkat and Daudi. PBMCs were only used for whole cell protein extraction. Quantity 
and concentrations of protein obtained were determined by the Bradford assay (Section 
5.2.4). Flasks of cells were set up (Chapter II, Section 2.2.7) on independent days and 
for each type (nuclear or cytoplasmic) different extractions were performed from 
separate cell harvests to control for replicable results. The results were consistent in all 
cell lines and PBMCs. It was found that the cell number required, for airway epithelial 
cells (A549) in order to gain sufficient nuclear extract yield (ranging from 0.31 to 1.049 
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mg and concentrations from 1.24 to 2.91 mg/ml) was substantially lower (2.1 x 10
6 
-3.3 
x 10
7
) 
 
than that required for the other cell lines (Table 5.8). For the lymphoblastoid cell 
lines higher cell numbers were used (3.2 x 10
7
-2.5 x 10
8
)
 
to provide sufficient nuclear 
extract with 1.4 and 1.696 mg and concentrations 1.75 and 2.12 mg/ml. The 
cytoplasmic extracts showed similar results with substantially higher yield as expected 
(Table 5.9). The A549 cytoplasmic extractions yields were 10.77 and 11.57 mg/ml and 
the Jurkat and Daudi cytoplasmic extractions yields were 16.81 and 13.3 mg/ml 
respectively. Similarly, the cytoplasmic extractions were more concentrated than the 
nuclear extractions (Table 5.9). For the EMSA experiments 2 to 20μg of nuclear protein 
extracts are required, whereas for the Western blots 30μg of protein extracts are 
required. From the protein extraction method, sufficient amounts of protein extracts 
were obtained for the subsequent EMSA and Western blot experiments. 
 
Cell type Extraction 
date 
Number of 
cells 
Concentration 
of protein 
extracts 
(mg/ml) 
Volume of 
protein 
extracts (μl) 
Amount of 
protein 
extracts (mg) 
A549 05/06/09 2.1 x 10
6
 1.24 250 0.310 
24/06/09 3 x 10
7
 2.71 400 1.086 
29/06/09 3.3 x 10
7
 2.91 360 1.049 
Jurkat 05/07/09 8.5 x 10
7
 2.12 800 1.696 
Daudi 17/06/09 3.2 x 10
7
 0.425 300 0.127 
05/07/09 2.5 x 10
8
 1.75 800 1.400 
Table 5.8. The nuclear protein extraction results for A549, Jurkat and Daudi. 
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Cell type Extraction 
date 
Number of 
cells 
Concentration 
of protein 
extracts 
(mg/ml) 
Volume of 
protein 
extracts (μl) 
Amount of 
protein 
extracts (mg) 
A549 24/06/09 3 x 10
7
 2.89 4000 11.57 
29/06/09 3.3 x 10
7
 5.38 2000 10.77 
Jurkat 05/07/09 8.5 x 10
7
 4.20 4000 16.81 
Daudi 05/07/09 2.5 x 10
8
 4.43 3000 13.3 
PBMCs 
(average per 
sample) 
06/06/09 1 x 10
6
 2.10 100 0.21 
Table 5.9. The cytoplasmic protein extraction results for A549, Jurkat and Daudi and 
the whole-cell protein extracts for PBMCs. 
 
 
5.3.3 EMSA and rs6585018 
5.3.3.1 EMSA Optimization  
When conducting any EMSA experiment (Section 5.2.5) a degree of optimization is 
initially required.  The type and the amount of the co-polymer (non-specific 
competitors), the pre-incubation and incubation duration and temperature of reactions 
and the amount of protein and probe(s) included all had to be optimized in the 
preliminary EMSA reactions. For the non-specific competitors, 2 types of co-polymer 
were tested, the poly(dI-dC).poly(dI-dC) and the poly(dA-dT).poly(dA-dT). It was 
found that 0.75μg of the poly(dA-dT).poly(dA-dT) was the most appropriate co-
polymer to use possibly reflecting that the putative binding site for the Myb 
transcription factor is GC-rich, and this particular co-polymer has less resemblance to it.  
A pre-incubation time of 10 minutes at room temperature and an incubation time of 20 
minutes at room temperature were found to be optimal for the reaction. The strongest 
and clearest signals were obtained with 3μl of the probe and 8-10μg of the nuclear 
extracts. For both the competition and the supershift assays the same parameters were 
applied. 
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5.3.3.1 EMSA Results  
EMSA reactions were first performed using A549 nuclear extracts and after which 
reactions were conducted using nuclear extracts from Jurkat cells (Section 5.2.3). The 
radioactive labelled probe was loaded in lanes 1 and 10 without protein extracts. Lanes 
2 and 11 contained the EMSA reactions without addition of the non-specific co-polymer 
and a very strong band was observed at the top part of the gel as a result of the 
unspecific interactions between the labelled probe and protein. Competition assays were 
set with a titration (15X and 60X relative to the labelled probe) of specific (lanes 4-5 
and 15-16) and non-specific (6-9 and 13-14, 17-18) unlabeled probe.  
For the A549 cell line nuclear extracts, a number of shifted bands were observed after 
gel electrophoresis and autoradiography (Figure 5.1). Bands 1, 2, 3 and 4 were observed 
in both the rs6585018_A and rs6585018_G probe reactions, but were more intense for 
the rs6585018_A probe. Band 4 did not appear to be specific since in the competition 
reactions it was competed away by either the specific or the non-specific competitor. 
Bands 1 and 2 although shown to be affected by the specific competitor more than the 
non-specific, they were shown to be not robust when compared to the results obtained 
for band 3. Band 3 appeared in both the A and G-probe EMSA reactions and it was 
completely competed away in all competition reactions of probe rs6585018_G. In probe 
rs6585018_A EMSA reactions, the band was present when specific competitor was 
used but not when non-specific competitors were used. For A549 nuclear extracts 
therefore, one specific protein-probe complex is observed which although formed when 
the G allele is present in rs6585018, it is only specific when the A allele is present. 
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Figure 5.1. Competition assay for PDCD4 SNP rs6585018 using 10μg of A549 nuclear 
extract (29/06/09) per reaction. Lanes 2-9 include the rs6585018_A hot probe and lanes 
11-18 the rs6585018_G hot probe. Lane 1 and 10 include just the hot probes 
rs6585018_A and rs6585018_G respectively. Lanes 3 and 12 include reactions with the 
hot probe and the extract. Lanes 2 and 11 included reactions with the hot probe, the 
extract but no non-specific co-polymer. Unlabeled probe in excess was added in the 
competition assays (lanes 4-9 and 13-18) as follows: lanes 4 and 13 and lanes 5 and 
14:15X and 60X of cold rs6585018_A respectively, lanes 6 and 15and lanes 7 and 16: 
15X and 60X of cold rs6585018_G respectively and lanes 8 and 17- 15X and lanes 9 
and 18- 60X of cold PDCD4 _unsp probe. 
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For the Jurkat cell line nuclear extracts the same EMSA reactions were conducted. A 
similar pattern of bands to that seen for A549 was observed (Figure 5.2). Bands 1, 2 and 
4 were strong in EMSA reactions with the rs6585018_A probe but in reactions with 
probe the G allele probe (rs6585018_G) bands 1 and 4 were completely absent. Band 4 
represented an unspecific complex whereas for band 1 the results were not conclusive 
(Figure 5.2). Competition assays revealed that band 2 that was present in both reactions 
(lanes 2 and 10) was specific only for probe rs6585018_A as it was present when non-
specific competitor was added into the reaction (lanes 7,8) and then disappeared with 
excess specific competitor (lanes 3 and 4). Band 3 was observed in both reactions as 
well (lanes 2 and 10) but was only specific when probe rs6585018_A was used as 
shown from the competition assays (lanes 3-8). For EMSA reactions with the 
rs6585018_G probe, band 3 was competed away when both specific and non-specific 
competitors were present in excess (lanes 11-16). These results indicated that the probe 
forms two types of specific complex with protein when Jurkat nuclear extracts are used. 
Although both these complexes can be formed in the presence of both alleles of the 
rs6585018 polymorphism, they are only specific when the A allele is present on the 
polymorphic site.   
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Figure 5.2. Competition assay for PDCD4 SNP rs6585018 using 10μg of Jurkat nuclear 
extract (05/07/09) per reaction. Lanes 2-9 include the rs6585018_A hot probe and lanes 
11-18 the rs6585018_G hot probe. Lane 1 and 9 include just the hot probes 
rs6585018_A and rs6585018_G respectively. Lanes 2 and 10 included reactions with 
the hot probe and the extract only. Unlabeled probe in excess was added in the 
competition assays (lanes 3-8 and 11-16) as follows: lanes 3 and 11- 15X and lanes 4 
and 12- 60X of cold rs6585018_A, lanes 5 and 13- 15X and lanes 6 and 14- 60X of cold 
rs6585018_G and lanes 7 and 15- 15X and lanes 8 and 16- 60X of cold PDCD4 _unsp 
probe. 
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5.3.3.2 Supershift EMSA Results 
Nuclear extracts from A549, Jurkat and Daudi cell lines were used for the supershift 
assays. From the transcription factor binding searches (Section 5.3.1), Myb transcription 
factor was found to bind to the rs6585018_A probe but not to the rs6585018_G. An 
antibody for Myb was tested in the supershift assays for rs6585018. The reactions were 
set up with and without 0.3 ng of the anti-Myb antibody for each of the nuclear extracts 
(Figure 5.3). In reactions minus the antibody, the bands observed had a similar pattern 
to the bands in the competition assays for both A549 and Jurkat extracts. For A549, a 
single band was observed, which was stronger in the rs6585018_A probe reaction (lanes 
2 and 9) and was completely super-shifted when the antibody was added (lanes 3 and 
10). For Jurkat and Daudi nuclear extracts the results were the same with the presence 
of two bands in the reactions not including the antibody (lanes 4, 6, 11, 13), although 
they were more intense in the reactions containing the Jurkat extracts (lane 6). The 
rs6585018_A probe was shown to produce stronger bands in both extracts (lanes 4 and 
6). Both bands were completely super-shifted when the Myb antibody was included in 
the reaction. 
These results indicate that the complexes formed in all nuclear extracts (Bands 1 and 2) 
are capable of binding to the Myb transcription factor antibody resulting in the 
disruption of the probe-transcription factor complex identified. The results suggest that 
rs6585018 probe could bind to Myb transcription factor. 
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Figure 5.3. Supershift assays for PDCD4 SNP rs6585018 using 10μg of A549 
(29/06/09), Daudi (05/07/09) and Jurkat (05/07/09) nuclear extracts.  Lanes 2-7 include 
the rs6585018_A hot probe and lanes 9-14 the rs6585018_G hot probe. Lanes 1 and 8 
include just the hot probes rs6585018_A and rs6585018_G respectively. A549 extracts 
are included in lanes 2 and 9 without the antibody and in lanes 3 and 10 with 0.3ng of 
the Myb antibody. Daudi extracts are included in lanes 4 and 11 without the antibody 
and 5 and 12 with 0.3ng of the Myb antibody. Jurkat extracts are included in lanes 6 and 
13 without the antibody and in lanes 7 and 14 with 0.3ng of the Myb antibody included 
in the reaction. 
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5.3.4 Western Blot results 
PDCD4 protein expression was investigated in A549, Daudi, Jurkat cell lines and in 
PBMCs isolated from peripheral blood using Western blotting (Section 5.2.6). First, 
nuclear extracts from the cell lines used for EMSA and whole cell PBMCs extracts were 
tested (Figure 5.4). The PBMCs were derived from four healthy volunteers. A band of 
approximately 52 kDa size was found to be present in all three cells lines but protein 
expression was noticeably lower in the nuclear extract from A549 cells. The 2 PDCD4 
isoforms, 1 and 2, encode for 50.8 kDa and 52 kDa protein products, which is consistent 
with the observed bands. Interestingly, one of the isoforms was not present in the A549 
cell line. For the four PBMCs samples, two samples showed no expression of the 
protein (Lanes 5 and 7), one sample showed levels comparable to that seen in Jurkat and 
Daudi cells (Lane 6) whilst the final sample had low level expression (Lane 4) similar to 
that seen for A549 cells (Lane 3). In the cell line nuclear extracts in addition to the 52 
kDa band a number of larger bands were observed possibly reflecting alternative protein 
isoforms or complexes of the PDCD4 with other proteins. PDCD4 also has a number of 
phosphorylated residues and the upper bands could indicate phosphorylated PDCD4 
forms.  
 
 
 
 
 
 
 
Figure 5.4. Western blot results for Jurkat, Daudi, A549 nuclear extracts and PBMCs 
whole-cell extracts for PDCD4 protein. A band of the expected size, approximately 52 
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kDa is present. Β-actin is used for internal control to ensure differences are no due to 
variability in total protein in the different samples.  
 
A second Western blot experiment was performed to compare nuclear versus 
cytoplasmic PDCD4 protein expression for the three cell lines A549, Daudi and Jurkat 
(Figure 5.5). Nuclear expression was the same as observed previously (comparison 
between Figures 5.4 and 5.5). Interestingly, the protein was present at a higher 
concentration in the cytoplasm (lanes 1-3) compared to the nucleus (lanes 4-6) for all 
three cell lines. The results however suggest there was not a complete separation of the 
nuclear and cytoplasmic extracts when B-actin, a predominant cytoplasmic protein was 
used as control. The different pattern of expression between the A549 cells versus the 
Jurkat and Daudi lines was again similar with A549 having a significantly lower level 
of expression (lane 1 compared to lanes 2 and 3). One of the PDCD4 isoforms was 
missing from the A549 cytoplasm, similar to the A549 nucleus results.    
 
Figure 5.5.  Western blot results for PDCD4 protein for both cytoplasmic and nuclear 
extracts of Jurkat, Daudi, A549 cell lines. A band of the expected size, 52 kDa is 
present. Β-actin is used for internal control to ensure differences are no due to 
variability in total protein in the different samples. Β-actin is used for control. 
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5.3.5 Immunocytochemistry results 
Immunocytochemistry experiments were conducted to investigate further the expression 
and sub-cellular localization of PDCD4 protein in intact cells of the Jurkat, Daudi and 
A549 cell lines (Section 5.2.7). Different assays were prepared containing DAPI nuclear 
staining and no nuclear staining. The primary antibody was rabbit anti-PDCD4 
(Abcam
®
) and the secondary antibody Alexa Flour 488-conjugated goat anti-rabbit IgG 
(Molecular Probes). For the Jurkat cell line including DAPI nuclear staining, the protein 
was found to be predominantly located in the nucleus and peri-nuclear region (Figures 
5.6a and b). The results were similar although when DAPI staining was not used 
(Figures 5.7a and b). For Daudi cells (Figures 5.8a and b) and A549 (Figures 5.9a and 
b) cells expression of the protein was lower than that seen for Jurkat cells but nuclear 
distribution was identical.  
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a. 
 
b. 
 
Figure 5.6. ICC results for Jurkat cells including DAPI nuclear staining. a) Negative 
control (no anti-PDCD4 antibody) and b) Immunostaining results after incubation with 
primary and secondary antibodies (rabbit anti-PDCD4 and Alexa Flour 488-conjugated 
goat anti-rabbit IgG respectively).   
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a. 
 
b. 
 
Figure 5.7.The ICC results in Jurkat cell line. No nuclear staining was used. a) 
Negative control (no anti-PDCD4 antibody) and b) Immunostaining results after 
incubation with primary and secondary antibodies (rabbit anti-PDCD4 and Alexa Flour 
488-conjugated goat anti-rabbit IgG respectively).   
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a. 
 
b. 
 
Figure 5.8. The ICC results in Daudi cell line. No nuclear staining was used. a) 
Negative control (no anti-PDCD4 antibody) and b) Immunostaining results after 
incubation with primary and secondary antibodies (rabbit anti-PDCD4 and Alexa Flour 
488-conjugated goat anti-rabbit IgG respectively).   
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a. 
 
b. 
 
Figures 5.9. The ICC results in A549 cell line. DAPI nuclear staining was used. a) 
Negative control (no anti-PDCD4 antibody) and b) Immunostaining results after 
incubation with primary and secondary antibodies (rabbit anti-PDCD4 and Alexa Flour 
488-conjugated goat anti-rabbit IgG respectively).  
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5.3.6 Associations results between PDCD4 SNPs and PDCD4 transcripts 
Previously, in the Molecular Genetics group, expression Quantitative Trait Loci (eQTL) 
analysis was performed in whole-genome transcript levels after  global gene expression 
arrays were set Epstein-Barr virus-transformed (EBV) lymphoblastoid cell lines from 
all children of the MRC-A panel (Chapter II, Section 2.2.1). Associations among 
408,273 genotyped SNPs and 54,675 transcripts representing 20,599 genes were 
identified 
226
. For the global gene expression experiment the Affymetrix Human 
Genome HG-U133 plus 2.0 chip was used. A database was created including all the 
whole-genome associations results for these traits (mRNA by SNP Browser v1.0), 
which could be used as reference for genetic studies in complex disease such as 
inflammatory, infectious diseases or cancer (Chapter III, Section 3.2.1). 
The PDCD4 SNPs genotyped as part of the fine mapping strategy in the region were not 
included in the initial whole-genome association experiment in the MRC-A panel. 
Therefore, the genotyping data for PDCD4 SNPs, rs4918605 rs1322997, rs6585018, 
rs11195360, rs1407696 and rs34104444 for the MRC-A children and the transcript 
levels from PDCD4 gene probes were used to test if there is any correlation among 
them. 
The statistical analysis was conducted by collaborators in the Centre for Statistical 
Genetics, Department of Biostatistics, School of public Health, Ann Arbor, Michigan. 
The 5% False Discovery Rate adjustments were calculated at Qvalue
286
 software in R 
language environment. 
The transcript levels of PDCD4 gene represented by a number of probes had been 
previously measured
176
 and they were used to investigate their association to PDCD4 
SNPs genotyped in the fine mapping step (Chapter IV). Five probes were available for 
PDCD4 gene by the Affymetrix Human Genome HG-U133 plus 2.0 chip, designated 
1557166_at, 202730_s_at, 202731_at, 212539_at and 212394_at (Figure 5.10).  
All PDCD4 SNPs, rs4918605 rs1322997, rs6585018, rs11195360, rs1407696 and 
rs34104444 were tested for their associations to the transcript levels of the probes. 
Three of the PDCD4 SNPs, rs1322997, rs6585018 and rs34104444 were found to be 
correlated with the expression levels of 212594_at PDCD4 probe, with LOD scores 2.6, 
2.4 and 2.6 respectively and correlations were still significant when a 5% FDR was 
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applied (Table 5.10). The probe was located from 112,645,708 to 112,649,761 bp 
(Figure 5.10). No other correlation was observed between the PDCD4 probes and the 
PDCD4 SNPs.  
Interestingly SNPs rs1322997, rs6585018 and rs34104444 were the ones showed to 
have significant associations to severe asthma in children (Chapter IV, Section 4.3.2). 
 
 
 
Figure 5.10. The available PDCD4 probes from Affymetrix Human Genome HG-U133 
(image adapted from the UCSC Browser, NCBI Built 36.1). The 2 PDCD4 isoforms are 
shown. 
 
 
 
SNP Chr Probe ID Gene LOD P-value P-value 
corrected 
rs1322997 10 212594_at PDCD4 2.64 0.000488 0.0082 
rs34104444 10 212594_at PDCD4 2.59 0.00055 0.0082 
rs6585018 10 212594_at PDCD4 2.43 0.000828 0.0082 
 
Table 5.10. The significant association results between the PDCD4 markers and the 
PDCD4 probes expression levels (Chr: chromosome, LOD: LOD score for each 
association; the selected in frame rows indicated the results with a significant 
association). The P values were corrected and adjusted for FDR 5%. 
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5.4 Discussion 
In this chapter preliminary investigations of the functional role of the SNPs of PDCD4, 
that showed significant association with severe asthma (Chapter IV, Section 4.3.2), 
were conducted. Bioinformatic analysis of the DNA sequences containing the SNPs 
revealed that SNP rs6585018, had the potential to influence the binding site of the Myb 
transcription factor. Specifically, when the A allele of the SNP was present there was 
the potential for Myb to bind, but when the G allele of the SNP was present the Myb 
binding sequence was abolished. The SNP was located close to the predicted promoter 
of the gene and it was included within the CpG island present in the 5‟ region of 
PDCD4 (Chapter IV, Section 4.3.1).  
To verify the bioinformatic findings in vitro, EMSA reactions were designed for 
rs6585018. The results confirmed the allelic-specific effect of the SNP in relation to the 
binding of the Myb transcription factor. Competition assays showed that when the A 
allele was present in the polymorphic position, the transcription factor would have a 
greater affinity for the specific DNA sequence (Section 5.3.3). Supershift assays 
involving a Myb specific antibody confirmed that the identified super-shifted bands 
contained the particular transcription factor.   
The EMSA experiments were performed in Jurkat, Daudi and A549 cells. Western blots 
showed that PDCD4 protein is highly expressed in the Jurkat and Daudi lymphocytic 
cell lines and moderately expressed in A549 epithelial cell line. The protein was present 
in both the cytoplasm and the nucleus of the lymphocytic cell lines, but showed 
predominantly cytoplasmic expression in the epithelial line, A549. Comparing the 
EMSA results between the different cell lines, similar results were obtained for the two 
lymphocytic lines, Jurkat and Daudi, but did differ to those seen for A549 cells (Figures 
5.1 to 5.3). Specifically, a second shifted band seen in EMSAs for Jurkat and Daudi was 
not present when nuclear extracts from A549 were used. The results could possibly 
reflect and be related to the differential expression of the protein that was observed for 
the Western blot experiments in which the concentration of the protein in the nuclei was 
considerably lower for A549 cells compared to either Jurkat or Daudi. The two Myb-
containing bands present in the Jurkat and Daudi possibly correspond to DNA-protein 
complexes of Myb transcription factor including other associating proteins. 
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Myb was identified as a proto-oncogene involved in human haematopoietic 
malignancies and other types of cancer
385-388
. It was later shown that Myb transcription 
factor was essential for haematopoiesis including the self-renewal, the expansion and 
the differentiation of the immature progenitor cells
389
. The protein is highly expressed in 
the progenitor cells and declines with differentiation, allowing the normal development 
of haematopoiesis. Perturbations in the Myb expression during any step of the 
haematopoietic process could result in malignancy
390,391
. Repression of Myb expression 
inhibits the proliferation events of the hematopoietic progenitor cells and induces 
apoptosis, whereas excessive expression of Myb prevents the differentiation of the 
progenitor cells which remain in the immature stage
392-395
. Myb transcription factor 
binds on the t/cAACt/gG sequence, known as Myb transcription binding site (MBS)
396
.  
More than eighty targets genes that characteristically have MBS clusters, have been 
identified  for Myb transcription factor
397
.  
PDCD4 was identified as a target for Myb transcription factor in a myelomonocytic 
chicken cell line which expressed an oestrogen-inducible form of Myb
301
. In a chicken 
pre-B-cell line, the disrupted expression of c-Myb resulted in reduced levels of PDCD4 
m-RNA levels emphasizing the important role of the Myb transcription factor in the 
transcription of the gene
347
. A number of Myb binding sites were found in the promoter 
site of chicken Pdcd4 gene
300
 and this was confirmed when the human PDCD4 
predicted promoter was analysed using the TFSearch
212,379
. rs6585018 was included in 
one of these recognition sites resulting in the allelic-specific binding of the transcription 
factor on the candidate PDCD4 promoter.  
Using the mRNA by SNP browser, SNPs rs6585018, rs34104444 and rs1322997 were 
found to be significantly correlated with expression levels of PDCD4 mRNA. One of 
the PDCD4 transcripts was to found to show significant association with the markers.  
The results from these experiments confirm the possible role of the variations in the 
expression of the gene. In combination with the literature information about the Myb 
transcription factor effect on PDCD4 expression, it could be proposed that rs6585018 
marker, the most significantly associated SNP with asthma, exerts its effect by 
disrupting the binding of Myb on the putative promoter of PDCD4 when the G allele is 
present on the polymorphic site, thus reducing the expression levels of PDCD4 gene. 
The results show that G allele is more frequent in the asthmatic group (causal allele) 
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whereas A allele has a protective effect (Chapter IV, Section 4.3.2), proposing the 
reduction of PDCD4 expression is associated with the disease. 
It should be noted that the Myb transcription factor is not the only mechanism by which 
the expression of PDCD4 is regulated (Section 5.1.1). Different mechanisms in 
transcriptional, translational and protein level are involved in controlling the cellular 
levels of the PDCD4 protein. The apparent involvement of rs6585018 in the expression 
of the gene through its effect on Myb factor binding may therefore only partly explain 
the differences of the PDCD4 levels between asthmatics and non-asthmatics. It has 
however increasingly become apparent that in common diseases subtle alterations in the 
mechanisms of production, regulation and function of the genes are likely to be 
responsible for the development of the common disease phenotype. The common 
variant/common disease hypothesis suggests that disease susceptibility is caused by 
multiple interacting genetic loci contributing small additive effects but not determining 
the overall disease risk
398
. The multiple mechanisms of PDCD4 regulation could 
nevertheless be all indispensable and their exact coordination could be key in resulting 
in successful control of the cellular PDCD4 levels. Any disturbance in these processes 
(e.g. the Myb transcription factor binding) could therefore have an important impact.  
Another possibility could be that the regulation of expression of PDCD4 is cell-specific 
and it is influenced by the Myb transcription factor in lymphoblast populations involved 
in the inflammatory events during asthmatic responses. PDCD4 protein is highly 
expressed in lymphocytes as shown by Western blots and immunocytochemistry 
experiments (Sections 5.3.4-5.3.5). The specific role of the PDCD4 protein is to 
regulate the transcription and translation of target genes and proteins involved in cell 
cycle, cell differentiation and tumour progression. Known PDCD4 targets are the 
translation of urokinase receptor (uPAR)
356
 and the activator protein-1 (AP-1)-
dependent transcription
337,363
. 
PDCD4 has also been found to suppress AP-1-dependent transcription by inhibiting c-
Jun and c-Fos activation
399
. PDCD4 exerts its translational repression activities during 
the expression of mitogen-activated protein kinase kinase kinase 1 (MAP4K1), a kinase 
upstream of Jun N-terminal kinase (JNK)
353
. AP-1 is a major pro-inflammatory 
transcription factor activating genes such as cytokines, chemokines, adhesion 
molecules, receptors and inflammatory molecules following extrinsic inflammatory 
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stimuli like IL-1β and TNF-α400. IL-1β and TNF-α are both pro-inflammatory cytokines 
that have been implicated in airway pathology in asthma, including stimulation of 
airway epithelial cells and cytokine production and fibroblast proliferation
401
. TNF-α 
was initially reported to include haplotypes associated to asthma 
167,402
 and the result led 
to a number of studies identifying TNF- α SNPs significantly associated to asthma110. 
For the uPAR gene, a negative correlation of PDCD4 and uPAR in a number of 
colorectal cancer patients was reported as well as a reduced uPAR promoter activity by 
PDCD4 through AP-2/Sp1/Sp3 motif binding. In addition, siPDCD4 was found to 
induce the  uPAR mRNA in colon cancer lines
356
. uPAR was identified as a promoting 
invasion and metastasis molecule
150,403
. Interestingly, uPAR has also been reported to be 
an asthma-associated gene
404
 and it was hypothesized to have a modulator role in 
neutrophil and eosinophil adhesion and migration in asthma. The expression of uPAR in 
airway eosinophils was correlated with airway hyper-responsiveness and reversibility 
proposing its role as a biomarker for disease severity
405
. Examining the mechanical 
stimulation of airway epithelium, the uPAR protein levels were 16.2-fold increased and 
immuno-staining in asthmatic airway confirmed the same result, supporting uPAR as a 
potential airway re-modelling molecule
406
.  
These two examples of PDCD4-targets show that PDCD4 could act as 
transcription/translation regulator in the expression of genes important in central 
processes in the asthmatic response. The published data also confirms the relevance of 
PDCD4 as a candidate asthma gene and proposes possible functions of the protein 
associated with molecules with a known role in inflammatory responses or airway 
remodelling. The functional role of PDCD4 in the development of asthma ultimately 
could be explained by identifying additional specific gene targets and their involvement 
in the asthmatic airway mechanisms (see Chapter VI).  
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Chapter VI: Discussion 
In this thesis, the findings of a Genome Wide Association Study (GWAS) in childhood 
asthma
191
 were investigated in an independent group of severe asthmatic children and 
adults from the UK. Severe asthma refers to the extreme differentiated phenotype of the 
disease and by using phenotypes at the extreme end of the disease distribution one can 
increase the power of a genetic study in identifying disease associations, even if a 
relatively small number of individuals are included. By selecting asthmatics with the 
most severe type of the disease, one is therefore effectively enriching for disease 
susceptibility loci. Study of the individuals with the most severe form of disease is 
extremely important since the highest expenditure of the overall cost of treating asthma 
is due to this particular group as a result of their frequent hospitalisations and regular 
treatment use
31
. 
After interrogation of the GWAS results using the Genome Scan Browser and SNP 
Browser V 1.0 (Chapter III, Section 3.2.1) databases, 11 SNPs were selected for 
genotyping in 397 adults and 94 children cases of severe asthma. The control group 
included data from the MRC-A panel (Chapter II, Section 2.2.1). Genotyping was done 
by TaqMan
®
 SNP Assays (Chapter II, Section 2.2.6). Genotype frequencies between 
severe asthmatic children and adults were compared to genotype frequencies in a 
control group (Chapter III, Section, 3.3.3-4). From the GWAS top hits selected for the 
case control study, three of the SNPs were found to be associated to severe asthma. 
SNPs rs10270097 (chromosome 7) and rs6585018 (chromosome 10), were found to be 
significantly associated to childhood severe asthma (P=6.1x10
-5
 and P=3.4x10
-7
 
respectively) and SNP rs7216389 on chromosome 17, was associated to childhood on-
set severe asthma in adults (Chapter III, Section 3.3.3).  
SNP rs7216389 was located within the 17q21 region that includes the ORMDL3 locus, 
originally reported to be highly significantly associated with childhood asthma (P<10
-
12
) by the first  GWAS for asthma
191
. Although rs7216389 was highly associated to 
childhood asthma in the original study, in the present study no association with asthma 
was identified in the children group. Importantly, an association with childhood-onset 
asthma was found and the direction of association was the same as the one in the 
GWAS (Chapter III, Section 3.3.3). 
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For SNP rs10270097, the minor allele, A, was more frequent in the healthy controls 
compared to the severe asthmatic children, proposing a possible protective effect against 
disease risk for the minor allele. For SNP rs6585018 (A/G) there was a significant 
increase in the frequency of the minor allele (G) in the asthmatic children group (10%) 
compared to the controls (0.03%). 
SNP rs6585018 is located within the predicted promoter region of the programmed cell 
death protein 4 (PDCD4) gene on chromosome 10q24. Bioinformatic analyses revealed 
that the area includes a CpG island, a common characteristic of areas encompassing 
regulatory elements in the genome. The marker exhibited the highest association 
(P=3.4x10
-7
) with childhood asthma (Chapter III, Section 3.3.4) and therefore it is 
possible that it could be of functional interest and importance. PDCD4 gene has been 
reported to be highly expressed in lymphocytes
328
, a cell type having a central role in 
inflammatory responses with inflammation being a key characteristic of asthma.  
Based on the significant association seen, the potential functional role of the SNP and 
also the cellular expression of PDCD4, it was decided to focus on the PDCD4 
association and conduct fine mapping in order to establish whether rs6585018 was the 
key causal variant underlying the association or whether other SNPs were involved 
(Chapter IV). The promoter and exon areas were re-sequenced in 15 homozygotes for 
the A allele (AA) and 10 heterozygotes (GA) to discover novel variations.  
Bioinformatic analyses of the PDCD4 genomic region were conducted to assess and 
prioritise SNPs for genotyping which were already present in the area and registered in 
publically accessible SNP databases. Additional information from the original GWAS 
study and genotyping from the British 1958 Birth Cohort 
(http://www.b58cgene.sgul.ac.uk/) was also used as well as haplotype analysis for the 
variations included in the area. Five SNPs were finally selected to be genotyped in the 
severe asthmatic children and healthy controls. In addition to the original association 
seen with rs6585018 (Odds Ratio 2.91 [95% CI 1.41-6.02]), two further SNPs, 
rs1322997 and rs34104444 showed significant associations with severe asthma, with 
odds ratios of 2.82 (95% CI 1.31-6.05) and 2.88 (95% CI 1.39-5.96) respectively. For 
all three SNPs the frequency of the minor allele was increased in the asthmatics 
compared to the controls. The ORs and the calculated relative risks (2.70, 2.63 and 2.67 
respectively) revealed similar effects of the three SNPs.  
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Haplotype analysis of the complete dataset (asthmatics and controls combined) showed 
that the three SNPs were actually in perfect LD and haplotypes containing the minor 
alleles of these three markers were also significantly associated to asthma. Haplotype 
analysis also revealed that the association seen at the locus was not due to a 
combination of the asthma-associated SNPs and that it is most likely that the association 
is due to a single marker effect. 
Typically almost exclusively those individuals having severe spectrum of disease 
exhibit steroid resistance.  It was therefore decided to examine whether the PDCD4 
locus was of particular importance to this steroid resistance phenomenon by genotyping 
a set of mild asthmatics for comparison to the severe group. A set of mild asthmatics 
was therefore genotyped for the 5 SNPs in order to allow comparisons to be made 
between mild and severe disease. Significant associations were detected for both 
genotype and haplotype data suggesting that the PDCD4 locus is important for the 
steroid resistant asthma. The mild asthmatics used as controls included adults and not 
children, therefore it could be possible that the effects reflect disease heterogeneity and 
they are not related to the degree of severity of the disease. 
Two of the PDCD4 SNPs (rs6585018 and rs1322997) are located within the predicted 
promoter region of the gene and the third SNP (rs34104444) is a synonymous SNP in 
exon 5 of the gene. Sequence variation in regulatory elements such as the promoter 
could potentially affect the transcriptional control of the gene.  Having established 
therefore that SNPs rs6585018 and, rs1322997 were associated with disease, the next 
logical step was to start functional investigations.  
In Chapter V, the putative promoter region sequences of PDCD4 containing the SNPs 
of interest underwent bioinformatic analysis to predict whether they had any potential 
effect on transcription factor binding. Most of the SNPs were found to lie within a 
transcription factor binding site (Chapter V, Section 5.3.1) and for the majority of cases 
the polymorphic site itself (i.e. which allele was present) did not affect transcription 
factor binding.  The exception however was the most significantly asthma associated 
SNP rs6585018. rs6585018 was found to have an allelic-specific effect in the binding 
of the transcription factor Myb. When the A allele was present at the polymorphic site 
Myb transcription factor binding could occur whilst the Myb binding site was abolished 
when the G allele was present. To investigate this finding further, EMSA reactions for 
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rs6585018 were designed to establish whether bioinformatic findings were also found in 
vitro (Chapter V, Section 5.2.5).  
The cell lines selected for the EMSA experiments were airway epithelium (A549) and 
B- and T-lymphocytes lines (Daudi and Jurkat respectively). The cell lines were chosen 
due to their relevance to airway modelling and inflammation, both features of the 
asthma phenotype. In addition PDCD4 protein has been previously shown to be highly 
expressed in B- and T-cells. This was confirmed by carrying out western blots and 
immunocytochemistry for all three cells lines and it was found that there was moderate 
expression in airway epithelium (A549) (Chapter V, Sections 5.3.4 and 5.3.5).  
EMSA experiments confirmed the bioinformatic analysis results that rs6585018 has an 
effect on Myb binding. Allele A had a higher affinity for Myb transcription factor 
compared to allele G. The results were verified by competition assays and supershift 
assays using a commercially available Myb antibody (Chapter V, Figures 5.1-3).  Myb 
transcription factor has previously been shown to induce PDCD4 expression in a 
chicken B cell line
301
. Using a B-lymphoid chicken cell line to disrupt c-Myb gene by 
homologous recombination resulting in c-Myb knock-out, PDCD4 expression was 
diminished, providing additional evidence to the effect of Myb transcription factor in 
the regulation of PDCD4 expression
347
. 
Using the SNP by mRNA by SNP browser (Chapter III, Section 3.2.1) that was 
developed by previous work within the group
176
  it was interrogated to see if the 
PDCD4 SNPs associated with transcript levels of the gene. Interestingly, after 
correcting for multiple testing, only SNPs rs1322997, rs6585018 and rs34104444 were 
associated to the PDCD4 full length transcript levels (Section 5.4.6). The three SNPs 
that were found associated to asthma, were also found to be in complete LD with one 
another (Chapter IV, Section 4.3.3).  Since however only rs6585018 appears to have a 
functional role on PDCD4 expression, it could be assumed that the effect of this group 
of SNPs is attributable to rs6585018.  
Previously  methylation has been shown to be related with reduced PDCD4 mRNA 
levels in human glioma cells
348
. It is therefore interesting to note that rs6585018 is 
located within a predicted CpG island close to the PDCD4 gene predicted promoter.  In 
addition to the effect the SNP has on Myb transcription factor binding and therefore 
potentially PDCD4 expression, it could be important to investigate further the role that 
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epigenetics mechanisms may have in gene and protein expression. Taking into 
consideration that epigenetic mechanisms participate in the regulation of PDCD4 
expression, the individual role of rs6585018 and Myb-specific PDCD4 control in these 
processes needs to be further explored. Methylation arrays and bisulphite sequencing 
could be used to examine the PDCD4 methylation pattern in families including an 
asthmatic proband, such as the MRCA group and compare it with the eQTL and the 
genetic association results found for this subject group. 
Nonetheless the results from this collection of experiments have shown that the 
promoter-located PDCD4 SNP rs6585018 is highly associated to severe asthma in 
children and it influences the transcription of the PDCD4 gene. Many other studies 
using various cell types and diseases have shown that the regulation PDCD4 expression 
can occur at many levels including transcriptional and translational (Chapter V, Section 
5.1.1) and that these mechanisms could be essential for a coordinated and controlled 
regulation of cellular protein levels. MicroRNA miR-21 was found to regulate the 
protein levels of PDCD4 by preventing the translation of the protein by a number of 
studies
344-346
. Recently, miR-21 has been shown to be overexpressed in allergic 
inflammation and control IL-12 transcript levels
304
. Further microRNAs studies could 
elucidate the specific effect of miR-21 in PDCD4 expression in the asthmatic airway. 
A subtle alteration in any of these mechanisms could therefore disturb the balance of 
normal levels of PDCD4 and interfere with the downstream molecular pathways and 
functions of the protein. This hypothesis harmonises with the “common disease-
common variant” which proposes that for complex diseases a number of variants will 
cause small or additive effects, conferring susceptibility for the disease, rather than 
strong and dramatic phenotypic changes. 
The actual function of PDCD4 protein is not clear, although it has been hypothesized 
that it functions as a transcription regulator
353,355
. It would be interesting to examine the 
expression of the protein in severe asthmatics and non-asthmatics depending on their 
genotype for the rs6585018 polymorphism. Western blots or ELISA (Enzyme-Linked 
Immunosorbant Assay) could be established with results compared to housekeeping 
gene protein products in the case of the Western blots whilst for the ELISA a reference 
would need to be established to generate a standard curve.  This could either be full 
length PDCD4 protein or a peptide of the protein (http://www.abcam.com).  Protein 
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levels could then be compared to gene transcript levels and rs6585018 genotype to see 
what correlations exist (Chapter V, Section 5.3.6). The effect of the regulatory PDCD4 
SNP rs6585018 in the expression of the gene can be assessed in the transcriptional level 
by measuring the allelic ratios in mRNA in heterozygotes providing evidence whether 
there is a differential transcription of alleles in linkage disequilibrium to the regulatory 
SNP (such as rs34104444 synonymous SNP). mRNA stocks of the EBV cell lines for 
the MRCA children are available at the Molecular Genetics group which could be used 
for this experiment in the future.   
It would also be interesting to investigate further the proposed role of PDCD4 as a 
transcriptional regulator.  The involvement of PDCD4 in the pathogenesis of asthma 
could be established if relevant target genes are identified. These genes could be coding 
for important inflammatory molecules or signal transduction molecules involved in the 
asthmatic response.  
Yeast two- hybrid analysis has previously been conducted in senescent diploid 
fibroblasts and identified 40S ribosome complex interactions with PDCD4
296
. The 
method could be applied in a leukocyte cDNA library as PDCD4 is highly expressed in 
lymphocytes, to discover novel and lymphoblast-specific PDCD4 interactions. Possible 
novel targets of the protein could be found by using siRNA knocking down of PDCD4 
protein and measuring the alternate global protein expression in selected cell lines. 
Functionally more could be learnt about PDCD4 by conducting siRNA knockdown in 
lymphocyte, epithelial cells lines and primary cells from peripheral blood and/or lung 
epithelia to examine the gene expression genome wide.  
The rs6585018 SNP was selected for investigation in severely affected asthmatics non-
responsive to steroids, as a result of it showing association with childhood moderate/to 
severe asthma in the GABRIEL GWAS. It would be interesting, pending on the 
availability of additional phenotype information, to look at whether the locus shows 
association to other recognised quantitative traits and sub-phenotypes of asthma 
including for example eosinophil counts or IgE as this may assist in dissecting out 
further the PDCD4 association with asthma and it aetiological role. 
Although association has been found and functional investigations have indicated how 
the locus could be influencing disease outcome, the association of the PDCD4 gene 
with the severe asthmatic phenotype needs to be validated in larger datasets including 
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samples with UK and non-UK origin. Severe asthma genetic studies have the potential 
to be extremely valuable in identifying factors contributing to the most difficult-to-
manage form of the disease as well as providing general insights into the disease 
mechanisms. AUGOSA is on-going GWAS investigating severe asthma in adults, 
including more than 400 severe cases from the GABRIEL Phase II project and 600 
additional UK severe asthmatic adults (personal communication M.F.Moffatt). The 
hypothesis of the study proposes that genetic variation underlying severe asthma and 
relevant subphenotypes are different from those responsible for the development of the 
disease per se.  There is also the FP7 UBIOPRED program investigating clinical 
biomarkers in severe asthma and the aim is the application of the results for more 
efficient therapeutic strategies (personal communication M.F.Moffatt).      
The present study did consist of a relatively small number of subjects. Nevertheless, the 
initial GWAS finding
191
, the consistency of the association results and the statistically 
significant results (robust after correction for multiple testing), the selection of the 
extreme phenotype, the confirmation of the functional role of the variation and the 
functional relevance of the protein provide strong evidence of the candidacy of PDCD4 
as a novel asthma gene.   
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Future Directions 
For the steps following the results of this study, the specific functional role of 
rs6585018 PDCD4 SNP will be further investigated. Additional phenotype data (IgE, 
eosinophil counts) from the severe asthma population will be also tested for association 
with the PDCD4 markers. Another set of EMSA experiments on Jurkat cell lines 
including unspecific antibodies will be performed to test and confirm the specific 
binding of Myb transcription factor to the rs6585018 sequence. Luciferase assays will 
be prepared with constructs containing the alternative rs6585018 alleles and they will 
be transfected into Jurkat cell lines to test for the activity of the putative promoter 
region and the Myb-inducible transcription regulation effect. In addition, siRNA for 
PDCD4 gene will be transfected into Jurkat cell lines and the levels of key cytokines 
(IL-4, IL-10) will be measured and compared to wild type cells, by using Real-Time 
RT-PCR, Western blots and ELISA (Enzyme-linked immunosorbent assay). Ultimately, 
the results could provide with a hypothesis of the role of PDCD4 in severe asthma 
development pathways.   
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APPENDIX   
 
                                                                                      GATA-1,-2/AP-1          MYB 
TGACTGGGCAGCCAAGGGAAAGCGCTGGCCTGTGCGGGATGAGGCAGTTG
GGTT 
                                    PBX-1     GATA-1,-2                HSF-2 
CTGGAGAGCACAAGCAATCATTCGGTGCTGCCCATCAGACAACTGAAAAAT
CTG 
                                                               MZF-1/Iκ-2-3                CdxA 
ATCAGAGGCAGTGGCTAAGTCCCCGCCTGGGAACACAAAGGAAGCCTAAG
GTTC 
              GATA-1,-2                                           RORα                        GATA-2                   
CP2 
TGGTTATCACCCTCAGGGGACCGTGACCTTGAAAGAGTAAGGATAGTACCA
GCC 
SRY             MZF-1 
AAAACCAATGCAGCCAAGAGGAAAAGTCACAGAGAACAGCGAGGGGAGG
TGG 
HSF-1                              CdxA                                                           AML1-α 
AAGTTTCAATACAGAAATTGTAGCCATGGCTGAGAACCCCAGCACTGGAGG
CCG 
        CdxA        Oct-1                     c-
ETS 
GAATTTGTGCGTTTGAACGCCAGAGGCTTGGCTAGTCATGATTAGCAAAGG
AAC 
                              E2F                       CdxA                        Iκ-2 
TTCAAAGAGTTTTGGAGCCTGCTTTATATCTGTGAAATGGGAATTATTTCC
ATC 
                                   NF-κB/GATA-1                 HSF-1,-2 
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TCAAAGGTTTGAGGGGATTCGCTGAGAGAAACTTCTTAGCATGGGATC
TCC   
                                                                    v-Myb/c-Myb 
AGAAACTGGAAGCCACAGAGAAAGCAACGGCCAGAGGGAGGAGGAAT
CGG 
         Nkx2 HSF-2                                               CdxA               
Sp1 
ACAGGCTGATCACTTGGAGTGTTCGCCTAAGCAGTTTCTAGAAATGGA
GGC   
                          c-ETS        C/EBPb 
AGGGACCATCAGGAAGCTCAAAACCTTTGCTTCAGCCGAGTTTGCAGA
ACG 
                HSF-2  
CCCTGTGAGGAGAATGGGTGAGCTGGGTCGAGGAAGCTTCATCCTCGT
CCC 
GATA-1,-2,-3/MZF-1  Iκ-2/Lyf-1/C/EBPb         GATA-1,-2 
CATCCCCCAGCACTGCCCTTTTCCCAACGCTCCCATCCCGCCACGCCTC
CCA 
                                                     Elk-1/c-Ets/Iκ-2 
ACATACCCCCACCCCGACTTCCCGCTCAACTCCCGCTCCAGCCAGTCCC
AG 
            MZF-1/Lyf-1  
GAGCCACATGCGCATGCGCCCTCCCGCGCCCCTCCCCAACTTTCCACG
TTTC 
  p300               GATA-1  
ACTCCTCTCCCTTTTCCTCCTCAGCTCCGGCTCCGCCGCCACGATTGGC
CAG  
                                                      USF 
CCGACCACCCGGCCTCGGCCAATAAGCGCCGCCCTCTCGCCCCCGTGT
TAC 
      SRY/HNF-3b   
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TGGGTAGAAGAAAACAAAAACAAACAGAGCGAGAAGGGCCAGAGACTC
TCC 
 
GAGGCGGCGGCAGAGACAGAAGAGCGGGGTCGGGGCCGGCTGACCAG
GAA   
 
CCTGGGCGAGCAGCGGCGGGGGCCCGAGGGGTCAGTACCAGTAGGCG
CGG 
  Iκ-2                                                                   GATA-1,-2,-3/MZF-1 
CTCACACGCTCGGGAAGACTGCGCCCTCTCCCCCATCCCTCCTCGGAG
GCA 
            GATA-1  Sp1   EGR-3 
GCCGCAAGATGGGAGGGGGCGGGGGCGGAGGCGTGGGGGTCGCGGT
CCT 
         AML-1a  
GTCAGGTCCGGGCCTGCGGTGCGGGGGTCCGGCTGCCTTCTTGTAGCC
CCG 
                                        CP2/MZF-1/Lyf-1                                               c-ETS/GATA-
1,-2 
CAGGTCCAGCCGCGCCCTCCCCAACGCCCCGGACTGCGGGCATCCGGC
CTG 
 CdxA Sp1 
GTTCCCTCTTTCTGAGCCCAGCCTGGAGCGTGTCGGCGCGGGCCCGCC
CCC 
  GATA-1,-2/MZF-1/SREBP 
TCCCGGAGCCATCTCCCCACTGAGAGGGGCGCGCGAGGCGCTCGCCCT
TGA 
MZF-1         
 GATA-1 
AGGTCCCCCTCAGCCCTCCTCCCCCTCTGGCGGAGGTTGAATTCGGGG
GCC 
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       GATA-1   Elk-1/c-Ets         HSF-2 
GGGATTGGAAGGCGTGTTTCCGGCTGGACTGAAATCCTGTGAGGAAGA
TTC 
       Sp1/MZF-1                     Iκ-2  NF-κB    GATA-1,-2 
GCGCCCTCCCCGCCCCCTGCCCTCCCTGGGAATCCTCTGAAGATGCGG
CCC 
                                                                                                                                          
NRF-2 
CCTGTCCTTCGTGAACCCGGAGCCCCGGCCTCGGCCCCGGCCCAGCCC
CTT 
c-ETS    Iκ-2 
CCGGGGGCCGACCCGGGCTGGGACTTCGGGGGTCCTAGCCTGAGCCC
GCT 
         MZF-1                   GATA-1,-
2,-3 
GCGGGAGAACAGGCCCGGCCGCTGTGGGGAGGGGCCGCGCGCTATCC
TCG 
                          Lyf-1               USF/GATA-1,-2,-3/ Arnt/N-Myc/E47/Max 
CCGGGGGCGCTGGGAGGCGAACACGTGCCCGCCGCCCCATCCCTGCG
CGA 
            NRF-2/STATx/c-ETS/Elk-1         CRE-
BP/C/EBPa  
ACTTCGTCGCGCCCGTCTTCCGGCAAAGGGTCTCTTTTTTTTAGTTTAG
GTA 
   Lyf-1 
AAATAAAATCTCCCAGAGAAAACAAAGCCGGGAAGGGAGCCCCCTTTCTG
TGA 
       GATA-1,-2             VBP                
C/EBPa,b/c-Rel 
AACGCATGCCATCTTCTCCATTTGTCAGTTTGATGCTGTAACGTACATGGGG
TTT 
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                                               CREB/CRE-BP                MZF-1 
TGCAAGAGCTTCAAAACTGTCTGCAGACGTCAATTTCGCCCCCCTCCCCCTT
GTG 
                 CdxA/C/EBPb  
AGAACTCGCTACGTAGCCAGCAACTGTGTAGTGTCTACAAATGATGAAAAC
GAT 
         MZF-1  Evi-1 
CAGAAATGCGATTAGGTGTCGGGGAAAAAAGGGTTTCCCCTGTTTTTAACT
TGTA 
 Sox-5,S8          CRE-BP         Iκ-2/Lyf-
1/STATx  
TTTTTACTTTAATTGTTACAATCTTGATATTCTTAACGTGACTTTTTTGGGAA
ACC 
     p300         CdxA 
ACCAAGTGCTTTTTAAGCAAGGAGTTACTGGTATTTATGCCCTTAATATTCC
TTC 
  CdxA/Oct-1 CdxA/Oct-1                                       CdxA/Tst-1/Nkx-
2  
ATTATAGGCTTATTGAATACGTTAATATCTCAGTAAGTGTATTTGAATTATA
ATT 
      CdxA CdxA  CdxA 
GACTGGCTTTTTCTGTGGTACTAATGTGAAAGGAAAAAATATTAGGACTGCAAAAATA
AAT 
    Oct-1                   CdxA 
GCCGCTTGAATATTATCTGTAGTGCTTGCTTTTGCATTACTGTAGTAGAATGCTTTTAGCTGG
TTTT 
    S8/Oct-1       v-Myb     CdxA/HNF-1/YY1 
AAGCTGCTAATTAGCCGTTCGTAGCCGAAGAATGAATACAAGTAATCCTAGTTAATAAATG
GCCA 
         CdxA          STATx/c-Ets/CdxA    
AAGCTTGACTCCCCAAAATGCCAGAGCAATTTATGAGGTATATTTCAGGAAATACATATGT
ATAT 
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MZF-1/p300       Iκ-1,-2     HFH-
1,-2 
ATTTCGTGGGGGAGTGGAGGGTCTGTCTCTTAGGGAATGTCTTGGCAGTTGAATACTTCTGA
TTGT 
 
            SRY                  CdxA/CRE-BP 
ATATTTCGTGTAACACACTGGAGAAAAGAACAGTGTTTAATGTCAGCCTTCATTTTCTTCTA
ACTT 
        HFH-1,-2/Brn-2     CdxA     HNF-
3b 
GTATGTATAGTTTTCTCATCGAAAATTCATTTTTGTAGGTTAGTATGAAGGAAATAGCGTTT
GGAT 
        HNF-3b/CdxA/SRY/HFH-2 S8         CdxA/C/EBPa  
TTTTTGCTTTATATTTTCTTGTTTGGGCCAATTAAGGGTTGTTAAATAAATTGGAAAAAATCC
TACT 
 GATA-X-1/Evi-1 
ACTTTAAAGAGCGTAAAAACGTGGAACATGTCTTATCTAAACTCTTAAAACGTGTTTGTTGC
TGTC 
CdxA                            GATA-1,-2    C/EBPa/CdxA                                                   
CdxA     
AAATATGACTTGAGTTCCTGATCGGGTTATCATTGCCTAAAGACACAGGACTATTTTTTTTA
TTAA 
GATA-2    GATA-1,-X/CdxA/SRY       GATA-1,-2 c-Ets                        CREB 
GATAACTTTGTTTTTATCTTAATAAAAGAGATGATAGTCATTTCCTGACAGTTTTGTCTGAC
GGAA   
       CdxA              S8/CdxA/Oct-1                C/EBP/SRY             CdxA  
TGCCTTCTGTATAATAGTTTAAAATAATTATTTTTAGTGTTTGGAAAACAGCATTTAAAAGT
TTGA 
            HSF-1,-2                           HSF-1,-2/c-Ets/GATA-2 
ACAGCAGAAGTCTGTTTTAAGAAGCTTCTGTTAACCCTTGAAAAGAATCTTCCTGTGGGATA
TTAA 
           C/EBP                   Lyf-1 
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AATTTTGGATTGAACTTGTGCAAACAGTACTGGATTTGGAAGGTCTGGATTCTCATCCTGGC
TGTT  
     GATA-1,-2,-X/deltaE              v-Myb/c-Myb 
CCACTAAGCAGCTGTCTGTCCTTGGACATATCACCTACCCTCTCTGAATCTGTTCAGTTGTGT
GTA 
deltaE                       CdxA 
AGGTGGAATACCTACCCGAAGGTTTTTCTGTAAGGTACATTA 
 
 
Figure A1. Sequence Analysis of transcription factor binding sites within the PDCD4 
extended promoter region (chr10:112,620,693-112,623,962, NCBI Built 36.1). The 
sequence includes PDCD4 intron 1. SNPs are indicated in blue, transcription factor sites 
are indicated in annotated boxes, the predicted CpG island (predicted by 
http://cpgislands.usc.edu/) is indicated in bold. The predicted promoter area has a font 
size 12   and the non-promoter regions have a 10 font size. v-Myb/c-Myb binding site 
including SNP rs6585018 is highlighted in yellow. 
 
 
 
 
Figure A2. The GC% and the CpG islands as predicted by MethPrimer software. The 
first CpG is expanding  from 112,621,363 to 112,622,128 and the second CpG island is 
expanding from 112,622,134 to 112,622,503. 
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The exon 6 sequence with the primers (underlined) selected for sequencing and the 
SNP position 
Rs41292600=R (G/A) 112.637.423 bp (NCBI Built 36.1) 
 
TACCATGTAGCCTACATGTAGGCTCTGCCATTTAGGTTTGTGTAAGTACACTCTATAATG 
ATTGCACACTGATGAAATCACCTAAATGGTGAATTTCTCAGAATGTATCTGTGTCGTGAC 
CCATGACAGTATTTTAAAGGTATTTCACATTTTTGAATTTAGCGATGTTAAGGCAGTTAA 
AGCTTGACAAAGTGGATCAATGTCTGATTTAT GCACAGGGAAAGGTGTGTTTATCCTATC 
[TTCTAAAACATGACTGGGTCTTTTGATTATTTCCAAAGAGTGAGACGTAGAGATATATAG 
ATAAAAGCTCAATTTTTCAAAAATAAAATTTTATTGAACTATAGGTAGTGATACACTTTT 
AAAATGTTTTTAAATTATTTTTTTGAACAGGAAATGTTAARAGATTTAAATCTTGGTGAA 
ATGAAAAGTGGAGTACCAGTGTTGGCAGTATCCTTAGCATTGGAGGGGAAGGCTAGTCAT 
AGAGAGATGACATCTAAGCTTCTTTCTGACCTTTGTGGGACAGTAATGAGCACAACTGAT] 
GTGGAAAAATCATTTGATAAATTGTTGAAAGATCTACCTGAATTAGCACTGGATACTCCT 
AGAGCACCACAGGTTTGTATGATTCTTCTTTTTGTTCATTCCCTCCCACTACTATATTCC 
TAATTGTGGAAATAATGTATACTCCTAGGAAATTTTAGTAGATGGAAGGGGATGGCCAAC 
ATTTCCTACGACACCGAAATATTCCGCTAGCATTTTGATGTATTTTTTCCTAGTTCTTTT 
GTTTTTTAAACATGGTCTTCA 
 
The exon 10 sequence with the primers (underlined) selected for sequencing and 
the SNPs position 
Rs41292602=Y (C/T) 112.644.228 bp (NCBI Built 36.1) 
Rs41292604=S (C/G) 112.644.259 bp (NCBI Built 36.1) 
 
AAATCTAATAGATTGATATGCTGCTGAAAGAATATTTACTCTCTGGAGACATATCTGAAG 
CTGAACATTGCCTTAAGGAACTGGAAGTACCTCATTTTCACCATGAGCTTGTATATGAAG 
TAAGATTACCTTGCCATGTCAAAGATAATTATTAAGTGTTCCTTTTTGTACTGTAGCGAC 
TTATGCTTTTTAAATAATGTACATCCTTTTTTTAATATCAAAGGAGGAAGTGGTTATTAA 
ATTTCTACGATTACAGAAGGCATCTAGGTGCATTTTAGGAGCAGTTTCATATATGAATTA 
[ACCAAAAATTCACTCATTGATTCAATTTTTAGGCTATTATAATGGTTTTAGAGTCAACTG 
GAGAAAGTACATTTAAGATGATTTTGGATTTATTAAAGTCYCTTTGGAAGTCTTCTACCA 
TTACTGTAGACSAAATGAAAAGAGTAAGTATAACATTGTTTTTGAACAACTTGTAGGATT 
ATGTCTTAAATATATGATTGAATACAGATTATGAATTGTCAGTGAAATTTTCTTTAGGTA] 
TGTTTAGTGTTAATATGCCTATATGTTTTGTTTTTTCTTAATGGTAATGTTTGAGGTTTG 
AACCTTTTGCAACCATTTTTTGGAAAGTAACACTGCAGTGTTTTTTTTTTTTTTTTTACC 
TACTTTAACAAATGTAATTATGTATTCTACCTCAAGGGTTCGGTTTCTAAGATGTGACAA 
TTTCTATTTTATATCTAGAGAGAAACATGAACCTTTAACTTTTAACAAATTATAAAGTAC 
TTTTTTCCTATTAAAAATTTT      
 
Table A1. The exon 6 and 10 sequence of PDCD4, including the variations and the pair 
of primers used for sequencing. 
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Name Chi Square Permutation p-value 
Block 1: ACG 8.859 0.013 
rs1322997 8.783 0.014 
rs6585018 8.607 0.015 
rs34104444 8.075 0.018 
Block 2: TTA 7.243 0.022 
rs1407696 3.177 0.366 
Block 2: CGG 2.995 0.387 
rs4918605 2.94 0.399 
Block 1: GAA 2.94 0.399 
rs11195360 2.58 0.452 
Block 1: AAA 0.002 1 
Block 2: TTG 0.022 1 
Block 2: TGG 0.027 1 
Table A2. Association results after 1000 permutations for single markers and 
haplotypes for severe asthmatics versus healthy controls. 
 
Name Chi Square Permutation p-value 
rs6585018 12.803 0.004 
rs1322997 11.267 0.005 
rs34104444 11.673 0.005 
Block 1: ACG 11.812 0.005 
Block 2: TTA 10.754 0.006 
Block 2: TTG 3.335 0.239 
Block 1: AAA 2.922 0.455 
rs4918605 0.044 1 
rs11195360 0.016 1 
rs1407696 0.01 1 
Block 1: GAA 0.062 1 
Block 2: CGG 0.04 1 
Table A3. Association results after 1000 permutations for single markers and 
haplotypes for severe asthmatics versus mild asthmatics. 
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